var title_f37_42_38560="Terbinafine: Patient drug information";
var content_f37_42_38560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Terbinafine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/46/9957?source=see_link\">",
"       Terbinafine (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/53/39763?source=see_link\">",
"       Terbinafine (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11078 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DE6246C94F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38560=[""].join("\n");
var outline_f37_42_38560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/46/9957?source=related_link\">",
"      Terbinafine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/53/39763?source=related_link\">",
"      Terbinafine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_42_38561="Heel pain (caused by plantar fasciitis)";
var content_f37_42_38561=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Heel pain (caused by plantar fasciitis) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/42/38561/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38561/contributors\" id=\"au314\">",
"       Rachelle Buchbinder, MBBS, MSc, PhD, FRACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/42/38561/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38561/contributors\" id=\"se6980\">",
"       Zacharia Isaac, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/42/38561/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38561/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/42/38561?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PLANTAR FASCIITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Plantar fasciitis is one of the most common causes of foot pain in adults. Plantar fasciitis is caused by a strain of the ligaments in an area of the foot called the plantar fascia (",
"     <a class=\"graphic graphic_figure graphicRef73704 \" href=\"mobipreview.htm?25/7/25713\">",
"      figure 1",
"     </a>",
"     ). The plantar fascia (pronounced FASH-uh) is a thick, pearly white tissue with long fibers that starts at the heel bone and that fans out along the under surface of the foot to the toes. The fascia provides support as the toes bear the body&rsquo;s weight when the heel rises during walking. Jumping or prolonged standing may strain the plantar fascia. The outcome for people with plantar fasciitis is generally good, with approximately 80 percent of people having no pain within one year.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PLANTAR FASCIITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptom of plantar fasciitis is pain beneath the heel and sole of the foot. The pain is often worst when stepping onto the foot, particularly when first getting out of bed in the morning or when getting up after being seated for some time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PLANTAR FASCIITIS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Plantar fasciitis is more likely to occur in a person whose lifestyle or occupation causes repetitive impact to the heel. Activities such as running, marching, or dancing may trigger or worsen symptoms. Possible other factors that increase the risk of plantar fasciitis include obesity, prolonged standing, and limited ankle flexibility.",
"    </p>",
"    <p>",
"     Plantar fasciitis occurs more frequently among runners, and, in this group, possible factors that increase the risk include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Excessive training (particularly a sudden increase in the distance run)",
"      </li>",
"      <li>",
"       Improper running shoes",
"      </li>",
"      <li>",
"       Running on unyielding surfaces",
"      </li>",
"      <li>",
"       Flat feet",
"      </li>",
"      <li>",
"       High arches",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, evidence of an association for many of these factors is limited or absent.",
"    </p>",
"    <p>",
"     Plantar fasciitis usually occurs in people without underlying medical problems, but it can be associated with other rheumatic disorders such as ankylosing spondylitis or psoriatic arthritis. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/38/19045?source=see_link\">",
"      \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/36/36419?source=see_link\">",
"      \"Patient information: Psoriatic arthritis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      PLANTAR FASCIITIS TESTS",
"     </span>",
"    </p>",
"    <p>",
"     To diagnose plantar fasciitis, a healthcare provider will take a medical history and will examine the feet to locate painful areas (",
"     <a class=\"graphic graphic_picture graphicRef72846 \" href=\"mobipreview.htm?19/41/20112\">",
"      picture 1",
"     </a>",
"     ). It is important to notify the provider if there are other areas of tenderness or pain not found during the examination.",
"    </p>",
"    <p>",
"     Depending upon the duration of symptoms, the severity of pain, and other individual factors, the provider may recommend x-rays to determine if another disorder, such as a fracture or infection, is causing the pain. If the symptoms and signs are typical, then no x-rays or other tests are required.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PLANTAR FASCIITIS TREATMENT",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Conservative treatment of plantar fasciitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Plantar fasciitis is usually treated conservatively. However, many commonly used treatments have not been proven to improve the symptoms of plantar fasciitis.",
"    </p>",
"    <p>",
"     Commonly used treatments for plantar fasciitis include the following:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Rest",
"     </span>",
"     &nbsp;&mdash;&nbsp;Limiting athletic activities and getting extra rest may help to reduce symptoms. Excessive and repetitive heel impact from jumping, walking, and using a trampoline should be avoided. A complete lack of physical activity, though, can lead to stiffening and to a return of pain and is not recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Icing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Applying ice to the area, for example, for 20 minutes up to four times daily, may relieve pain. Ice and massage may also be used before exercise.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Stretching",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stretching exercises may be helpful. Home exercises include the calf-plantar fascia stretch (",
"     <a class=\"graphic graphic_picture graphicRef82144 \" href=\"mobipreview.htm?11/28/11712\">",
"      picture 2",
"     </a>",
"     ),",
"     <span class=\"nowrap\">",
"      foot/ankle",
"     </span>",
"     circles (",
"     <a class=\"graphic graphic_picture graphicRef70569 \" href=\"mobipreview.htm?20/9/20627\">",
"      picture 3",
"     </a>",
"     ), toe curls (",
"     <a class=\"graphic graphic_picture graphicRef56422 \" href=\"mobipreview.htm?0/29/468\">",
"      picture 4",
"     </a>",
"     ), and toe towel curls (",
"     <a class=\"graphic graphic_picture graphicRef70243 \" href=\"mobipreview.htm?20/60/21442\">",
"      picture 5",
"     </a>",
"     ). Be sure to perform these exercises with care to avoid causing more pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Pain medication",
"     </span>",
"     &nbsp;&mdash;&nbsp;A clinician may recommend a short course of a nonsteroidal antiinflammatory drug (NSAID) such as ibuprofen or naproxen to relieve pain. However, these medications have many possible side effects, and it is important to weigh the potential risks and benefits. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Protective footwear",
"     </span>",
"     &nbsp;&mdash;&nbsp;Athletic shoes, arch-supporting shoes (particularly those with an extra-long counter, which is the firm part of the shoe that surrounds the heel), or shoes with rigid shanks (usually a metal insert in the sole of the shoe) may be helpful. Cushion-soled shoes with gel pad inserts or heel cups may provide temporary pain relief. Silicone inserts have been found to provide better support than felt pads or rubber heel cups. Magnetic insoles have not been found to provide any additional benefit.",
"    </p>",
"    <p>",
"     Splints may be helpful when worn overnight to position the foot and heel to provide pain relief and a gentle stretch. These splints can usually be purchased in pharmacies that carry orthopedic supplies.",
"    </p>",
"    <p>",
"     People who work or reside in buildings with concrete floors should use cushion-soled or crepe-soled shoes.",
"    </p>",
"    <p>",
"     Wearing slippers or going barefoot may cause symptoms to return, even if the floors are carpeted. Thus, the first step out of bed should be made with a supportive shoe or sandal on.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Tape support",
"     </span>",
"     &nbsp;&mdash;&nbsp;Taping the affected foot with a technique known as low-Dye taping may be beneficial for some people, particularly those with &ldquo;first step&rdquo; pain. Four strips of tape are applied as illustrated in the figure (",
"     <a class=\"graphic graphic_picture graphicRef53721 \" href=\"mobipreview.htm?15/9/15507\">",
"      picture 6",
"     </a>",
"     ). The tape should not be applied too tightly. Hypoallergenic tape may be recommended for people with allergic reactions to tape.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Other modes of plantar fasciitis treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;If these noninvasive measures fail to improve the pain, a healthcare provider may recommend one of the following treatments:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Steroid injection",
"     </span>",
"     &nbsp;&mdash;&nbsp;An injection of a steroid (glucocorticoid) medication may be given into the foot to relieve pain, although the effect may wear off after a few weeks (",
"     <a class=\"graphic graphic_picture graphicRef55689 \" href=\"mobipreview.htm?15/47/16127\">",
"      picture 7",
"     </a>",
"     ). The injection can be repeated, although many clinicians limit the number of times they will give injections because they believe repeated injections may weaken the tissues of the sole of the foot. However, this belief is unproven.",
"    </p>",
"    <p>",
"     The injection can be painful and has a very small risk of causing infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Casting",
"     </span>",
"     &nbsp;&mdash;&nbsp;Another option is a short walking cast, which begins at the calf and covers the ankle and foot up to the toes. This type of cast has a rocker-shaped bottom that allows you to continue walking while wearing it.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Shock wave therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some clinicians recommend shock wave therapy (the generation of sound waves that provide a burst of energy to the sole of the foot). The treatment is initially painful and has not been proven to be more effective than sham treatment (treatment with a low, nontherapeutic dose or pretend shock wave therapy).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery is rarely required for people with plantar fasciitis. It would only be recommended if all other treatments had failed and if the person had persistent symptoms for at least 6 to 12 months.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2519908579\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112840434\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/5/40018?source=see_link\">",
"      Patient information: Heel pain (caused by plantar fasciitis) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/37/8786?source=see_link\">",
"      Patient information: Metatarsalgia (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H112840449\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/38/19045?source=see_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/36/36419?source=see_link\">",
"      Patient information: Psoriatic arthritis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/6/28775?source=see_link\">",
"      Clinical features and management of heel pain in the young athlete",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14711?source=see_link\">",
"      Evaluation of foot and ankle pain in the young athlete",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/4/34890?source=see_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44681?source=see_link\">",
"      Plantar fasciitis and other causes of heel pain",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/57/9114?source=see_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Academy of Orthopedic Surgeons",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://orthoinfo.aaos.org/\">",
"        file://orthoinfo.aaos.org/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Podiatric Medical Association",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.apma.org/\">",
"        www.apma.org/",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/42/38561/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H95985258\">",
"     <span class=\"h1\">",
"      ACKNOWLEDGMENT",
"     </span>",
"    </p>",
"    <p>",
"     The editors of UpToDate, Inc. would like to acknowledge Robert P Sheon, MD, who contributed to earlier versions of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/42/38561?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38561/abstract/1\">",
"      Cole C, Seto C, Gazewood J. Plantar fasciitis: evidence-based review of diagnosis and therapy. Am Fam Physician 2005; 72:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38561/abstract/2\">",
"      Buchbinder R. Clinical practice. Plantar fasciitis. N Engl J Med 2004; 350:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38561/abstract/3\">",
"      Thomson CE, Crawford F, Murray GD. The effectiveness of extra corporeal shock wave therapy for plantar heel pain: a systematic review and meta-analysis. BMC Musculoskelet Disord 2005; 6:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38561/abstract/4\">",
"      Porter MD, Shadbolt B. Intralesional corticosteroid injection versus extracorporeal shock wave therapy for plantar fasciopathy. Clin J Sport Med 2005; 15:119.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f37_42_38561=[""].join("\n");
var outline_f37_42_38561=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PLANTAR FASCIITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PLANTAR FASCIITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PLANTAR FASCIITIS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           PLANTAR FASCIITIS TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PLANTAR FASCIITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H95985258\">",
"           ACKNOWLEDGMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/7/25713\" title=\"figure 1\">",
"           Plantar anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/41/20112\" title=\"picture 1\">",
"           Palpating plantar fascia PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/28/11712\" title=\"picture 2\">",
"           Calf stretch PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/9/20627\" title=\"picture 3\">",
"           Foot ankle circles PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/29/468\" title=\"picture 4\">",
"           Toe curls PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/60/21442\" title=\"picture 5\">",
"           Toe towel curls PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/9/15507\" title=\"picture 6\">",
"           Foot taping PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/47/16127\" title=\"picture 7\">",
"           Plantar fasciitis inject PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f37_42_38562="Clear cell carc MRI B";
var content_f37_42_38562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance images (MRI) of clear cell carcinoma of the kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal three-dimensional T1-weighted fat-saturated gradient echo image after administration of gadolinium obtained during the excretory phase confirms the presence of enhancement (compared to pre-contrast, not shown) within the mass. After nephrectomy, a low grade (Furhman nuclear grade 2) clear-cell renal cell carcinoma was confirmed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38562=[""].join("\n");
var outline_f37_42_38562=null;
var title_f37_42_38563="Myometrial and endometrial arteries";
var content_f37_42_38563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Stereographic representation of myometrial and endometrial arteries in the macaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Above are shown parts of myometrial arcuate arteries from which myometrial radial arteries course toward the endometrium. There are found larger endometrial coiled arteries and smaller endometrial basal arteries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Okkels and Engle. Acta Pathol Microbiol Scand 15:150, 1930. Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy; 1980 McGraw Hill. p.25.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38563=[""].join("\n");
var outline_f37_42_38563=null;
var title_f37_42_38564="Fish-hook removal techniques";
var content_f37_42_38564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fish-hook removal techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38564/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38564/contributors\">",
"     Joan Bothner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38564/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38564/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38564/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38564/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38564/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/42/38564/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fish-hooks may lodge in any body part, but the fingers and feet are most commonly involved. Most embedded fish-hooks can be removed in the emergency department. The choice of removal technique depends on the depth of penetration, body part affected, and type of fish-hook. This topic will discuss fish-hook removal techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any clinician may remove fish-hooks that are superficially embedded in the skin. Fish-hooks embedded in the eye, eyelid, or in vital structures should be removed by the appropriate surgical specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no absolute contraindications to fish-hook removal. Subspecialty consultation should be obtained for fish-hooks lodged in the eye, eyelid, or in vital structures (eg, carotid artery, radial artery, peritoneum, testicle, urethra) or when a hook is embedded very near to these structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38564/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial emergency management of penetrating injuries to the eye is found in the table (",
"    <a class=\"graphic graphic_table graphicRef50022 \" href=\"mobipreview.htm?16/28/16845\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=see_link\">",
"     \"Open globe injuries: Emergent evaluation and initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF FISH-HOOKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fish-hooks lodge in the dermis or subcutaneous layers of the skin. The most common type of hook has an eyelet at one end, a straight shank, and a curved belly that ends in a barbed point on the inner curve that points away from the hook's tip (",
"    <a class=\"graphic graphic_figure graphicRef52017 \" href=\"mobipreview.htm?11/47/12030\">",
"     figure 1",
"    </a>",
"    ). Because the barb is set into the tissue, the fish-hook cannot be pulled out by the shank without causing tissue damage unless the barb is somehow disengaged from the tissue.",
"   </p>",
"   <p>",
"    Fish-hooks without barbs are easy to back out with minimal tissue damage. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Back-out technique'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some commercial fish-hooks have prominences along the shank and may have multiple hooks with barbs. The approach to removal of multi-hooked fish-hooks involves the same techniques as described for single barbed fish-hooks. However, the multiple hooks should be clipped so that they are no longer connected to the main shank, yet retain adequate individual shank length to permit individual removal of each hook. Removal of multi-hooked fish-hooks tends to be associated with greater tissue trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preparation for fish-hook removal involves assessment of the type of fish-hook that is embedded, the circumstances of the injury, the depth of the fish-hook barb, and the potential for injury to the eye or other vital structures. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Key interventions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Wound preparation",
"      </strong>",
"      &ndash; While stabilizing the lodged hook with a hemostat, fishing line, lures, weights, and any other material attached to the embedded hook should be removed using scissors or wire cutters or by disassembling them. The surrounding skin should then be cleansed with betadine.",
"     </li>",
"     <li>",
"      <strong>",
"       Pain control",
"      </strong>",
"      &ndash; When indicated, local or regional infiltrative anesthesia suffices for most cooperative patients. A digital block is often necessary for hooks deeply seated in the fingers or toes. Occasionally, young children may warrant procedural sedation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=see_link\">",
"       \"Digital nerve block\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=see_link\">",
"       \"Procedural sedation in children outside of the operating room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Tetanus prophylaxis",
"      </strong>",
"      &ndash; Tetanus status should be verified and prophylaxis given when indicated (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques for removing fish-hooks have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38564/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The choice of technique varies depending upon the type of hook, the depth of the entrapped point, and the body part involved. All share the same objective; to disengage the barb of the hook so that atraumatic removal is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four most commonly used techniques include the back-out method, the push-through method, the string technique, and the needle technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Back-out technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The back-out method is the easiest method of removal. However, it can only be used with barbless hooks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the skin and hook are prepped with betadine solution, the shank of the hook is grasped with a hemostat and backed out of the wound.",
"     </li>",
"     <li>",
"      Infiltration of local anesthesia may or may not be necessary depending upon the patient's ability to cooperate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38564/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Push-through technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The push-through technique causes minimal additional soft tissue trauma and is most effective when the point of the hook is near the surface of the skin (",
"    <a class=\"graphic graphic_figure graphicRef66718 \" href=\"mobipreview.htm?18/4/18497\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To avoid inadvertent injury from the barb, the patient, clinician, and other care providers in the room should wear protective eye gear.",
"     </li>",
"     <li>",
"      The skin overlying the point of the hook should be anesthetized, when indicated, either by local infiltration with 1 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or by digital block.",
"     </li>",
"     <li>",
"      After anesthesia is obtained, the shank of the hook is grasped with a hemostat or gloved finger and thumb, and the hook is advanced into the wound until the barb reemerges from the skin.",
"     </li>",
"     <li>",
"      The barb is cut off with a wire cutter and the remainder of the hook is then backed out of the wound.",
"     </li>",
"     <li>",
"      The resultant exit wound is small and does not require suturing or definitive repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38564/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     String technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The string technique can be used in the field for single barbed hooks and has been employed by fishermen for many years with excellent success. This technique can only be used when the fish-hook is embedded in a body part that can be firmly secured so that it does not move during the procedure. Because the technique is rapid and causes little additional trauma, it can often be performed without local anesthesia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To avoid inadvertent injury, the patient, clinician, and other care providers in the room should wear protective eye gear.",
"     </li>",
"     <li>",
"      A piece of string or large (3-0) silk suture is looped around the belly of the fish-hook (",
"      <a class=\"graphic graphic_figure graphicRef79538 \" href=\"mobipreview.htm?39/25/40351\">",
"       figure 3",
"      </a>",
"      ); the ends of the string should be wrapped securely around the clinician's index finger.",
"     </li>",
"     <li>",
"      The hook's belly should be directly in front of the clinician with the shank pointing in the opposite direction.",
"     </li>",
"     <li>",
"      The shank and eye of the fish-hook should be firmly depressed with the clinician's other hand; this force will help to disengage the barb from the surrounding tissue.",
"     </li>",
"     <li>",
"      The string is pulled slowly until it is taut in the plane of the long axis of the hook; when it is taut, it is jerked quickly and firmly in the same direction, which pulls the hook out of the skin (",
"      <a class=\"graphic graphic_figure graphicRef79538 \" href=\"mobipreview.htm?39/25/40351\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The freed hook should be examined to ensure that the barb of the hook is present and not broken off within the wound.",
"     </li>",
"     <li>",
"      Failure of this technique is most often due to a less than sudden and forceful jerking on the string [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38564/abstract/4-6\">",
"       4-6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Needle technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The needle technique uses a needle to cover the barb, permitting the hook to be backed out of the entry wound. This technique is most effective when the hook is superficially embedded and works best with larger hooks. Although presented here, the needle technique may be difficult to perform successfully and may be best reserved for patients in whom the string or push-through technique has failed. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Push-through technique'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'String technique'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The areas alongside the hook and at the entrance wound should be anesthetized, either by local infiltration with 1 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      or by digital block. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=see_link\">",
"       \"Digital nerve block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An 18- or 20-gauge needle is inserted through the wound along the shaft of the hook. The needle is advanced along the hook's belly, with the bevel of the needle facing the inside of the curve of the hook, until the needle opening slides over the barb.",
"     </li>",
"     <li>",
"      Once the barb is engaged, the needle and the hook are held firmly together and backed out of the wound as a unit (",
"      <a class=\"graphic graphic_figure graphicRef64418 \" href=\"mobipreview.htm?26/28/27073\">",
"       figure 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38564/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSTPROCEDURAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications, including infection, after fish-hook removal are rare. The wound should be thoroughly irrigated with normal saline and covered with antibiotic ointment after the procedure is completed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38564/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Empiric antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No trials have addressed antibiotic therapy for fish-hook injuries. Although most superficial fish-hook wounds heal well without sequelae, we suggest that the occasional patient who has a fish-hook that is deeply embedded in an infection-prone area (eg, fingertip, ear cartilage) receive empiric antibiotics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fish-hook wound infections are commonly caused by Staphylococcus aureus and Streptococcus pyogenes originating from the patient's skin flora that is introduced into the wound during the injury. Empiric antibiotic therapy for these organisms is the same as for the treatment of uncomplicated cellulitis (",
"      <a class=\"graphic graphic_table graphicRef64128 \" href=\"mobipreview.htm?23/12/23756\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the hook was contaminated (eg, exposed to river, lake, pond, or sea water), then empiric antibiotic coverage may be warranted for other bacterial pathogens, including Aeromonas, Edwardsiella tarda, Erysipelothrix rhusiopathiae, Vibrio vulnificus, and Mycobacterium marinum. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31687?source=see_link&amp;anchor=H12#H12\">",
"       \"Soft tissue infections following water exposure\", section on 'Empiric antibiotic treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated superficial fish-hook injuries who do not receive empiric antibiotic therapy should be told to soak the wound in warm water two to three times per day until healing is established and advised to return if any signs of infection appear.",
"   </p>",
"   <p>",
"    Patients with deeply embedded or contaminated fish-hooks who receive empiric antibiotic therapy should be scheduled for a follow-up evaluation in two to three days to assess for signs of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any clinician may remove fish-hooks that are superficially embedded in the skin. Fish-hooks embedded in the eye, eyelid, or in vital structures should be removed by the appropriate surgical specialist. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common type of hook has an eyelet at one end, a straight shank, and a curved belly that ends in a barbed point on the inner curve that points away from the hook's tip (",
"      <a class=\"graphic graphic_figure graphicRef52017 \" href=\"mobipreview.htm?11/47/12030\">",
"       figure 1",
"      </a>",
"      ). Because the barb is set into the tissue, the fish-hook cannot be pulled out by the shank unless the barb is somehow disengaged from the tissue. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Types of fish-hooks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to removal, the clinician should assess the circumstances of the injury, the depth of the fish-hook barb, the type of barb, and the potential for injury to the eye or other vital structures. Key interventions include removal of fishing line, lures, weights, and any other material attached to the embedded hook, pain control, and provision of tetanus prophylaxis, as needed (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although most superficial fish-hook wounds heal well without sequelae, we suggest that patients with fish-hooks that are deeply embedded in an infection-prone area (eg, fingertip, ear cartilage) receive empiric antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Empiric antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several techniques for removing fish-hooks have been described. The choice of technique varies depending upon the type of hook, the depth of the entrapped point, and the body part involved. All share the same objective: to disengage the barb of the hook so that atraumatic removal is possible. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The back-out technique is appropriate for barbless fish-hooks. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Back-out technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The push-through technique is most effective when the point is near the skin surface (",
"      <a class=\"graphic graphic_figure graphicRef66718 \" href=\"mobipreview.htm?18/4/18497\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Push-through technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The string technique can be used in the field for single barbed hooks with excellent success. This technique can only be used when the fish-hook is embedded in a body part that can be firmly secured so that it does not move during the procedure (",
"      <a class=\"graphic graphic_figure graphicRef79538 \" href=\"mobipreview.htm?39/25/40351\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'String technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The needle technique may be difficult to perform successfully and may be best reserved for patients in whom the string or push-through technique has failed (",
"      <a class=\"graphic graphic_figure graphicRef64418 \" href=\"mobipreview.htm?26/28/27073\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Needle technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38564/abstract/1\">",
"      Aiello LP, Iwamoto M, Guyer DR. Penetrating ocular fish-hook injuries. Surgical management and long-term visual outcome. Ophthalmology 1992; 99:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38564/abstract/2\">",
"      Malitz DI. Fish-hook injuries. Ophthalmology 1993; 100:3.",
"     </a>",
"    </li>",
"    <li>",
"     Su, E. Removal of a barbed fishhook. In: Illustrated Textbook of Pediatric Emergency and Critical Care Procedures, Diekema, RA, Fiser, DH, Selbst, SM (Eds), Mosby, St. Louis 1997. p.727.",
"    </li>",
"    <li>",
"     Diekema, DS. Fishhook removal. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King, C, Henretig, FM (Eds), Lippincott, Williams and Wilkins, Baltimore 2008. p.1102.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38564/abstract/5\">",
"      Friedenberg S. How to remove an imbedded fishook in five seconds without really tryping. N Engl J Med 1971; 284:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38564/abstract/6\">",
"      David SS. Fish-hook removal. Lancet 1991; 338:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38564/abstract/7\">",
"      Doser C, Cooper WL, Ediger WM, et al. Fishhook injuries: a prospective evaluation. Am J Emerg Med 1991; 9:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6323 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38564=[""].join("\n");
var outline_f37_42_38564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF FISH-HOOKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Back-out technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Push-through technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - String technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Needle technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSTPROCEDURAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Empiric antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6323|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/47/12030\" title=\"figure 1\">",
"      Fish-hook structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/4/18497\" title=\"figure 2\">",
"      Push through method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/25/40351\" title=\"figure 3\">",
"      String technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/28/27073\" title=\"figure 4\">",
"      Needle technique for fish-hook removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/28/16845\" title=\"table 1\">",
"      Open globe rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/52/8013\" title=\"table 2\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/12/23756\" title=\"table 3\">",
"      Empiric antibiotics cellulitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_42_38565="Prostate cancer glands light";
var content_f37_42_38565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prostate adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of an hematoxylin and eosin-stained sample of prostate cancer, demonstrating that the malignant glandular structures of the adenocarcinoma (arrows) are smaller in size than the benign glandular structures (arrowheads).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ximing Yang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38565=[""].join("\n");
var outline_f37_42_38565=null;
var title_f37_42_38566="Malignancy in dermatomyositis and polymyositis";
var content_f37_42_38566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Malignancy in dermatomyositis and polymyositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38566/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38566/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38566/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38566/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38566/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38566/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38566/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/42/38566/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatomyositis (DM) and polymyositis (PM) are two distinct forms of inflammatory myopathy. The hallmark of these disorders is muscle weakness. However, a variety of other disease manifestations are also characteristic of these conditions, even though not all features are found in every patient. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin findings such as Gottron's sign and heliotrope rash (DM only)",
"     </li>",
"     <li>",
"      Interstitial lung disease",
"     </li>",
"     <li>",
"      Raynaud phenomenon",
"     </li>",
"     <li>",
"      Inflammatory arthritis",
"     </li>",
"     <li>",
"      Serum autoantibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, both DM and PM are associated with malignancies in a significant minority of cases. The close relationship between inflammatory myopathy and cancer is consistent with the concept that paraneoplastic processes linked to oncogenesis and autoimmunity contribute to the disease in a subset of DM and PM cases.",
"   </p>",
"   <p>",
"    Issues related to malignancy in patients with DM and PM will be reviewed here. The clinical manifestations, diagnosis, and management of both the adult and juvenile forms of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise links between malignancy and inflammatory myopathy remain incompletely understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, the temporal relationship in some patients between the development of cancer and diagnosis of inflammatory myopathy is reminiscent of that seen in neurologic paraneoplastic disorders in which the antigens targeted for an immune response are expressed at high levels in both the inciting tumor and the affected neuronal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regenerating cells in myositis muscle but not in normal muscle express high levels of myositis-specific autoantigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/1\">",
"     1",
"    </a>",
"    ]. These same antigens are expressed at high levels in several cancers known to be associated with the development of inflammatory myopathy but not in corresponding normal tissue. These observations suggest that the link between malignancy and inflammatory myopathy relates to the expression of common autoantigens between cancer tissue and muscle tissue in some patients with DM or PM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE OF MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between malignancy and inflammatory myopathy was suspected as early as 1916, when the simultaneous occurrences of PM and gastric carcinoma were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/5\">",
"     5",
"    </a>",
"    ]. A review of 258 cases of DM and cancer reported in the literature through the mid-1970s estimated that the incidence of cancer for patients with DM was increased fivefold to sevenfold compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/6\">",
"     6",
"    </a>",
"    ]. The increased risk has subsequently been confirmed in population-based studies from a variety of countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Population-based studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Investigations from Sweden, Australia, and Scotland have confirmed the increased risk of malignancy among patients with inflammatory myopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study from Sweden investigated the incidence of cancer and the rate of mortality from cancer in a population-based cohort of 788 patients diagnosed with either DM or PM between 1963 and 1983 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/7\">",
"     7",
"    </a>",
"    ]. The data among DM and PM patients were compared with those of the general Swedish population using the well-organized, comprehensive national Swedish disease registry. The investigators concluded that both DM and PM were associated with an increased risk of malignancy, with the relative risk being somewhat higher among those with DM. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 392 patients with DM, 59 (15 percent) had cancer diagnosed either at the same time as or after their DM diagnosis. The relative risk of cancer among patients with DM was 2.4 (95% CI 1.6-3.6) for males and 3.4 (95% CI 2.4-4.7) for females.",
"     </li>",
"     <li>",
"      Among the 396 patients with PM, 37 patients (9 percent) had cancer diagnosed either at the same time or after their PM diagnosis. The relative risk of cancer among patients with PM was 1.8 (95% CI 1.1-2.7) for males and 1.7 (95% CI 1.0-2.5) for females.",
"     </li>",
"     <li>",
"      DM but not PM was associated with an increased risk of cancer mortality compared with the general population. Among the DM patients, 57 male patients and 110 female patients died. Sixty-seven (40 percent) of the deaths were caused by cancer. Compared with the general population, the mortality ratio due to cancer among patients with DM was 3.8 (95% CI 2.9-4.8).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A population-based, retrospective cohort study from Australia confirmed these findings in 537 patients with biopsy-proven DM or PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/8\">",
"     8",
"    </a>",
"    ]. The study included 85 patients with DM and 321 with PM, as well as 52 with inclusion body myositis, 30 with myositis associated with a connective tissue disease, and 49 with childhood DM. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standardized incidence ratios (SIRs) were calculated to compare the incidence of malignant disease in patients with inflammatory myopathy and the general population. A SIR is defined in the following manner:",
"   </p>",
"   <p>",
"    &nbsp;SIR = (Observed cases of malignancy &divide; Expected cases) x 100",
"   </p>",
"   <p>",
"    The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A total of 116 malignancies were found in 104 patients. Ninety-four of these cancers (81 percent) occurred in patients with DM or PM.",
"     </li>",
"     <li>",
"      The relative risk for malignancy in DM compared with PM was 2.4 (95% CI 1.3-4.2). DM was also associated with a higher SIR than PM (6.2 versus 2.0).",
"     </li>",
"     <li>",
"      SIRs were also increased for inclusion body myositis (2.4, 95% CI 1.2-4.9), myositis associated with connective tissue diseases (4.6, 95% CI 1.2-11.7), and childhood DM (29.0, 95% CI 3.5-105). The findings in childhood DM reflected only two malignancies, and an increase in malignancy risk was not noted in another population-based cohort study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link\">",
"       \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The excess risk for a cancer diagnosis decreased with time from the diagnosis of myopathy: SIR 4.4 in the first year, 3.4 between one and three years, 2.2 between three and five years, and 1.6 beyond five years. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Repeat cancer screening'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TEMPORAL RELATIONSHIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer can be diagnosed before, simultaneously with, or after the diagnosis of inflammatory myopathy. The peak incidence of malignancy diagnosis occurs within the two years on either side of the inflammatory myopathy diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/7,8,10-12\">",
"     7,8,10-12",
"    </a>",
"    ]. In the Australian study, for example, 36 percent of the cancers were identified within seven days before the diagnosis of inflammatory myopathy or after the diagnosis. The remaining cases preceded the diagnosis of myopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, the inflammatory myopathy is diagnosed at the time of recurrence of previously diagnosed cancer. In others, previously-diagnosed muscle disease becomes reactivated when the cancer appears [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most studies have concluded that the risk of cancer is greater in patients with DM than in those with PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/7,8,15\">",
"     7,8,15",
"    </a>",
"    ]. Other risk factors noted in individual studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evidence of capillary damage on muscle biopsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      DM complicated by cutaneous necrosis on the trunk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cutaneous leukocytoclastic vasculitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Older age (greater than 65 years) at diagnosis of DM or PM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one report, 11 of 23 patients (48 percent) with DM or PM older than 65 years of age were found to have a malignancy, compared with 9 percent of 56 patients younger than 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/19\">",
"     19",
"    </a>",
"    ]. Ten of the 11 malignancies in the older group occurred in patients with DM rather than PM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Serum autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Cancer-associated myositis\" (CAM) in adults has been associated in several studies with an autoantibody",
"    <span class=\"nowrap\">",
"     (anti-155/140,",
"    </span>",
"    <span class=\"nowrap\">",
"     anti-p155/140,",
"    </span>",
"    or anti-p155). This antibody also has an association with DM in general, including juvenile DM, but the frequency of the autoantibody in the malignancy subgroup seems to be higher than in other adults with DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. More study is required to determine the utility of this antibody for cancer screening in patients with myositis.",
"   </p>",
"   <p>",
"    Additionally, an increased risk of CAM was found in one study in patients who lacked evidence of",
"    <span class=\"nowrap\">",
"     myositis-specific/associated",
"    </span>",
"    autoantibodies on &ldquo;routine&rdquo; laboratory testing; such testing included assays for anti-Jo-1, anti-PM-Scl, anti-U1-RNP, anti-U3-RNP, and anti-Ku antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TYPES OF CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenocarcinomas of the cervix, lung, ovaries, pancreas, bladder, and stomach account for approximately 70 percent of the cancers associated with inflammatory myopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/6,7,9,24-26\">",
"     6,7,9,24-26",
"    </a>",
"    ]. Several studies suggest that the risk of ovarian cancer may be particularly increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/7,27\">",
"     7,27",
"    </a>",
"    ]. In some populations, the types of malignancy associated with DM or PM reflect cancers found in particularly high prevalence within that population. As an example, Southeast Asian patients with DM are at increased risk of nasopharyngeal carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TUMOR MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor markers may provide a clue to the presence of an underlying malignancy in patients with DM or PM. This issue was addressed in a study of 102 patients with newly-diagnosed DM or PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients underwent extensive cancer screening at baseline, including computed tomography scans of the chest, abdomen, and pelvis; upper and lower endoscopy; and a serum tumor marker panel that included CA125, CA19-9, and carcinoembryonic antigen (CEA). Patients were followed for a mean of five years. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten patients developed a solid malignancy.",
"     </li>",
"     <li>",
"      The odds ratio for developing a solid malignancy was 30 (95% CI 8-107) with an elevated CA125 at baseline and 4.5 (95% CI 1-19) with an elevated CA19-9 at baseline.",
"     </li>",
"     <li>",
"      Four patients had abnormal CEA levels. None of those patients developed malignancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INFLAMMATORY MYOPATHY PHENOTYPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a tumor does not appear to affect the severity or distribution of weakness, the duration of weakness prior to diagnosis, the height of creatine kinase elevation, or the incidence of some extramuscular disease manifestations (eg, interstitial lung disease). However, patients with tumor-associated DM or PM are less likely to have myositis-specific autoantibodies such as antisynthetase antibodies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases, the inflammatory myopathy responds to successful therapy of the underlying malignancy. There may also be an association between the onset or relapse of inflammatory myopathy and the presence of malignancy. Thus, the development of any new sign or symptom not readily explained by the inflammatory myopathy should raise the possibility of a malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SCREENING FOR CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The investigation of inflammatory myopathy patients for an underlying malignancy should be guided by three principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Findings obtained by a thorough medical history, physical examination, and laboratory testing are often essential in making the diagnosis of cancer.",
"     </li>",
"     <li>",
"      Age-appropriate cancer screening tests (eg, mammography and colonoscopy) are a valuable part of the work-up of a patient with DM or PM. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of preventive medicine in adults\", section on 'Cancer morbidity and mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limited additional testing, such as computed tomographic scans of the chest, abdomen, and pelvis, is recommended for patients with significantly increased risk of malignancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All adult patients with a new diagnosis of DM or PM should undergo a complete physical examination with breast, rectal, and pelvic examinations. In addition, laboratory studies, radiologic studies, and other testing are appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests should include the following tests, if appropriate to the patient's age and gender:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate and serum C-reactive protein",
"     </li>",
"     <li>",
"      Serum chemistry panel",
"     </li>",
"     <li>",
"      Urinalysis with microscopic examination for blood",
"     </li>",
"     <li>",
"      Serum CA125 and CA19-9",
"     </li>",
"     <li>",
"      Serum prostate-specific antigen",
"     </li>",
"     <li>",
"      Stools for occult blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Imaging evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiological evaluation should include chest x-ray and, in selected high-risk patients, computed tomography (CT) scans of the chest, abdomen, and pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/24,30,31\">",
"     24,30,31",
"    </a>",
"    ]. In addition, some experts recommend pelvic ultrasonography and transvaginal ultrasound for women with DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Screening for cancer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Positron emission tomography (PET), using [18F] fluorodeoxyglucose (FDG) and combined with computerized tomography",
"    <span class=\"nowrap\">",
"     (FDG-PET/CT),",
"    </span>",
"    is a highly sensitive imaging technique that has been used increasingly for the detection of malignancy, but only limited studies have examined its role in screening for malignancy in patients with DM and PM. In a prospective three-year study of 55 patients diagnosed with myositis, both",
"    <span class=\"nowrap\">",
"     FDG-PET/CT",
"    </span>",
"    and conventional screening (thoracoabdominal CT, mammography, gynecologic examination, ultrasonography, and tumor marker analysis), which were performed within six months of initial diagnosis of myositis, were comparably effective for the detection of occult malignancy (sensitivity of 67 and 78 percent and specificity of 98 and 96 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/33\">",
"     33",
"    </a>",
"    ]. Additional study is needed to establish the optimal malignancy screening algorithm for DM and PM. Further study is required to determine whether",
"    <span class=\"nowrap\">",
"     FDG-PET/CT",
"    </span>",
"    has a role in screening strategies in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Repeat cancer screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of annual reevaluation for underlying malignancy was assessed indirectly by a study from the Danish Cancer Registry that evaluated 539 patients with DM or PM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/27\">",
"     27",
"    </a>",
"    ]. The excess cancer incidence declined steadily with time following the initial diagnosis of inflammatory myopathy. The cancer risk was increased sixfold (SIR 5.9, 95% CI 3.8 to 8.7) during the first year but was lower during the second year (SIR 2.5, 95% CI 1.1-4.8). There was no significant excess in cancer incidence in subsequent years of follow-up.",
"   </p>",
"   <p>",
"    Similar findings were noted in the Australian population-based cohort study cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/8\">",
"     8",
"    </a>",
"    ]. The excess risk for a cancer diagnosis decreased with time from the diagnosis of myopathy: SIR 4.4 in the first year, 3.4 between one and three years, 2.2 between three and five years, and 1.6 beyond five years",
"   </p>",
"   <p>",
"    These findings indicate that, among patients with DM or PM who are several years beyond their diagnosis, there is little evidence to warrant extensive preventive and screening measures beyond those recommended for the general population. It seems reasonable to continue surveillance for two to three years after the diagnosis of inflammatory myopathy. Continued annual evaluations after that period are unlikely to be useful unless specific signs suggestive of an underlying malignancy appear or a relapse of the inflammatory myopathy occurs after a period of remission.",
"   </p>",
"   <p>",
"    The one exception to this guideline is ovarian carcinoma, which can occur even five years after the presentation of DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/26\">",
"     26",
"    </a>",
"    ]. As a result, some experts recommend screening female DM patients with a serum CA125 determination at least twice yearly and the performance of annual pelvic and transvaginal ultrasound for up to five years after the diagnosis of DM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38566/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both DM and PM are associated with malignancies in a significant minority of cases. The close relationship between inflammatory myopathy and cancer is consistent with the concept that paraneoplastic processes linked to oncogenesis and autoimmunity contribute to the disease in a subset of DM and PM cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Population-based cohort studies from a number of countries have confirmed the increased risk of malignancy among patients with inflammatory myopathies. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Population-based studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The relative risk of malignancy appears to be somewhat higher among patients with DM than among those with PM. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Population-based studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cancer can be diagnosed before, simultaneously with, or after the diagnosis of inflammatory myopathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Temporal relationship'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adenocarcinomas of the cervix, lung, ovaries, pancreas, bladder, and stomach account for approximately 70 percent of the cancers associated with inflammatory myopathies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Types of cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cancer screening in patients with inflammatory myopathy is guided by three principles (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Screening for cancer'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Findings obtained by a thorough medical history, physical examination, and laboratory testing are often essential in making the diagnosis of cancer.",
"     </li>",
"     <li>",
"      Age-appropriate cancer screening tests (eg, mammography and colonoscopy) are a valuable part of the work-up of a patient with DM or PM. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=see_link&amp;anchor=H9#H9\">",
"       \"Overview of preventive medicine in adults\", section on 'Cancer morbidity and mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Limited additional testing, such as computed tomographic scans of the chest, abdomen, and pelvis, is recommended for patients with significantly increased risk of malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/1\">",
"      Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/2\">",
"      Levine SM. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 2006; 18:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/3\">",
"      Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/4\">",
"      Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 2004; 4:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/5\">",
"      Stertz O. Polymyositis. Berl Klin Wochenschr 1916; 53:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/6\">",
"      Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 1976; 84:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/7\">",
"      Sigurgeirsson B, Lindel&ouml;f B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/8\">",
"      Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/9\">",
"      Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001; 85:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/10\">",
"      Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd. Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 1986; 61:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/11\">",
"      Manchul LA, Jin A, Pritchard KI, et al. The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. Arch Intern Med 1985; 145:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/12\">",
"      Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/13\">",
"      Callen JP. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol 1982; 6:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/14\">",
"      Cox NH, Lawrence CM, Langtry JA, Ive FA. Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy. Arch Dermatol 1990; 126:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/15\">",
"      Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994; 21:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/16\">",
"      Urbano-M&aacute;rquez A, Casademont J, Grau JM. Polymyositis/dermatomyositis: the current position. Ann Rheum Dis 1991; 50:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/17\">",
"      Basset-Seguin N, Roujeau JC, Gherardi R, et al. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol 1990; 126:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/18\">",
"      Hunger RE, D&uuml;rr C, Brand CU. Cutaneous leukocytoclastic vasculitis in dermatomyositis suggests malignancy. Dermatology 2001; 202:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/19\">",
"      Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999; 78:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/20\">",
"      Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/21\">",
"      Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54:3682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/22\">",
"      Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/23\">",
"      Trallero-Aragu&aacute;s E, Labrador-Horrillo M, Selva-O'Callaghan A, et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/24\">",
"      Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/25\">",
"      Bivalacqua TJ, Alphs H, Aksentijevich I, et al. Paraneoplastic polyarthritis from non-small-cell lung cancer metastatic to the bladder. J Clin Oncol 2007; 25:2621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/26\">",
"      Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore) 1994; 73:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/27\">",
"      Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/28\">",
"      Ang P, Sugeng MW, Chua SH. Classical and amyopathic dermatomyositis seen at the National Skin Centre of Singapore: a 3-year retrospective review of their clinical characteristics and association with malignancy. Ann Acad Med Singapore 2000; 29:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/29\">",
"      Amoura Z, Duhaut P, Huong DL, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 2005; 14:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/30\">",
"      Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 1996; 34:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/31\">",
"      Sparsa A, Liozon E, Herrmann F, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol 2002; 138:885.",
"     </a>",
"    </li>",
"    <li>",
"     Provost TT, Flynn JA. Dermatomyositis. In: Cutaneous Medicine, Provost TT, Flynn JA (Eds), B.C. Decker Inc, Hamilton 2001. p.82.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38566/abstract/33\">",
"      Selva-O'Callaghan A, Grau JM, G&aacute;mez-Cenzano C, et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 2010; 123:558.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5162 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38566=[""].join("\n");
var outline_f37_42_38566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE OF MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Population-based studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TEMPORAL RELATIONSHIP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Serum autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TYPES OF CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TUMOR MARKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INFLAMMATORY MYOPATHY PHENOTYPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SCREENING FOR CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Imaging evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Repeat cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_42_38567="Insertion of Nexplanon";
var content_f37_42_38567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Insertion of Nexplanon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 681px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAKpAiUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorn/HWqX2keHxcaU1st7Le2dpG9zE0saefdRQliqspbAkJxuHIHNVPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjj/AKGHw3/4IZ//AJMoA6uiuU+xeOP+hh8N/wDghn/+TKPsXjf/AKGHw3/4IZ//AJMoA6uiuT+x+N84/wCEh8N/+CGf/wCTKX7F44/6GHw3/wCCGf8A+TKAOrorlPsXjj/oYfDf/ghn/wDkyj7F44/6GHw3/wCCGf8A+TKAOrorlPsXjj/oYfDf/ghn/wDkyj7F44/6GHw3/wCCGf8A+TKAOrorlPsXjj/oYfDf/ghn/wDkyj7F44/6GHw3/wCCGf8A+TKAOrorlPsXjj/oYfDf/ghn/wDkyj7F44/6GHw3/wCCGf8A+TKAOrorlPsXjj/oYfDf/ghn/wDkyj7F44/6GHw3/wCCGf8A+TKAOrorlPsXjj/oYfDf/ghn/wDkyj7F44/6GHw3/wCCGf8A+TKAOrorlPsXjj/oYfDf/ghn/wDkyrfgXVL7V/D5uNVa2a9ivby0ke2iaKN/IupYQwVmYrkRg43HknmgDoKKKKACiis/Wdc0nQ44pNa1Sx06OVtkbXdwkIdvQFiMn2oA0KKAcjI6V5f4Z+Kc17ZaFqHiDRrfS9L1q1nurWeC+a6ZPKjMjrInlIR8isQV3dMdxQB6hRWDqXi/Q9MtnuL2+8qFLBtTZvKdsWykAvwp/vDjrz0qvaeO/Dl1aajcjUGhg0+Fbi5a6t5bfbE2dsgEiqXRtpwy5BxwTQB01Fef6j8U9GttS0a1t7XVrgX9xJBLjS7tZYAsDShvJ8ne27aAAAOCzDIRsdKvinR2tpbj7Uwiivo9NctDIpW4kZFSMgrnlpEGegzyRg4ANuiuSb4ieGVOo7r6cRafLJBdTGyn8mOVH8tozJs2F93AUElsjAORWx4f8Qab4giuH0yaVmtpPKningkglibAOHjkVXXIIIyOQeKANWivMtW+KUcWj+JZ7SxuYLnRr0Wxe6s7jyHQSxIzmTYqhsSHCbieAeRXSx+PfDjabf3z30sMFi6RzrcWk0Mqs+PLAjdA7bsjbtB3ds0AdRRWX4f1/TvEFtPNpc0jiCUwTRywyQSRSAAlXjkVWU4IOCBwQaxrnx5orXF7Y2NzJLqEK3Cx7rSYQPLCpLoJtojZl2nKhsjB9KAOtorhR48sj4TjurnUrWy1RdKg1K6b7HLcQ2wkVTllQg8knC7wxHPIBrRn8feHINZm0uW+lF3Bcx2cxFnMYopn27EeUJsXdvUDLAEnA5BoA6miqWqapZ6WLU383ki6uEtYiVJDSvwq8DjJ4yeKxP8AhONAubZjZarEZGuLmyjfyJHUTwIzSAqACQoQnOQDwAeRkA6iivObT4l29xd6hp8MFxcz22lW2oQ30Wn3P2e4M0UjgkbCIkwikFn53Fc7katbwD460zxXZWEcczDVZbCO8liNrNCjAhQ7RM6gOoc7cqWxxk0AdhRXK3XjO2tfHq+GJbK+MjWsdwtxFaTypueQoFYrGVVRjJcsFHQ4xWT8NviTpvijQNHkv7hbfVrqx+1yp9mmhgJUDzfLkcbWClhkBmI70AegUVz/AId8Y6H4iumttKu5ZJhF9oVZbaWDzYs48yPzFXzEzgblyORzyKz73xxbW3ji88MyWt4ksNjFdLeLZzzRhpGkGG2ptVQIwd5YAklcgqaAOworh0+JXhy0sLFr/VHuZptOi1NpbPTLkobd92JyoVzGmUb7zfLxk8jPawTR3EEc0EiyQyKHR0OQykZBB7jFAD6KKKACiiigDlfiX/yLln/2GdJ/9ONvXU1y3xL/AORctP8AsM6T/wCnG3rqaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACg0UUAJ/FjFLSHO4ccUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFJkUtABXLfDT/AJFy8/7DOrf+nG4rqa5b4af8i5ef9hnVv/TjcUAdVRRRQAVwvxS+F+g/EqHTU8QSX0RsHdoWtJVQkPt3KdysCDtXtnjrXdUUARWlvHaWsNtAu2GFFjRc5woGAPyrzTwZ8KbXR/AcOm37ebr39ly6c12bqa5ig8xSGMKSHCA8ZCqucV6VeXEdpaT3M5KxQo0jkDOFAya8xvviNrDeHPth0KGwGqaTcahpExvvMJ2ReYFmXy8RuUO8AFxwQSKAKuq+BfFmuaTqFrqP9hWzv4ck0W38i5lkDSMUPmOTEu1Ts6AEj/ara8e+BL7xLqesXFvd21ulzplrbwGQMxE8F01wu9cfcJ2g4OevHrd8Fw6ppvw2NxMpfVXtTcqbjVZ70SOYgVYySplASASiqVXJwDmuQ0zxN4yvNP8AhnezWtpPfalCZGjj1Jo47tWs9/mT4hAQgndsVXAPTNAHTarpPjHVLvRNVmtfD8d/pF8Z4bNL2YxSo9vJC+6Yw5DZkyAIyOMEnrVC78IeJ3vLm2g/sb+y7rX7XXJJnuJfOQRyQO8ITy9pOYjhywzwCq5yIrv4uwQWmlo9rpdnqt39rE0Wp6slpbwG3mMLjzyh3kuPlATkZJ24NdlofiqDWfAsXia0gYQyWj3IhZweVByu4ZB5UjI69aAOavPAN5deDr/S5biIXTa9NrNuYriWJWBu2nRGkTDoSpwWXJU8jOOdnwB4dudEfVLi+tILa4vHjJ2ardai7BFwC81wAe/ACgAetc/B8UZ7PTlv/E2hJp1pPosmtW32e9+0O8aGMNGw2IFY+amOSDnkgjFUo/jTp8Nhqst9FpLzWlvDPGNN1mK7hcyyCJY5JdqiJgzLuzlQuWBIFAGjqXg/X57bxRpkP9ltp+qaimpQXL3EiyoweAtG0YjIxiJ8MH9BtHJB4u8AX2t61rOoRTwgTSadPaxi6mt2ZrYy71eSMbowwk4ZdxB5wcYMGlfFddUlk07T7LTL/XDeRWkEen6sLi0k8yOSXebgRgqFWGXcPLJBUYB3CsiDxBq8Wt6NJq91Laj/AISe+iuoIrt5YhEllI4QEhdyAgMAVHPOAaAO7+H/AIeuNCTVJb60t7a5vZ1kYR6nc6gzBUCgvNcYYnjAAUADA561zcHgfX08QXdxA1jpllPJeSTpZ6jcvFe+cjhd9q6+XE25ldnQkkqeOal8DfFez8Va5p9gkWmqupQSXFsLXVI7qeIKAdtxEqjyWKnOAz8ggkGtr4i+MZfCFstzt0FofLdymo6wLGWRlGdkSmJg5IHGWXn86AOOg+GGt6b4F1Xwxpt5YTWepWEfmPdSP5kN4FRXIcIS8TBeN2CuAAMEBeg1PwTqV1o/i20jnsxJq+uW+pQFnbCxR/Zchvl4b9w+AMjleeuINS+JN8p1KbRvD8d7p+naPb61PNNf+Q3kyrI2xU8tsuFiJAJAPOSOMz6v8Q7uNNWu9E0WG+0rSmhjurie9MDl5ER9saCNw21ZYydzLycDOKAOg+IehXXiLwhfafpk0UGpZjns5pc7Y54pFkjY4BIG5BnAPHrXDaF8KLjRtakmt7yBtPGitaxwsWDG/eKOKSduMEMkKc9cs3HrG3xAPhjV/FMeoXEU8s/iIWVkuo34tra3QWcMjbpWBEaD5jgKSWYYBJrY0T4ly+IY7C28PaXZ3ur3D3QkT+0h9kjS3ZFeQXCRsXUmSMLhOd3O3BoAg0XwV4g0YGG3/sq4gvPD9npF2z3EkbQy28cq74wIyJFJl7lCMfhW1onhS+sdY8I3c0tsY9I0OXTJwrMS0rfZ8FOOV/ctycHkcdcWfhjeXl74B0+6v3aS9fzi5lmLnIlcYLnkgYAzjoOlcVr3xJl1DQ/GWkRy6TFqlr4dvdQhudD1n7Z5RjTaQzCONo3DOhHH0ORQB299pGrRfEC31zTksZ7OWyWwuo553ikiUSl/MjwjBzhmG07eg+auXt/hvfSeEvCWiX13bINN0m5028khZiSZbfyt0eVGcHJ521JJ8SLzQbSSHxJogivF06K9s1tr3zzdbpUgCOWRdj+ZLFn7ww+cnFXZviBeadeyabreiQ22qpd6fD5UF6Zonhu5vJWVXMaklWDgqVHK9cHNAEfgLwZf6Lrtve6lZ2q/ZbFrOKca5fX8jbmjJ2pPhIUPlglV3HO0ZwOdPVtB1g+OLnV9OSwmsr7S49NuFnuHikhKSSuHQCNg+fOIwSvTrWR408Y61BeyWXh61tlns9dstPka4udizpNGkhH+qfaDvCkgEgDI9K7e8h1O90IxR3MelapJGu6WAC5WBuN23eqhu4BKj1x2oA8l0nwr4t0i/TRtNtNNlK+ELHSp765llSBJVe4VjGRGfMIDZ2HYcFeRmvW/Dmlpofh/S9JhkaWOwtYrVXbqwRAoJ9zivJW8aa7baf4ltrPVrm6ePUdO06wudUskgu4Dcsqu8kIjj+QbsoWRdxB+8Bzd1DXPFNhe+IdBh1LUL8addafK2pQ2MU17FaTh/M2xJHsdlaM9IydrE4JFAHr1Fc38O7rV7zwpbTeIFnF6ZJQrXEIgmkiEjCJ5IwAEdkCkqAME9B0HSUAFFFFAHK/Ev/kXLP8A7DOk/wDpxt66muW+Jf8AyLln/wBhnSf/AE429dTQAhzjijk0tIeKQC0UDpSd+tDAWikzS0wCiiigAooooAKKKKACiiigAooooAKKKKACiiigBCeQKWk70tABSMQFJJwAKWsTxrqi6N4U1a+Yruht32BujORhR+LED8aAOU8H/FGz8U+MrvRNPsZfs0SuY73zMiTbjPy44HPr2r0WvF/2dPDA06xuNVdeXU28TkcuN2Xb6ZwPwNe003a+g5WT0CiiikIKD0opjyIgy7BfrQA4HJpapS6laRZBlGfaqFxru3Ihjz7sanmSHys2jgdajmuIoVJkkVQBnk1y1zrF1Ln59g9F4rNlmeRtzsxJ9TU899ilHudLfa/DEpECNI2OD0FZnwokM3hGWVvvPq2qMfx1C4rEkkG0ljgdya1vg8wbwOGU5B1PUyD6/wCn3FOLuwlGx2tFFFWQFFFFADJ4o54ZIZkV4pFKOrDIYHgg1xFn8M9MgtxbTanq93aQ2E2m2UFxLGVsYZF2sIyEBJ2gKGkLkAY9c91RQBVtbGG30yGwG54I4RAN55ZQu3nHtXNaB4EtdH/sRV1XVLuHRdy2Edy0JEMZi8oR5WNSyhem4k8ck119FAHHReArS0EUmlarqmnXsc11ILuAwtIVuJjNJGRJGyFd+MZXIwOeTnfi0lF0BtKmu7u5R4Whe4nkDTOGBBYtjGefTHtWlRQBydz4C0e7t9PguzdTQWWlS6OsbOAHhkEQYsQAd/7lcEEYyeOmB/BYurO6t9X8Qa3qayrH5bXDwobdkcSJIgjjQb1dVIZgx45yMiusooA5F/BTTKsl34k1251CKdbi2vZDb+ZauEeM+WiwiIApI4OUOc+oBEdl8PdNt5LGSe+1K9ltdQm1LfcvGxmllhaJw+EA27WPAAwfbiuyooA5rw/4U/sSa1EOu6zcWFpH5NrYTyReTCmAAMrGrvtAAG9mP481X8T+BrXXtZfUxqmp6ddS2J06ZrMxfvYCxbaTJG5U5ZuUKnnnOBXW0UAclB4C0uGw1W0Se9Meo6TBo0pLrlYYkkRWX5eHIlbJORkDgd+X8TfDvVr3UJrTRLw2GiXptmvj9uBMzRKi7jB9nJ3FI0X5ZkBwCQcYPqtFAHJT+BLBru+vba91C01C51D+0kuoWjL28pgWAhAyFSpRcEOG6k+mFl8F7/ssw8Q62uqQCZBqW6BpmjlKF4yDEYwpMaEBUGNvGMnPWUUAYekeGbLTPCY8PLJcz2PlSQs80mZHVyxbLADn5jzXNW/ws06O2nt7nWdau4pNGn0KNZWgUQW0uzdsCRKN42DDNknvnjHoNFAHFN8OtOurK7t9Z1DU9Vea1WzjuLlokkt4lcOojMUaDIdUbcwJyoyT0of4d2Nxa3/2/VdWvdSvJLaU6lK8QuImt23w7AkaxgK2WxsIJJznNdrRQBxP/Cu7NrO/jn1nWZr28vodSN+8kXnRzxBAjIBGEAwg+UoV5PGK6O+0qS80E6bJqmoxzFFU38LpHcblIO/KqEBJHIC7TkjGOK06KAOJf4caZc2mspql/qeo3uqmAz387xrOnkndD5floqJsbLDC8knOa2PDHhmDQbjUro3t7qOo6jIslzeXhTzJNi7UXEaIgVRnACjqa3qKACiiigAooooA5X4l/wDIuWf/AGGdJ/8ATjb11Nct8S/+Rcs/+wzpP/pxt66mgAoIzRRQA0HnFOpD3pAeOhoAXaKCo9KWigA70UGkDZPQ/lQAtFFFABRRRQAUUUUAFFFFABRRSZ5oAWkOD1paM0ANY+nWnDpTWpCwRSWOBRcCHUL2306ynu72ZILaBDJJI5wFUDJJr588da94m+Iqi38L6Xff2SWzCzx+VHJ/00Z2wPcLn9a901OQXkTQPEkkDH5lkUMGxzyPrVRouOpqfaJbGkY21Zi/CuLU9C8GW+m+IvL+1WzMkfluHJj4IyRxnJI+gFdX/akX8KOT6VmPApx8xpqxBWzlhx1zWbm7j5Vcuy6wwbCoB7Zqq2rXWPvKPwqHbHyAjA988UMke3LAYPajmY+VEc1/cufmmfr2OKrySswOWJ5xk1YVQd3ACj2pMx48xgAPRRRdhYpTnYwUPu9xUOST3rQ3hW3Davrx2qo11mQxQRmV+wUcfiaQyCQ7Qdx49TVJriSaTy7NGlYdSB8o/GtePSXufm1GTCf88kPH41oRW0UESpAoWNRgAelTca1MC20VpSJNQkMrDpGOFH1rY+EqhPBzqoAC6rqgAHb/AE+4qZiF64AqP4Uc+EZcdP7W1T/04XFXT3IqbHYUUUVsZBXC/FL4oaD8NYdNfxBHfSm/d1hW0iVyAm3cx3MoAG5e+eeld1WfrOh6TrkcUetaXY6jHE2+Nbu3SYI3qAwOD70AW7S4ju7WG5gbdDMiyI2MZUjIP5V574S8bXMHwQ0zxbr5kv7w2SzS+WqI00jNtUADCjJKjsBXo4GBgdK4DTPhla2XhlfDkviDXbzQFtzbrYz/AGYKF/hIdIVk3KcMDu6gZz0oAZdeP7/SZp7XxBoUVreQGzlkFtfGeL7NcTeSZQ5jUkxt95do45BNU9M+Ldnf3Dxrp0kYTULmBmeX/lzhgab7WPl5VgoAX1brxW23w9sLnTtbt9W1LVNUuNWsxYzXt28XnJCobaseyNUXBdmztyW5OaXTfhx4f0/WrbUoIZTLBpC6II2YeW0APUjH38cbs9CeKAOS0/41W11ZXtx9i0yRo9HudXghstYjupMQqGMVwFT9y5BH98cMM5GK9G8PX+r6hpbXWpaZZ2Msih7eGO9M25SuR5jeWoQ54IXePc1i/wDCAxyaReaVd+IdeutMn0+XTUtpZYQsELps+UrEC7BeA0hc9zkk56+2hW3t4oUJKxoEBPXAGKAPFbXxT4yvfCvgHULmC1kvbzWEjUQag0YvFNvdEiYCFVRQVQ4AfO3OMgA7+ofFePT7W0hv7TTLHWZr65sXivtVW3tIzBje/wBoKZIIdMDy8ktjAwTW9pngCysE0yFdT1Saz0u++32NtK0RS3bZKhQERh2TEzcMxI2rggZBkl8DWYlkubHUdRsNQa8nvUvIDE0kZmAEiAPGyFDtXhlJ4BzkUAXvAviWDxd4ZttYtY1jWV5ImRZRKoeORo22uvDrlSQw6gg1yEHxS2apqWn3lvoc91a6Zc6io0nWhejMG3dFL+6RoidwwSCDg+mK7vT9IW20P+zLq8vNQVldZLi7kDSy7ySclQoH3iAFAAGAAMVxP/CrLez0loLHWNSuZbbSLrStPivGhWCBJlUciOJSeUXLHLHnOeKAIdQ+J1/pGmXN1rfh6K3kOjS6zZRw6h5onSPZvjc+WNjjzEPAcYJ54xVD4g+Mtai0m/0q/sTomqo2nXcEtlfmYPC9/FE6lgiFWGdrKMqQ33iM1e1T4YTXHg7VLU6tc6hr1zoraRbz37oIrZCBlF8uNflLKuWYMxCjmti5+G9hfR3x1bVtX1G7u/sytd3EkQkSOCZZkjQJGqBd65Py5OTz0IAM6LxxJDq15pOjaRJd6tca1cWUcd1qL+URFDHJJKXZXMSAOAI0UjPQcml8Y/ETUPCWkRX+taboFqwtzPPZT6+sd0SrNuWBDFtm+UAr8ykk4wD11Lv4eadNdSXltf6nZaidSk1SK8t3j8yGSSNY3VQyMpQqgBVlb+WKGpfCyyv1v/N8QeIFk1Gx/s+/lEsBkuo8v95miJX75GE2qQACMDFAFKTx1q+l6x40vtQtbW48NaQkUyGO4IuFVrcOqpH5QDF2Izucbc9wKtap8QtT0SDUY9c8OxQ6nb20F3Bb2+oeak8ckyxEeYY12urMMjaRyMMe2tffD/Tb251IzXl/9h1O1W1vrENH5NwFjMauSU3qwGOUZeVGQcVCfh3ZXEN7/amr6xqdzdRwQG6upIvMjiikEiouyNVwWGSSCx7ngYANW+v9bh8Hape3FlZWmrRW8skMMV200YIUlSXMQwfUbSPc1yuh+NfEcumeGbGXRtPvPEGq2JvVxqLRw+QkcZaWRvIyjs8gAjVGHP3sV6Nd28d3azW067oZkaN1zjKkYI/KuLg+HUNva6UkHiLXY7vSo2t7K9DW/nRW7KqmA/udjp8inLqzZGd1AG/4U15PEfhq21WCBoHlDo8ErcxSxuyOhYejqwzjtmud8H/EBdd8Wz+H510RrtLRrsSaRq4v0ULIqMkn7tCjZdSAQcjPPBro9N8N6dp3hUeH7dJDp/kPA25yXcPnezN/eYsxJ9Sax/CvgK18PatZ36atqt9JZ2D6bbR3RhEcUDNG2AI40ycxr8xyTk5J4wAdjRRRQAUUUUAFFFFABRRRQByvxL/5Fyz/AOwzpP8A6cbeuprlviX/AMi5Z/8AYZ0n/wBONvXU0AFFFFABRRRQAUUUUAFJznpS0UAICe4xS0UgzgZ5NAC0UUUAFFFFABRRz2ooAO9HNHf2oAoAQ57Ud6U0hOCKAEkbauay7m6MjEKMgVNqdwFTyxjJOSayxJ145rKTuaQVtScNge5prN71GJAOtNLipLE3HIpSaizz1FIWx1ouA8kd6hfAYkemOtRXU8Num+eVY4x1ZjVGW9naLdbw7I+vmzAjj1C9T+OKai29CHJR1ZfZgis0jbVHJJOBWeNTilcpaRyXAB+aVFPlr9SB/LNZctjc3l0XuzJcbfuxnAUemR0H05PrVC6uIYPMihgWeVTtJVRsHtn+gzWypLqzCWId7RRqWN6LrxL/AGZfysqSj9wUUgEgcqcgHNdlHbxWsflwoFHfivJ7i21SO7sNReJttrOsgQLj3xXrVvKuoKstmQ6OAwOCAM9jUVIW2NaNTmXvEL/dJ7UQW0twpMS8f3jwK1INORTunO8+nYVeCgAAcAdqlU+5cqnYo2mmRQkPJ+8kA6np+ArE+GYx4buwP+gzq3/pxuK6quW+Gn/IuXn/AGGdW/8ATjcVolYzbudVRRRTEFFFFABXhHw+8W6z4S+HPhSbVE0+70iTQLi6hhtonjnj+zwCQBnLFX3KCOEXBx1r3esK18I6Ha2ek2sOnp9m0qB7a0jd2dY42TYykMTuBXj5s0AcLfeOfEuh6XdS6wujXNxN4cu9csvssEiLFJAisYpQZGLr+8TDgpnDDA4q0+pa+virwzBqR8NtqGo6ffXEN4umyE2QRYCEDGbLKS/zYKbtq9MV0Vl8PvDVnZ39rDYStBe2bafKs15PKRbMCDChdyY05PyptH5Cruu+EdE11IF1SzaUQ2s1lHtnkjKwyhRIuVYdQijPXjjqaAPPtN8d+KrjTorlW0W5ttW1aLStGvhZSwJIu2RpLh4zMxaP92wQBlLYzkAirbeNPE76vaeHoRoq6x/bUml3F21vK1u0YszdLIkYkyG27QULnkEZGcjqYvAHh+PSm00w6hNZExFEuNUupjAYz8hhZ5CYiPVCpq5p3g/Q9ONg1rZsJLK5lvIZJJ5JJDNIjI8juzFpGKuwy5P6DAB56fEHirWta8LRWupafYXkepanp93i0lkt52gVwH8sTKdpC5CljhjnJxzpy+PbyHxpYWFvf2Gqabc6m2myrb6RdRfZ32vx9qLtC7qygFMKeT0xXVXngjQLuFY3tJoyt5LfpLb3c0EqTy7vMdZEcOu7c2QCBg4xUMHw/wDDkGqRahFZ3AniumvY0N9OYY52JLSLEX8sEliThecnNAGT8IJmt/g/pUyAF47eZwD0yJHNc2vxL8Q6N4a0bXfEUGk3ltq2hzarFb2EMkLwvHAsoVmZ3DKwbBOF2nH3q9Q0/Q7LS9AGj6XF9mskjeONNzPs3ZJ5Yknkk9a57wf8N9C8PaRZ2ssT6jdRacumyz3cssqvHtAcJHI7LEjkZKJgducUAYl74u8X6S11YXVlpuratJpQ1O0TTreRAuJUjlRkMjGTaJAykFS+1hgGqln4uu9S1fw9BcNoWoXraxPZLcNpVxbTWeLN5ATBM2+KQkYPJDIeCM8ddB8O/DMNhd2a2Nw8N1HHC5lvriSRY423RokjOWjVWwQEIAIq1YeCtBsZ7SeG0le5trpryOee6mmlMxjMRd3diz/ISoDEgDGMYFAHm/hvW9Ys/B3gK+8Qy6ZrX27U0ijkmsnM9uPJuWZxI0rbpPkADALgFhg5yNTSvH3iBtO0HVdSi0lrLxDZ3FzZ29vHIJLRkgadBI5ciQFEIYhUw2BzmuxsvA3h+ye3NvaTqlteC/t4mvJ2igmxIN0cZcqgxLJlVAU55HAw3TvAPhvTZ5JbPT2TdFLAsbXMrxwpIcyLFGzFYg3fYFoAw/BPijxDeaxoVr4i/sl49a0d9Uh+wwSRmBkMIKMXdt4ImByAuCCOeteiVlWnh7S7S6024t7XZNpto1jat5jHy4W2ZXBPP+qTk5PHXk51aACiiigAooooAKKKKACiiigAooooAKKKKAOV+Jf/ACLln/2GdJ/9ONvXU1y3xL/5Fyz/AOwzpP8A6cbeupoAKKKRqAFooooAKKKKACiiigBMfWgjAPP/ANaloPSgAFFNzzz0oBXJPT3oAWl7U0YPSl4AoADyKPxoOOaRetACge5paQkDrQMEUABxt5P402VgkbOxwqjJp3GPas7XZdlosYyDK4Xj06/0pMDMmkeZy8gG48nHb2po47/rUfBPzEEjnJ61Dd3dvbgfaJo48nADMAT9B3rI22LDdetNxxnNVoJZrplWytJnVv8AlrL+7T9efyFXZ9FlmtXE9yxk6hYvkT6HufzpqDZEqkUU5bqNX2Juml/uRDcR9cdPxpFtdTu2OQlpAR7PIf8A2UfrTPD2r29tcPpkiGNkzt+Ucn+79e/IFWNS19I5PItlae5Of3UXJGPX0HbP8q0jTSMZVZPREkWl2dmDLNmWTqXdtzfmen6VBdXdtbnMimWYLxDGfmH1P8P1PPpjpWbbwaxqsqmMLHHk8hvlBPcsvX0wpJ9Sa6DTvC1tDEq3rtcsDnbjZEO/Cjr9Tmq22Eot7nMObnVysRZUgH/LvbKWUfUjlj9eK29N0B4njMNtFD/elmO6T/gKD5V/EmutihjhQJEionoowKfgUrlKJRt9LtYcsyeZIxyzvyT/AID2HFW440jUKihVHQAYAp9FBQUUUUAFct8NP+RcvP8AsM6t/wCnG4rqa5b4af8AIuXn/YZ1b/043FAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr8S/+Rcs/+wzpP/pxt66muW+Jf/IuWf8A2GdJ/wDTjb11NABSHqKWigAooooAKDRRQAgGO9LRRQAUU0gk0vPtQApOBSZ9RQcmloAbk+lC85px6U1e9ADqKKKAEPajPPSlooAaSccDmsLxBFevIXt4UkSKJmG9sAt6cfQVv011DoVPQjFDVwOB0CG51eLzL27aBlkeNo7bCLkHj5jluVw3bg10VtpOm2r71gj83/npIdzfmeaz9Q8L3P8AaDXelXhtZJAPMGAyyY6blIxn/aGDSTaJOsIbVtbmjU8FbaNIy/sCAWz9OapWRi1JvU0dR1fTtOgMt3cQQwjje7AD6ZrFv/E90/lppthKfN4SScGNWHqowXbj+6pHuBzSw2ttb3Ai0mxC3AHM8i+ddfUsxO3/AIG3/Aa1LPQdwDXrEbvvojlmfn+OQ/Mw9hgdsYpcwKn3OSttO1LVLmd5pHQuQjw2qhHP/XR8sFGP4cn6Cus0fwvbWUOx0QIQN0EQwjf7xPzP+Jx7Vv28McEQSGNY0HAVRgD8KlpGqSQ2NFRAqqFAGAAMU6iigYUUUUAFFFFABRRRQAVy3w0/5Fy8/wCwzq3/AKcbiuprlvhp/wAi5ef9hnVv/TjcUAdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByvxL/5Fyz/7DOk/+nG3rqa5b4l/8i5Z/wDYZ0n/ANONvXU0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFJjnrS0UAAooooAKKKKACiiigCvfXItbdpCkkh6BI1yxPoKx4dJuLqdpruUwpIMFEcmQj0L/wAI9lA+proKAMUAQWtpBawCG3jWOMcgKKkK4FPoPNACL0oalAxQRmgAAooooATPOKWkIFNHUUAPpCcUtIRmgBaKKKACuW+Gn/IuXn/YZ1b/ANONxXU1yvwz/wCRcu/+wzq3/pxuKAOrooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4l/8AIuWf/YZ0n/0429dTXKfE1gvhu1ZiAo1nSSSew/tC3ro/ttr/AM/MP/fYoCxYoqv9utf+fmH/AL7FH221/wCfmH/vsUDsyxRVf7ba/wDPzB/38FH221/5+YP+/goCzLFFVxe2p/5eYf8AvsUpu7cDJnix/vigLMnoqv8AbbX/AJ+YP+/gpVu7ZhxPEfo4oCzJ6Kg+12+cefFn/fFL9pg/57xf99igLMmoqH7Vb/8APeL/AL6FILu2OcXERx/tii4WZPRUP2qD/ntF/wB9Cj7Vb5/10f8A30KAsyaioftUH/PeL/voUG6tx/y2i/76FAWZNRUP2q3/AOe0f/fQo+1Qf89o/wDvoUXCzJqKh+0wf89o/wDvoUv2mD/ntH/30KLhZktI1RfaYP8AntH/AN9Cj7TB/wA9ov8AvoUXCzJKKiNzb/8APaP/AL6FL9qgx/ro/wDvoUXCzJATjNBOe1Rfarcj/XR/99ChbmDP+uj/AO+hRcLMmHvS1EbmAdZo/wDvoUn2qD/ntH/30KLhZk1GKh+1Qf8APaP/AL6FH2qD/ntH/wB9Ci4WZNSHpxUX2qD/AJ7R/wDfQpPtMGf9dH/30KLhZkw5FLUP2qD/AJ7R/wDfQo+1W/8Az3i/76FFwsyauW+Gn/IuXf8A2GdW/wDTjcV0n2mD/ntH/wB9Cua+GRDeG7sggg6zqxBH/YQuKBWOrooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4f40KH8Ayqejajpo/8noK4b+z4QOWf867v4yf8iK//AGEtN/8AS+CuS2sc4X6V5WYSqKUVA7cK3Z2KqaZbk8lyfrUq6Tbr0Mn/AH1Uq+Z/dqypO0ZxXmOpW7s6vmUTp8II35P405dNs+pWQH1DVaf730pOT7U/aVurYXFt7CNvuO4/GtCKxjwN7uT+H+FVIHaM54I+tWVuiWwEB+hqeev3ZV+rJTp8RP35P0/wqWPT4QpDFzz7f4UiXI4ypFSveAKQqc/WjnxHmJSXcjNjFyMtj8P8KlXToJe7foP6VAbtz0UClimkRht5GeaTliPMbn5lj+zII+8hx7j/AAp/9nQkfeb8h/hTZLxtuNo+pNRi6Zic7eOnNLmr+YlLzJDp8S92z9B/hQLGI9Sx/L/Cmm6cjhMH1zTY5ZC7FiAKOav1uPn8yUWK54cj8v8ACnfYU7yP+g/pTRcHHOB75qSO4GACw/3qOev5g5+YLYx93k/Mf4U46dF18yT9P8KWS4XjBH4Go/tDY+/S5sR5hz+Y4WEX9+T9P8KT+zoxj53/AE/wpv2l/wC8KRbmQg7tufrRzYjuw5vMmGnxsOXfP4f4U4aXH/z0k/T/AApILgAkOw+uaka8HGCv51PPiPMnnfRif2ZF/fk4/wB3/Cm/2fESfnk/T/CnfbBtwxH4Gk+1Lnqv50+fEeYcz7jTp0fZ3/T/AApp06NuC7/kP8KsG6QD7yfnUMt0NvyEZzS58R5gpPuR/wBmRryjsPwH+FOXT1xhpH+nH+FSx3Kj7xX86HuE6hl/OjnxHmPmfciOnxdnkz+H+FOGnx95JfzH+FBuBzyPzpiXZAwxB96XPiPMd2/tEn9nQ/35PzH+FN/syI/deQfl/hSfaef4cfWpftQX+6f+BUufEeYnJ9yI6ZEOWdyfw/wpj2MIGC8uPw/wqSS7yTwPzqu9wSe59vSjnxHdlJvqytNptuv3PM6d2/8ArVo/CFQngsqOg1TUwP8AwPuKp+YWPIwKvfCT/kTW/wCwrqn/AKX3FeplTqOcufsc2NacVqdlRRRXuHnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnvx7Yp8L9QYZyLuwIx/1+wV4WmozAY3MR717n8fjj4Waif8Ap7sP/S2Cvn5mJHIY/SuLFLVH0GTSahK3c0RfyH7znFP+3uAPnl/ACslS27g8+9PwT1HNclj3VJ7XNVNRkB4kmHtxT11CUtxLN+lZAB/yMU4H3P5CgpXa1Nj+1LjoJZc0o1K6zzJLWPuB75x6ilDDHIoNEkba6pcEgGWT8qk/tWX/AJ7SA/SsRJQP4T+BxUy3LdU3D/gRpXGlrc1P7VnBz5zkVMmsTY5eQ1imUt1zx6mnK/BpFcsX0Nr+13/vzA/UU8as/H72fB9xWJuPrUo+6vNF2gdOPY2f7YYDGZT9Wpp1icj5GdffP/1qywcignAoUmNU4vSxs/2xPu/1jEfUf4U8avNxy5z6n/61YgkycgYp6uSMU+Z9x+yh2Ng6zcDgMw/GlGs3X981kbvXFPVhjrRzPuX7Olb4Ua66zcf3zn60v9tXPZuKxSxBODT/ADBg45p88u4vY0n9k1xrd1/epRrN0f4/yrF309X44NLnl3D2VL+U1zq92ekmBTW1m7/564x7VmBsjrSF8GnzS7lexpfyo1F1i5yMzt+VEms3AHErk/hWQz0wtn0o55dyXRpfymuNZuT/AMtHpv8Aa91n/Wufx/8ArVlq3Whn9qOZ9x+xp/yo0m1i4Xq7DPv/APWqF9WuNpxI4P1rOd8nmmF+RxmjmfcXs4dEXjrN3jHmn8BSf2zc4P7189ulZztz0A+lRk0XZDhHsaZ1m7IyXOfaoW1m7yfmPX1qgcgdaYT1ouxqEexonWro/wATf99V7N8CXMnw0snb7zXuoE/jez14Nv8AbNe7/ATn4X2H/X5f/wDpbPXXhd2fP5+kqcLdz0Giiiu0+XCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPPPj/x8LNSP/T1Yf8ApbBXz4CdwyxH0719BftAc/CvUuv/AB9WHT/r8gr5+RVJ5EhH0rjxO6PeydLklfuSqUA/1pJ+lOBQ9ZXoVIQPmRzSj7N/zzf865T3YoB5feR/yoIj7u35Um6AHhWA+tJmFj0YVJpy9hypEern8qUCHnEh/KkCRd3YUCO3B/1kn5UxXs7EqeUOC559qczRdEJPvUBEKniRvxFH7rtI2fYUjSOmxYUpwO/1qUFQpzHu9/SqaFA2dz/lTlI7FqRdiyrDPEa/iTTzIOM9qrhjjrSg7j1osUvMn8zLVKGGCCG6VWxznNShvlpMdx6suehxmn71zxwKgzSggigtNE6uOxpC3NRhgBSFgaYN6EwagNUQanHgUAmyQHJpysV7ZqFWyakDDnrmkCZKHB601pB0BqIv6moy3NA3KyJfMIUjim5yajL8Um7PSmK5OrY60jMCetRlueOlMYkmgdyYsAOtRFgaaWpkjBRwfzoFcV3+lR7s1GWz0603dtPNOxLJCTmk3L61FJJx8vWm7uMmmib2JS4AJGM+te8fAM5+F2nn1u7/AP8AS2evAcrnnNe/fAL/AJJbp2P+fu//APS2eurC7s8DP/4cPU9CooortPlwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzv8AaAz/AMKr1LHX7VYf+lsFfPSCQnO4mvoX9oDn4V6kD/z9WH/pbBXz2OPu5rjxW6PoMmfuS9SQISOWK+9OCkdHB/CmIGY4BqXyzkZOK5D3OawwA9c/hTtrYB4pxQEH5gKTYf7w/WgrmG5Y9DQFf1U/jQw5+UilCtj3oCTVxpDE9F96UKSMgU8IT6Z+tIA4GMj86B8ysIODSg+9Gw496cIm9RSL5gBP4U9WFMCt0wSPam4fceMD3osWmWt2DTlbvUPIzTgTgUguTbqTdzUYPNKxoKTHZ5yDT1bjk1CvenZoH1Jtwpd2agzTwwoGiVTg07fUO4A8UF6BXHs3NJk1GXzSF/Sgd7khNCnmoyaTcaYkyXNNLUzcaax5osDY4mmMfek3VEXOaYx2ADTWNNZzmkz60yHLsIxPSkzQ3JpCRjrQJsTdzX0F8Af+SWad/wBfd/8A+ls9fPIIJr6G+AH/ACSvTf8Ar7v/AP0tnrqw27PCz9/u4ep6HRRRXYfLhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnnx+G74WaiD0N3YD/ydgr58NsoP3yfwr6C/aCOPhTqZHUXVj/6WQV83+c+c5P51yYlXaPeyh2jL1L4hQdc/nSbVB+8KpfaD2J/OlWZiDlq5Nj3E2aCLnlXT8RUhTj76/hWZ5owMnJ7mmiZs9SfqaB3ZoNCc/epCGH8bfnVX7QQOpzTVnZm6DH0oC77F5VZuhB/GpQj4+6B+NZolYbsn8qDNIOFY4oY9TR8mQ84H51GqOAcnBqks7k4ZiAOmKkEnoc0blJstbWOPmz+dIA4I+ZR16g1V81i3bFPVsY5zRYaReAyPvAcUAcY3VUMnpSq/rU2LVyzvyfSnZGOtQbhS7qLFEwb0NPAGQSwqtuHejcPWiwF0CLAJkwe9IoA6sCKpZFO34FOwNF0bOpYU0sufl5B6+1U/MOOgoLk0WBF1GixyD+dOzAfWqAbil8zFFg+ZeAh6ktz700mHPBY+xNU/MHtSFyfu9aLE6rqaGIh6fTdUMnl57/nVNnphY4yKLDsWm2DJwTn3prbSOEwe3NVjIPxpN/0p2FzMnwDjnmmlAD97iqzuc8U3d27fWnYW5aITvzURAycdKgL4PFIZD2osJk+EH8X6V9DfAD/klem4/wCfq/8A/S2evnHzW9a+jf2fTn4U6YT3ur7/ANLJ66cMtWeFnf8ADh6nolFFFdh84FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYfjXw1a+LvDd1ot/Pc29vcNE5ltiokUxyLIuCysPvIOoPGa86/4UHof/QxeJf8Avu1/+MV2PxWtoLzwlFa3cMU9tPq2lRyxSoGSRDqFuCrA8EEEgg1N/wAK48D/APQm+G//AAVwf/E0nFPdGkKtSnpCTXoziP8AhQWh/wDQxeJP++7X/wCMUf8ACg9D/wChi8Sf992v/wAYrt/+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/ian2cexf1qv/O/vZxH/Cg9E/6GLxL/AN92v/xij/hQeif9DF4l/wC+7X/4xXb/APCuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTR7OPYPrVf+d/eziP+FB6J/wBDH4k/77tf/jFKPgJog/5mPxJ/33a//GK7b/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4mj2cew/rdf+d/ezif8AhQmif9DH4l/77tf/AIxSj4C6KP8AmY/Ev/fdp/8AI9dr/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TR7OHYPrdf8Anf3s4n/hQui5z/wkfiT/AL7tP/kel/4UNow/5mPxL/33af8AyPXa/wDCuPA//Qm+G/8AwVwf/E0f8K48D/8AQm+G/wDwVwf/ABNHs4dg+t1/5397OL/4UPo3/Qx+JP8Avq0/+R6X/hRGj/8AQyeJP++rT/5Hrs/+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaPZw7B9br/wA7+9nGf8KJ0f8A6GTxL/31af8AyPR/wonR8f8AIyeJP++rT/5Hrs/+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaPZw7B9cxH/Px/ezjR8C9IHTxL4k/76tP/kel/wCFGaT/ANDL4k/76tP/AJHrsf8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+Jo9nHsH1zEf8/H97OO/4UXpP/Qy+JP8Avq0/+R6P+FGaT/0MviT/AL6tP/keux/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJo9nDsH1vEf8/H97OO/wCFGaT/ANDL4k/76tP/AJHo/wCFGaT/ANDL4k/76tP/AJHrsf8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+Jo9nHsH1zEf8/H97OO/4UZpP/Qy+JP8Avq0/+R6P+FGaT/0MviX/AL6tP/keux/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJo9nHsH1vEf8/H97OO/wCFGaT/ANDL4l/76tP/AJHo/wCFGaT/ANDL4k/76tP/AJHrsf8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+Jo9nDsH1zEf8/H97ON/4UXpH/Qy+JP8Avq0/+R6X/hRmk/8AQy+JP++rT/5Hrsf+FceB/wDoTfDf/grg/wDiaP8AhXHgf/oTfDf/AIK4P/iaPZx7B9bxH/Px/ezjf+FF6Qf+Zk8Sf99Wn/yPR/worSP+hl8S/wDfVp/8j12X/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TR7OPYPreI/5+P72cZ/wonR/wDoZPEn/fVp/wDI9H/CidH/AOhk8S/99Wn/AMj12f8AwrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATR7OPYPrdf+d/ezjD8CNHP/MyeJP++rT/AOR6T/hQ+jf9DJ4l/wC+rT/5HrtP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiafJHsH1uv/z8f3s4r/hQ2i/9DH4k/wC+7T/5Ho/4ULov/Qx+JP8Avu0/+R67X/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4mjkj2D63X/nf3s4n/hQui/9DH4k/wC+7T/5Hr0TwV4atfCPhu10Wwnubi3gaVxLclTIxkkaRidqqPvOegHGKo/8K48D/wDQm+G//BXB/wDE1D8KbaCz8JS2tpDFBbQatqscUUSBUjQahcAKoHAAAAAFNRS2RnOtUqK05N+rOwooopmYUUV5p8a/il/wrG10ib+w59W/tCV4/km8pY9oXqdrZY7uB3weeKAPS6KrRsL/AE1WKzwC4hBKklJI9y9OOjDP4GvAdK8Y6vHc+Fbm/wBXuktvCxGn+IN8jbZ5JZ5LRWm5+ZgYRJk5xvz3oA+h6K8M8Lv4k1DxL4Sv7K9t49U1PQtR1B5NUjkuFiimu7eRI1RXU/KGjQDcAoB64wafjbxY/iPwNe3E2m2EM+oeCbm9knWPMyMJI1MavnPl5YnBHUA0Ae/0V5HefEPXE1q+t9I017i00y6hszbJpF5PJdZWMyOLiMeVFtD8Bg2duTtBFdJ8WP8Ajx8M/wDYxad/6PFAHcUV4JaJceLvEfhG1a08O2+mibWpDYSaWZbcvBdpH5hTzVHmFXyGxwzOcHcAun4U1bWovCvw+uNem0vWW1HVo7eKWezcz2wMVyzOJGlbMnyABgFwpYYOcgA9ooryXRviB4gjsdB1bXo9Kk07VoLuQQWVvKksJhieUHe0jBtyxsMbRgkcmtrwz4h8SzeIdAttdbR2tdY0u41BYrS3kV7do2t8IZGkYSDE/LBVyR0FAHoFFcFqcuvv8X7K10/VbaDTf7JaaW2mtpJQ+J0DEYlUByDgMVOOeDmuP8AeJtY8NeFfCg1AWFxo17bXhiht4XFxH5MckwJcuVbcEYbQgwSOTQB7bRXmXw98beINd1ewi1PTybK+s2uTJFo95aLZuNpWNpZxsmDKxwybeVPGCDU/xE8X654e1ry7dbOx0eO0Sc6he6dc3MDyGQq0byQnFuAoU73DA7vY0AejUV5J4T8Szj4ga94b0oWyXEusTXlxPdg7fJEUIKRAEb5CSM4OEHJzkAx+FPE+v6mdC0nw5b+HdKS6tdSu5N1lI0UfkXgiXZGki/e35bnqS3+yQD1+iua8Ja7eeJPh/p+tW8EEOo3lkJVibJjWbb06g7d3vnFeYp8aNRuow9nYWYW5sYILRpFcg6q/kb7dgG5VRcpwOfkfn0APc6K8WudW1u78aWFpoE+l6PjxRfWc2yzdkuiun+YHnVZU8w/e6nqIz/BhpNJ1jX/D994gvkfS5dJbxVHZ3EJgk89zMYImdH37UCl1IUq2RnkUAey0Vw3xRn1iFvCy6FqMVjLPrMUMjSQvIrgxyHDKsibl45XPPHTFcedW8ReHfEPj/VYJtJmtbTUdP+2xvbSB7hmtLVX8siTEQwcjd5nofUgHtNFeUXvxD14+Jr+HTNMe4sLLU0082qaPezSzJuVZZRcqPJj27iQpByF5IyK9XoAKKKKACiiigDlfiX/yLln/ANhrSf8A0429dVXK/Ev/AJFyz/7DWk/+nG3rqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5X4af8i5ef9hrVv8A043FdVXK/DT/AJFy8/7DWrf+nG4oA6qiiigAooooAK4mTwz4N1HTdQgSxW90/wAWS+fcyWpmmiuWC7g5kQkRjCjByoJ6cnnsriJbi3lhcuEkUoTG7IwBGOGUgg+4IIrwP4aXdtZaL8LrLSNXumuXuzb6taf2lLL5Ui2U58p4mciMBlzswBlQccCgD26HQ9Og1G0v4bYJdWlo1jA4dsJCxRimM4PMackZ468mshvAHhltOFi2mZtRp76UE8+X/j2dgzR53Z5Kg7vve9eW/CHWTfXHgJtL8RajrGoXNjK/iCKbUZLpYV8rKM6MxWJ/MCKMBSwLZ3da6z4i6jaweN7K18T65e6J4dOmSywzQXslmst2HAKmRCCzBOVjJIOT8pxQBra9pnhE+KrezvY9QOq3oSZraykvDFIFIRZLhIT5ePlC75Rg7cZ+XjpdXtNK1a5tbHUTFLc28seoQwecVcNG4KybQQSA2OvHY15b8NbO71Px5aan4hfUV1ceGNOuJVN1NCGcy3K5kiVwvKqpKEYDFjgEk1r+JodJg+NOjXOtahcWPn6W0dqx1Ga1jmnW4j2xAK6q5O7mPnd3BxQB03hTR/DM9tpms+H4N0KC6e1m3yjH2iQPMdrn+J0B5HGOMCn2Xgbw/ZPbm3tJ1S2vBf28TXk7RQTYkG6OMuVQYlkyqgKc8jgY8p8Hpf6JoXga60S81Ga81OC/ja1mu5HgcrBLJGqxE7Fw6LyoBwTknNXvhFqd/deJdMWTxBaXbyadI2o2n9uz6hM02UId4XhVbVlJZSgI64wSuaAPUrfwnolvb6VBFYr5Ol+Z9kRpHYR70ZHzk/NlXYfNnrXM+Bvhz/wjevpq11qEdzJBaPZW0FulwkUMbMjEBZp5iANigKpVQM8VT8a2s2p+ONStX1TV7W2tvDv2qOKyv5bZfO82QBzsYZIwPY45BFef634h129t4bnUtftdKkl0GxuNOluddm04NM8W6SVIY4mF02/goScDA2jcDQB7tqnhzTNT1ex1S6inXULMFYp7e6lgbaWVijeWy70JVSVbK8dKoT6P4a0RPDtvNbiJLW4a20xC0jhZJI3BXqc5Tf8AfyPxxXkt5rOvN4suft+v2Fhqy6pbpawTa5cQl7f938qaesJWZJAW+ckkEnldhxaj1CzvPEPhltT1u4m8WN4jlFxppvnK20SmdUX7Nu2IAgjw5UM2cgkNQB6R4J0Twx5cGs+Gzdywqsltbma8uZI4VV9jpFFKxWNQ0e3CqBhRjjFXdc8F6FrmoNe6lazyzSRrDKqXk0cc6KSQssaOEkHJ4YEc14dY6hfW+ieH4LnUbfTtCMepOJLjXpdHjkuPt0gx50cbFmVTkRkgHLHB217F4C8Qxy6T4f0jVNUjv/EE+mLePJDFJtmjUhTLuKLjJI6hSSeBQBpz+EdEnffJZfvBfDUlkWV1dbjaF3qwYFcqACAQCMgggnOXoFv4TsNWCaLbz/bdOmm0omKK4lEDTFbmRWOCoBOxt54BIUEZxXG/GjVzpuvr5mttHGmmmSPS4dYm0y5eTzDiSAopS4kIG0Qt3A/vc5sOoXtt4puTYy3MDXPjiKOWPzDGZVOlbvLkx1G5VJByMgelAHrunJpHhqHSdAsh9mjdWis4PnfIRdzDcc9BzyapQ+BPDUMNlFFpUSpZ6g2qwDe/7u5YkmQc+rH5fu9OOBjyfQdQS4v/AAndWms3OqeNGsLye/tJb6SUW90bYt5RgLFICr5TaFU4HIPWtD4Ranf3XiXTFk8QWl28mnSNqNp/bs+oTNNlCHeF4VW1ZSWUoCOuMErmgD0S98J+GL65nspY9t7Jdf2uywXssNwkrL5XnKyOHQEDb8pAPI9aNF0jwzrvhyK602JrnStSuItXWRpJQZZVKOkh3EMOY0ODjOORya5vWINJt/jhaXGr389lJc6XEtmG1GW3juJ1uG/dBQ4WQ4Zf3ZBBznB5rifBKapoHgrwNceHbzUrjUNR0C7YWk908sLypbh4QkTEomGAA2gZBOc0Ae5a/oen6/YraapC8kSSrNG0czwvHIpyro6EMrD1BBqkfCGiNZ6jayWskkWotE935lzK7TNGiIhLFt2QsSAnPOMnJJJ85+EGpXl34nhjGv2N7E2ltJe2sevT6nKZ98eJGV4lW2I3OpjBHXhflJq747guL/xr4lj/ALW1i0h0/wAMRXlvFZX8tuizmS6/eEIwyfkUYOQcDIOBgA7a98GaJe6o9/Pb3ImklSeSOK9niglkXG13hVxG7fKvLKT8o9BXRV86+J/EWvS3NzPe67ZaTcHTrOXSZLnXJrHc7Qq7yLaxwuLrMpZSpzwAABkGr+r6vrY8b6gl3rtjp2px6vDHZ28+uzxFrYGP5UsFhKzLIpb5ySQSfmXYcAHt9/qVpYT2EN3L5ct/P9mtxtJ3yeW8m3gcfLG5ycDj1IpuiatZa5pUGo6XN59lOCY5NjLuwSDwwBHIPavF9KvrO88T+CHv9cubrxY+uXLX+nvfu62gFtdgL9n3bIto2hTtDMMnJyTXO6bqV/beG/DNvdalbaZof9lTSQy3OvS6Qr3RuJA2JI428xlUIRGTj5icHsAfTFFY3gua7uPB+hzalcxXd7JZQvNcRKyrK5QEuAwUgE84IB56DpWzQByvxL/5Fyz/AOwzpP8A6cbeuprlviX/AMi5Z/8AYZ0n/wBONvXU0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy3w0/5Fy8/7DOrf+nG4rqa5b4af8i5ef8AYZ1b/wBONxQB1VFFFABRRRQAVS0TVbPXNIs9U0ubz7G7iWaGXay70IyDhgCPxFWbiGK5t5YLiJJYJVKSRyKGV1IwQQeCCO1fPvhvw/Y2XhbwTbaj4SvfsFgxj8RWiaLKfPuBEVileMJm5UMG+ZQ4BYH3oA950TSrPQ9Is9L0uHyLG0iWGGLczbEAwBliSfxNQWOtwXF9BYTxT2eqS2zXX2OcKXSMOEJLIWTqRwGPWsP4VWd1ZeFDFc29xaWxvLl7G1uARJBatKxiRgeVwuMKeVGB2rzPwT4ct9P1Hwhe+I/CtxNINLlt0lbSWneC6F2Gj3YQmI7SSHbao5+YUAe+VhTeI418VLoNrp99d3KQpcXM0IjEVrG7OqGQs6k7jG+AgY8cgV5t8GdHfSvEW2DSJPs405km1O60efTrsyeapEc5dily5G4+ao42nn5uZ/F/gxdW8RfEu7i0GGbUbvw9DBp929qu552hu42EcpH3tpiVsHptB4xQB6V4q1y28NeHr7Wb9JpLWzj8yRYQC5GccAkDv60mia9a6xfaza20cySaVd/Y5zIoAZ/LSTK4JyMSDrjnPFeP+Lze+JdI8QHTNE10AeG4rRBcabNC0som3FEV1DMQPQfTI5r0LwBZ3Vr4g8dSXNtNDHc6yJYWkQqJU+ywLuUn7wypGR3B9KAN/wAP65ba4uom0SZBY3stjJ5oAy8ZAYjBPy88ZwfatWvBta8P6tNHMbqyf+yB4n1C5uYLnSZ7+OVGX9zI1tGyvLHuzjG4ZKkjAJE3g/wRBqGv6FBr2lzalosGnamYlvtLktoIi91AY4xDIzlVC79iudwCg4G0YAPc6yrjX9PhudVtvNZ7rTLZLu5hVDlY3D7CCcAk+U/APbnGRXicFiYfD+hyePtD1PUbC38NCK3im0+W5Ftdq7bzIu0+W/l+ViR9oAVvmFP8LaBZ28i3eoeG5J72/wDCempp96mltOUuEt5UkBlVD5T7TEMsVyABk4AoA9z0fUItW0ix1G3V1gvIEuI1kADBXUMAcEjOD60yPSbKPW59XSAf2jPAls8xYk+UjMyqATgDLseAM55zgY80+H3hZfDviHwhLp2jyWCXHhyRNTkWFl3zhrYoJiR/rBmXG7nG4DgYr1mgAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4l/8i5Z/9hnSf/Tjb11Nct8S/wDkXLP/ALDOk/8Apxt66mgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuW+Gn/IuXn/YZ1b/043FdTXLfDT/kXLz/ALDOrf8ApxuKAOqooooAKKKKACiorqdLW1muJt/lxIZH2IXOAMnCgEk+wBJrMg8TaPcf2N9mvUm/thDJY+UrP5yBN5bgfKoBGS2ACQOpAIBsUUUUAFFFFABRRSOwRGZyAqjJJ7CgBaKw/CPiFfE+lR6nbadf2ljOqyW0l2I1+0xMMrIqq7EKRgjeFPPStygDK1nw5oeuTQS61o2m6jLb58l7u1SYx5wTtLA46Dp6VqgYGB0rK03XLbUNc1jSoY5luNLMQmZwAjeYm9dpzk8dcgVq0AFFYPhPxLF4n0rTdT0+xvY9Pv7UXUc83lgLk4EbAOW3Y54BXA+9nirfiTWrfw/o8upXqTPBE8aFYgC2XdUGMkDqw79KANOiqWrarZ6RDBLqE3kxz3EVrGdrNullcIi8A9WYDPQZ5xV2gAooooAKKr2c8lwJjLaT22yVo1EpQ+YoPDrtZvlPbOD6gVFb6pZXGr3mlwzbr6ziimni2sNiSFwhzjBz5b9DxjnGRQBdooooAKKKKACisvwtrdt4k8OadrVik0drfwJcRJMAHCsMgMASM/QmrOraha6RpV7qWoS+TZWcL3E8m0tsjRSzHABJwAeACaALdFMhkSaJJYzujdQynpkHkU+gDlfiX/yLln/2GdJ/9ONvXU1y3xL/AORcs/8AsM6T/wCnG3rqaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5X4geNtO8FaZHc36yTTzsUgt4sbpCBknnoo4yfcUJXBK51VFZfhnWI9f0Kz1SKCe3juU3rHMuGAz/LjIPcYrUoAKKKKACiiigAooooAKKKKACuW+Gn/IuXn/AGGdW/8ATjcV1Nct8NP+RcvP+wzq3/pxuKAOqooooAK80+NfhLxn4qtdITwL4l/sN7eV2uf38kPnAhdvzRgk7cN8p4O72r0uigCKzjlitII7iXzpkRVeXbt3sBy2O2TzivENT8GX9svxJGj2WonE1vFp8YLKDZuY7i7itugw7PMCFPUBe1e6E4GT0rhYviHp9/4q0qx0uYSabPb3U895NazRRFYgmGimcLG68tllLDpyO4Bwl9ozPpviibwloF/YeHRJpE8VgNPktmlmgulluJIrdlVh+6VAcL87IcZPXv8AwJcyaj4n8V6iLHUbS0uJbcQNe2klu0oWLaWCuA2M+oB9q1vDnjHRPEdy0Gk3UrzCEXCpNaywGSInAkTzFXemeNy5HvzUPiLx14f8O6lJp+q3c6XcdsL2SOGznn2QEsvmMY0YKoKNknpjnGRQB5l4l8ERajF411GbQJZtWl8TWX2W4ED+cbX/AENZDEw5CbTMGK8YDZPy8Wda0hvD48T6dpnhK1utBuNUszFbS6U91aW6tbjzJ0to1zJh1UEJjlskjk16Jqnjvw5pl8LW71EiTZHI7xQSyxQrIcRtLIilIw3YuRmovDHjW213xBrukLZX0E+l3r2gka1n8qULHGxYyGMIpy5AXcSQAwyGFAHkdtBq3hnwWfEdjYGK/wBH12aOxspLN7BLi1ufLjMUcMjFkQyMrquTymPYeu6J4Zj0f4df2FcKt65s5Fu9ybhczSBmlYjHO92Y498UnivxX4W0q9js/EEyPNbBL0g2clwtqNxCTSMqMsIznDsV6HmtCXxVo0X2wPdsHtLmK0lj8mQv5sm3ywq7cuG3DDKCOvPBwAeK/wDCGPY+GvAay6LaW+lroqm/tJfDs2oKb9o4QXmtoGRzLtDjzGDbSGzgkGodW8L6k1vpia0Lm/01NEW2s2vfDV1qEsUvmSbyIo5t1vLsMO13JOFA3KVbPtEHjbw/Prg0mK+Zrsztaq32eUQtMoy0Qm2+WZAAcoG3cHjisC7+LGg/YdKvdJi1LUrK+u4rYTw6bdbdrq7bk/dHzCNmCq8jPOOlADfhfp+oWWveIpNRS9Yy2+mqLq7hMbXDJaqrseSN27O4AnB4zXOQ6U6fFf7ZbaPNfTy6szyz32jzwzWsYiK74r8N5bw/KMRHk7uma9Wv9asNO0N9Y1Cc2mnpEJnknjaMqpxgFCAwbkDaRuycYzxWXZeOfD940ax3c8cj3SWXl3FnNA6TOu5FdXQFNw+6WADHABJIFAHjOkeH/EUXhDRYrfTNUhuo/BslrKqxPFIrfaYS8QJxtlMYfAyDU99pmk6jceNrHwf4eurOzbTtHjktE02S0d3+2TM7eWVV/uYy2BnaTyOa9a1jxf4Z+wvb6hK13BdTT2H2VLGW5NyyAiZFiVGMiDkMQCvUE9azdN8VeAvDdrFBpAtNOs540u2FjpzpDEsnCvMUj2xZ9ZNvSgDhvF3gyC3vNftrPwx5vh+31DRdQW0gsPMjk2ysLpo4wp3uYgAwUEkHBznnt/iDZRXvwW16z8N6ZMkUulyx2ljDZPC4ypwiwlQyn/Z2g+1bcnjXQY9abS3vJRcpMbdn+yy+QsoXcYzPt8sOF527s+1Zlx8Q9CudLuZ9O1Q2pijjnFxeaXcmJ4mkVA6AhPNUlgAyMQNwPI6gHFfEDwVaWOv6eLPSLGPw79kl3Q/8I/PqkbXbMoMjxQOreaUAxKwb7rcgkZw9Q8P3Ua6Q0um6jr+pQ6dZ28UOr6FO28q5O6K5jkIs5MH5y5OSoyTXtn/CVaMLU3BvD5Yv/wCyz+6fd9p8zy/L27c/e74xj5s7ear6b410DUtYGmWV80l07yRxE28qxTNH99YpSoSQrg5CMcYPpQB5LrmhSv8AazqWnXzp/b2qTxw3GgTanZzK4QI0sMZD89UkGQDu/GxoWkR6Trd1qmqeAg+q3Hh6yOnwCxa6VLmKOdXhNxtbymK+SmXIyABk4ru/GHi+707xvonhzTtsLXcEl3cXMmmXN4qxrIiBR5RAXJckuzbUAG4fMub9j8QfDN99oNtqLlIbaS88x7WZElgj+/JEzIBMo7mMt1HqKAPE20jU7jSvGC6X4dNlDfeGJUNppvh2406JrneNseyQ/vZAGYblVcjse3T+N/CV1pd9r9n4Q0a5h0i407T5LuCwQp9r2Xb+eqsPvTNDwedzAjOcivRB8Q/DhsoLpbm9aK4kEdsF025L3JKlv3KCPdKAASSgIHcimXfxH8K2kcLzalJskgFyzJaTuIIixUPNtQ+SuQRmTb0PoaAPOfEmiafdHTH8M+HpNO8LxXUr31pd+GrqeCacxRiKT7CpRyow67tuN3OD96vSPhVZTaf4GsLaeS6k2vMY/tNo9q6RmZyiiJ2ZkUKQFDMTtC5weB1gIYAqQQeQR3paAPnjwB4Yb+xPCkei6BfaZrNvpVzBrclzp8toZ99uVSNpJFVZT5uwjBbaFPQVbvLG88TeH4dLh0DVvNtfA99p7i+06SFPthFrsjUyKAzBoyQRkcZUnBx75RQBzfw+j0uLwvapomlNpVuAN9s2nPYkSYG4mNkU5z/FjB9TXSUUUAcr8S/+Rcs/+wzpP/pxt66muW+Jf/IuWf8A2GdJ/wDTjb11NABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRSEgDJIAFUptShThMufbpSbSGlcvVXvry1sLdp764ht4F6yTOEUfiaoHVX7RL+JrhPH3gqy8cCIavf6miQuZIo4ZVCITweCp7UlJDUX1LniL4t6BpqyLYSfb3Uf6xGCwj/gZ6/hn61zXhbQ7j4napH4l8RoP7Jj+S2i2lfOAOeB/zzz36t+tcnqfwJQL5mn6u1y6D5IrxSoX2DLn+Qr3X4fWMml+DdJsLgKtxbwBJEVgdp9OK05or4S3aK0OhVVRQqgBRwAO1LRRUmQUUUUAFFFFABRRRQAUUUUAFct8NP+RcvP8AsM6t/wCnG4rqa5b4af8AIuXn/YZ1b/043FAHVUUUUAFFFFAEF/bC8sbi2dmRZo2jLL1AIxkfnXl//CB+IdTs9M0jVzpFppNholzowms55JJpPNhSIS7GjVU4TOzc2P7xr1eigDg/C3hzXl8QaVqXiP8AsuEaTpj6dbpYSvJ55doy8j7kXaMQphBuwSfmq3rPhe9vfEfiK/ilthDqOgx6XErM25ZVe4YluOFxMvIyeDx0z2NFAHklz8PfEMWma5pNjNpL2XiCxtrS9nnkkEloyW628hiQIRICi5XJTDc811vhXQ9V0HxHrwC2U2i6ldC9SY3Di4jfyIoihj2FWH7rO7eDz0rrqKAPMPGngC+1PxBrF9Yww3sGrW8cM0U+t3tgkZRWQ7o4MrMhUj5W24wwyd3F+bwjqza/BrcDafFd2D28FnbB38qS1RWV/MJUkSHzZCpw23aADh3z6BRQB5Xovw6vNL1m1UwQXWnW2pSX8dzNrd8Su6R5Biz/ANSHBfG7dg8sVySKu23gzWbH4d+DdKtpNPl1fw/JbTMskrpBOY0ZGUOELKCGODsPQcV6PRQBy/jjw9ceK/BradK0dtfF7e52x3EgjEsUiS7PMUK4UlNu8AMM7gAQBXLWPgXVWt9RguLPT7SPVJ7ZL2Q6zeajObeLc3yyzqCH3EBcBduSwJYLXqNFAHmcHhDxJpd94e1DT20m9utFiudOSK5meFbi0kKGNy6xsUlXy1DYVg3JyM4Gbr/w71rU7zVru4g0+9m1uCIX0f8Abd/ZW8UixCJlEMPE8ZABwxQ9Rnnj16igDzKTwZry+LJb7Txp2nWr3bzyyQahcsl5H5ZVY5rNh5W4nbukDZ+XgVkj4ceIpNC1HTY5bHTrOW2ghh0+PVLm8tvMSdJDIvmpmAbVKiNNy8jnjNex0UAefnwLdH4onXftMH/CPki/Nl82/wDtARmAS4xt2+UfruAOO9ZXgz4c3mgatokc0EFxp+kSSPDdy63fTSHKOilbRv3MbYfBILDG7AGePVaKAOV1nw1PqfjKHUmljSw/sa70yQAnzN00kLBgMYwBG3frjg9uQj8BeJLrRtO0vU5dHjg0bR7jTbKa3lkLXTyQCFXkUoPKUKMlVL5J68CvWaKAOE1fwxrCXPhDVNHOnz6jodvJayW13K8UUySxorFZFRirAxqR8hyCRxWBr3gHXdTv9Rv7iCwu7jV7WOG8hXXL+xgiZVZCNkI/foVI4bYeG/vcetUUAQ2UAtrOCBQqiKNUAXOBgY4zz+dTUUUAFFFFABRRRQByvxL/AORcs/8AsM6T/wCnG3rqa5b4l/8AIuWf/YZ0n/0429dTQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUVzOlvEXkOB2Hc0l1cR20LSSnCj9T6VzFzcyXUpkkPHZR0FS3YpK5Zu72W5bn5Y+yioAaiU08Gsy9h2aXNJmjNFh3HA0F/LG7JXHcdqbRQIuwalNHgbhKnqf8avQ6pC2PMzGffkVhCQgL5qEdjs5/GnZqk2hNJnUo6OuUYMPUHNOrlFdkOUYqfUGrUWq3EWAxEgHqOfzquYnlOhorLi1qAj96rofpkVchvLeYfu5kPtnB/KncVmWKKKKYgooooAK5b4af8AIuXn/YZ1b/043FdTXLfDT/kXLz/sM6t/6cbigDqqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+Jf/IuWf8A2GdJ/wDTjb11Nct8S/8AkXLP/sM6T/6cbeupoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkNdvz9rH2sPDGM+WHUgYGMn9R+dV4J4pl3QSpIvqjA1u61tiuUllHyNGUDHovXP6EH6KfSoRYWF2A9xbQ+cOpKjcv40ezvqQ63K7WM4Glz71oPokGMRvMnoRIxx+BJFQjR5kPy3bv8A9dFU/wDoIFT7NlKvEr54pQc1U1w3WmCFt1vIJCRyCpzx05NW/sl9tVo44JFIznzCM/8Ajppckivax7i5opjJeRj5rN2P+w6n+ZFNLS8b7W4T/gIb+RNLkfYanF9SRuVIBx7iky55LkPnO5eKYZP+mU//AH5f/Cq8moWyNtklEZ9HBX+dKzHzLuWi2ANpDcA4z2ppJIztC57Z4FVY72yJxHc2xJOPldeT/jUokDt8ku5eu0MCM+tA7j2YOSQmwehOajcChpQCQH254OGxmkdx6igY6O5nh/1U0i+wbirMetXsfV1k9mX/AArPZ1HVgB9ajMsYGS6Y+tCuI3U8SOP9bbA/7rY/pUn/AAk1uPvW8w+mD/WuYa4h/wCesf8A30KieeHH+sT/AL6FO7FZHXf8JPZ94p/yH+NUPhZKs/hWeZMhZNX1Vhnrg6hcGubaRXjZoSJMcfKc1ufBzI8DLnOf7S1POf8Ar/uKqLYmkjtqKKKokKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5X4l/8AIuWf/YZ0n/0429dTXLfEv/kXLP8A7DOk/wDpxt66mgAooooAKKKKACiiigAooooAKKKKACiiigAoopGYKpLEADqT2oAWs/UtWt7BcOd8p6Rr1rN1PXWaU22mYd+jTdVX/P8AnPWqVnarDukJZ5W+87HP+f8AOa8/FY+FDRas6qWGv70x93e6heRMJbaMQk5CsQMe/XOffj8KraXFayl1TUpbS5Tho3ZWj/4CCOPwP59astE0jZNxKmey7f8ACkntLgRFoL24LgcZK/l0rlw+ZJO9SXysXVoxl7qiMll1G2Yi31DR7pR0DzmBv/Z8/pQdfmgz58ULH/pndQ4H5uD+lX9MhjvoMi8u0lXh0LjIP5VcOjITk3d0T/vL/hXtRq8yujglQUXZnC+J/E9tfWsUEV4tnKHDMz7sbe4yoIz071paH4y0uPToLe5v4pbmNdrPljuPYkkV0/8AYcOcme4z67hn+VB0OEjH2m7x/vj/AAp877EeyXczF8UWDEBbi2JPbzSP5inDWreUk+bagezo367x/KrE3haymOZJLhm9Swz+eKB4Ytl+7d34/wC2+R+RGKfOL2XmVn1CHqtxbBf9u5VT+in+dQi5tMfPf6cB6MTMR+JYfyq1L4XPWHUroH0kww/TFRf8I1MD80gl+kzx/wDxVHOw9kVZrnRd4Ml7E7qMjCDA/TkfXNc14svo5xpcFpc+cBexgLjkgkcE9fXv+VdSfD4U7XtLtuvMd2GH64rntW0W50/XtIv/ALLKbWKXMgLb2U4IB47Dg0N3Q4xszcuNLsw5HldOPvGqz6VaZ/1I/wC+j/jWg7EnOD+VMO7P3T+Vcup26GW+j2ZP+oX8z/jUL6LaZ4gX/vo/41sEN/db8qYyv/cf/vk09Re6Yp0e1H/LEf8AfR/xph0m3/54j/vo/wCNas0ixMqytsZvuhuCfpUZkXswouwsjJ06JdM1RoIU8uG5TPGcb1/xBP5V03wj/wCRNb/sK6p/6X3Fc3rbbbYTRMomt2Eq5PUDqPxGRXQ/B2RZvA4ljOUfU9TZT6g39xVwImdrRRRWhmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcT8Y3ePwMzwsUkXU9MKMOxF/b4Ncx/bGuf9BWX8hXTfGX/AJER/wDsJab/AOl8FcnxXl5hXnSklBnZhUmndFtNT1xlyNXk/ECnf2hrv/QWk/IVUR8dBmp1bcOmK8542v8AzHXyx7L7iT+0Nd/6C8n5Cl+36521eQn0wKhcgHk0m4djS+u1/wCYOWPZfcXrW+1ok79TkkH5Yq4l1qzLn7ew9t5/wrPtpApy3ANWRcxhgAaX16v/ADDtHsvuLPn6t/z/AJ/77P8AhUiS6qQc35J9fMP+FRrJGx4cCpTNEF++KX1+v/MNRj2X3IaLjVAeb1j9ZD/hUqyauRlL4jPq5P8ASq7XMeOMk0Q3mCPl5PbNH16v/MFo9l9yLQl1dcbr7P8AwLr+lOabVj927/8AHz/hSPdREdyfYVF9uXHyZwOoNL6/X/mDlj2X3IkNxqwOftXHu5/wqPyrq6wb28d0Bz5a56/Un+QFPe6j2A54PT1qKO43OQFwvck0pY2tJWcgsui/AuwxpFGFjAVfSpVzn2qklwhO0H8T2qdLiMZywIHcd65Hd6g0WWI7dqdv6Y6VU+0LuGB8p704zJ/Dk0ieUZdW3mSCWCUwXA6OvOfqOP5ik83VV4+1A+hDkf0pGuQOqmkW8VlztYGumniqtNcsXoPl7okEuqn/AJeR/wB/D/hTs6qR/wAfYH/bQ/8AxNJDcBzz1zVhpVU4HP0qv7Qr/wAwnHyX3Igzqo/5ewf+2h/wo3ar/wA/S/8AfZ/wqfzlKnnBqNZVGfmyfSj+0K/8wuXyX3IjL6qD/wAfI/7+H/CkMmq/8/X5Of8A4mrAlUjk4qOSUKMg59hR/aFf+YaS/lX3Ih83VV/5es/8DP8A8TTlk1Vh/wAfIH/Az/hU0ciuvzHH1prOF6H8qP7Qr/zDstuVfciPfqg/5fAf+2h/+Jozqx6Xf/j5/wDiaVpgBnv6UiXQxzkH0NL+0K/8wcnkvuQZ1b/n7/8AHz/8TRnVv+fv/wAfP/xNO+0gnFSiZf71L+0K/wDMJxt0X3IzL6wu7ySJ7uRZHiOUJkPy8EenuajOnT4++v8A38P+FaclynQZqrJPjk8Aeho/tCv3LjHyX3IybrSJnVklkjdWUqRuPIPGOla3wbiEHgVIVACx6lqaADoAL+4FRM4JyDVr4Sf8ia//AGFdU/8AS+4r08rxNStOSmzlxsUoo7KiiivaPPCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOA+OszW/w1vJkIDR3unuM+ovYDXjq+LL09ZI/++R/hXr3x+4+Fmo55H2uw/wDS2CvnxnQfwj8xXDi1do+gyZRcJc0U9eqOqTxVednjHvtH+FSjxTfdfOj/AE/wrkFlUH7gp2/ceFA/KuTlR7Xs6f8AIvuR16+KLw/ekhP5f4U7/hKLsfxxY9gP8K5Atz0H5j/Cnhv9z9KLIfsqf8i+5HXf8JXdAfeSnJ4sut3Bj/EA1yXOOsf4AU4EAdV/If4UWK+r0v5F9x2S+Lbz1j/Jf8KePFd538v8l/wrjA6dyP8AvmpA0Y/un8DRdjWFo/yL7jsR4sul6mMfgP8ACpF8V3RPMkY9yB/hXFhlP3QPwBpykHv+lF2UsHQf2F9x2v8AwlNz/wA94f8AP4Uo8UXOf9dD/n8K4sEevNOycD0oux/UaD+yvuO2PiiYD/WxH6f/AKqb/wAJXOOjp+X/ANauPVqeCO9HMylgMP8AyL7jsB4pm/vIfp/+ql/4Smf+8uPp/wDWrkQyjpTgw9aOZh9Qw38i+463/hKrjswP+fpTh4rn75/A1ye5eOf0pQ1HMyv7Pw38iOu/4SmRhySfwpB4olB4Brkw3pShqfMw/s7DfyI6z/hKZe24Uv8AwlU3+1XKCSjzKXMw/s7DfyI6r/hK588A/nR/wlc/pj8a5XfSM2afMw/s7DfyI63/AISqf+8B/n6UjeKZwOGUn8f8K5LdSFsUczD+zsP/ACI6r/hLbkDqv+fwpP8AhLrnPb/P4Vyhb2ppYUczF9Qwy+wjqz4uuP7w/wA/hTG8X3I6Mp/z9K5RmB6mmkii4fUcP/IjqT4zuwe3+fwpD4zuh1I/KuTJHrUbEGlcX1HD/wAiOsfxpd9j/wCOioz4zu++P++BXKk+1MZgPWgX1PD/AMi+46z/AITW7B6gf8AFel/BKdrn4eW87nLS3+oufxvpzXg25e9e5/AX/kmFhj/n8v8A/wBLZ668Juzws9oU6VOHJG2p6DRRRXcfNBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnnx/8A+SV6lxn/AEqw4/7fYK+flBOP3cf419A/H/n4V6lg4P2qw/8AS2CvnxI2J5mQfjXFit0fQZN8EvUmVDnJWMU8Qj/pl+dMFuMfNcR09YUH3biPNch7qXmKYh2Ef500wsTwB+dOMan/AJax/r/hTDEf4XQ/jQWvJjhA5P8ACfxp4t3Pp+YqIW8p6FD+NKLWX1XP+8KAUn3Jxat6j86UwhRzJz9Ki8iQD5gn/fQo8px/dP8AwIUilK/UmEYH8X6GnBUHWQg/Sq4Df7I/GpVLnuv5ig0v5koMf/PQ4/3acWj/AIWP5VF845wv5ikO4+n6UFJlhWXrv/Sngg/xCq6lvUY+opcn1H50iky0Mf3hTuB/EKrruI4P60/a5HT9RQUmSjH94U7f6VCDj0/OjdTGmWFcY5zSlh71CG46ijIpDuTBh1zil3D+9UIOR1FLjPdfzoC5MGXH3v0pCyf3ifwqAnHek3c8UAT707MfypC4J61EW4poPpjNMLkrN2DfpTG/3hTGJ9vzppY+1ArjzjHLCmk570wk/wCTTHBHp+dArj2YD/8AXUW8e9NZs8cVED6EU7EkxZSep/KkOPX9KhYn+8Pwpu4+v60CuTHZ3Y/lXuvwFx/wrCwx0+2X/wD6Wz14GVJ/jX8697+AfHwu08f9Pd//AOls9dWE3Z89n/8ADh6noVFFFdx8uFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAed/tAcfCvUuAf8ASrDj/t8gr57DNjhF/KvoT9oD/klepY/5+rD/ANLYK+fULAdq4sVuj6HJX7kvUcFcjOxaDuxzGtG5m6BfypQHPAH/AI7XIe6mHzd4x+tGT/d/SnBZewP6Um2TOSGoLUhueeENIRz80Z/OnZZTyv50b27jH4mglsQMB0Rvzo3D0P50oZuw/IGlLP6H8qCk0AIPeng1Hlsf/Wp67xn7360Fpjw3tTwaiyx65oyfU0i7lgNj0z9KXeaiDetOBoGSg+ppwaoc04Hn3oKTJgacGqDPvTweO9A7koalzUWacCTQO5Juo3e9R80E+tAXJM0m6o80bqAuPJpM00mkJPpQK47NNLU0tTSaYrgSaYTxQT1phNOwhcmmE0E0wmgTYpPNITSZppNMLik17/8AAH/klunf9fd//wCls9fPhavoP4Af8ks03/r7v/8A0tnrqwu7Pn8//hw9T0Oiiiuw+XCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPO/j+C3wr1IL1N1YAf+BsFfPHlzD72R9TX0P8AtAtt+FWpt6XVif8Aycgr51F4e2fyrjxW6PfydtQl6k6CX+/TlDnrk/Qiq4vH6YH5n/GgXLk5wv51yWPbTZaAf+49PPmY4Vx+NUxdSDnd+p/xpReOTknNFirskJlB/wAaXdL3H5CmfaSOdoP+fpSG6z0Qj8f/AK1FhXfYn3uOrN+VOWVv7zn8KgF04AwpH4//AFqU3sgGMD/P4UDV+xOXk6jOPpSeZITgD/x2oheyEUv2p+4/Qf4Uil6E6u/9zP8AwEf4U7526RN/3yP8KrfaWJ7fkP8ACk80nrj8qC16FvbL/cI/4DR82Tkc/SqwmbpmjeSec0FplrnPSgHmq4cjoaUSHPU0FJlkHFPRSemPxqr5h9TThK2PvGkO5cELEZyv5ik8s+351VEp7tS7/egLstiNsdaGQj7zVUL/AFpu+iwXZeCAj760eU3ZlqjvpfMPvTsGvcvCBznLqPz/AMKQwH++D+Bqn5rY6fzo81h/CaRF5dy2YD/eH5H/AAqN4mXqy1W89/Wkad8Yyfzp2HdkpUZOXWo2xnhgfzqMzNTGmc9SKBczJSM9x+tIUJ6EVCZWo81vX9KdhOTJdjfSmFGOc4qMzHPb8qaZCeuPyoFzMl8tx/CPzr6C+AIx8LNOz/z93/8A6Wz187eZjrn8K+iP2fzn4Vaaf+nq/wD/AEsnrqwu7PCz1/u4ep6JRRRXafNBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHI/Fbw7feK/At/o+lPbJezS28kZuXZI/3c8chBKqxGQhHQ84rxX/hSvjf18N/+DCf/wCR69z+Id3e2fhtG0y8lsbmbULC0+0RIjPGk15DE5UOrLna7YypqL/hF9X/AOh78Sf9+NO/+RaiVOM/iOijiqtBNU3b7jxH/hS3jj+94b/8GE//AMj07/hS/jj+94b/APBjP/8AI9e2f8Ivq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItT7CHY2/tLE/zfgv8AI8S/4Uv44/veG/8AwYT/APyPR/wpfxx/e8N/+DCf/wCR69t/4RfV/wDoe/En/fjTv/kWj/hF9X/6HvxJ/wB+NO/+RaXsKfYf9p4r+f8ABf5HiR+C/jk9W8N/+DCf/wCR6Vfgx44A6+G//BhP/wDI9e2f8Ivq/wD0PfiT/vxp3/yLR/wi+r/9D34k/wC/Gnf/ACLR7Cn2D+1MV/P+C/yPFf8AhTXjj18Nf+DCf/5Ho/4U144/6lr/AMGE/wD8j17V/wAIvq//AEPfiT/vxp3/AMi0f8Ivq/8A0PfiT/vxp3/yLR7Cn2H/AGpiv5/wX+R4r/wprxx6+G//AAYz/wDyPSr8G/HA/wChb/8ABjP/API9e0/8Ivq//Q9+JP8Avxp3/wAi0f8ACL6v/wBD34k/78ad/wDItHsKfYP7VxX8/wCC/wAjxf8A4U7449PDX/gxn/8Akel/4U7449PDf/gxn/8AkevZ/wDhF9X/AOh78Sf9+NO/+RaP+EX1f/oe/En/AH407/5Fo9hT7B/auL/n/Bf5HjP/AAp/xx6eG/8AwYz/APyPSj4QeOB/0Lf/AIMZ/wD5Hr2X/hF9X/6HvxJ/3407/wCRaP8AhF9X/wCh78Sf9+NO/wDkWj2FPsP+1cX/AD/gv8jxv/hUPjn08N/+DGf/AOR6B8IfHAP3fDX/AIMZ/wD5Hr2T/hF9X/6HvxJ/3407/wCRaP8AhF9X/wCh78Sf9+NO/wDkWj2FPsH9rYv+f8F/keOf8Ki8cf3fDX/gxn/+RqX/AIVH44/u+Gv/AAYz/wDyPXsX/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLR7Cn2D+1sX/P8Agv8AI8d/4VH44/u+G/8AwYz/APyPS/8ACpPHH93w1/4MZ/8A5Gr2H/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFo9hT7B/a2L/n/AAX+R49/wqTxx/d8N/8Agyn/APkagfCTxwP4fDX/AIMp/wD5Gr2H/hF9X/6HvxJ/3407/wCRaP8AhF9X/wCh78Sf9+NO/wDkWj2FPsH9rYv+f8F/kePf8Kk8cf3PDf8A4Mp//kaj/hUnjj+74a/8GM//AMjV7D/wi+r/APQ9+JP+/Gnf/ItH/CL6v/0PfiT/AL8ad/8AItHsKfYP7Wxf8/4L/I8e/wCFSeOP7vhv/wAGU/8A8jUH4SeOP7vhv/wYz/8AyNXsP/CL6v8A9D34k/78ad/8i0f8Ivq//Q9+JP8Avxp3/wAi0ewp9g/tbF/z/gv8jx3/AIVH44/u+Gv/AAYz/wDyPSH4ReOCfu+G/wDwYz//ACPXsf8Awi+r/wDQ9+JP+/Gnf/ItH/CL6v8A9D34k/78ad/8i0ewp9g/tXF/z/gv8jxv/hUHjj08N/8Agxn/APkekPwf8cenhv8A8GM//wAj17L/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItP2FPsL+1cX/P+C/yPGT8HvHB7eGv/AAYz/wDyPTT8HfHH/Utf+DGf/wCR69o/4RfV/wDoe/En/fjTv/kWj/hF9X/6HvxJ/wB+NO/+RaPYw7D/ALVxf8/4L/I8WPwb8cf9S1/4MZ//AJHo/wCFN+OfXw3/AODCf/5Hr2n/AIRfV/8Aoe/En/fjTv8A5Fo/4RfV/wDoe/En/fjTv/kWj2EOwf2ri/5/wX+R4qfg344PU+G//BhP/wDI9ez/AAq8O33hTwLY6Rqr2z3sMtxJIbZ2eP8AeTySAAsqk4DgdBzT/wDhF9X/AOh78Sf9+NO/+Ral+Hl3e3nht21O8lvrmHUL+0+0SoivIkN5NEhYIqrnai5woqo04x2OevjK2ISVWV7eh0tFFFWcwUUVzXjbx14b8ERWcninVI7BbtykG6N3LkYzwik4GRknjkUAdLRUJkM9mZbKSJjJHuhc/MhyPlPB5HTpXlWk/FDUb2+8CRNZWiw6pCw1lhnNrNlokEfzcAzRyKc5OAO9AHrdFeR6T8Q9au9d0Ocadc6hYanp+oXUNjpkce5kjuolglZ5XUD90ST8wBLgAZxU3jT4gofC1/qfhu/v4bqXw1Nq9mGghMKBWUBmDAt5gLAbeVxnIzigD1aiuKvPiDYWV1PFJYancWllLDbX2owxIbe1lkCkK2XDnG9CSisF3DOKv+PdXuNGstKnt7hbdZdUtYJ3YLjynkAcEt0GM89vWgDpqK43/hP7KW1sZbDS9WvZNQmkjsIIY41e7jQZaZN7qoiwR8zlc5GAcjMK/EjT7iC2Ol6VrGpXUkMs81pbRRiW1SORo38wO6gEOjrtUsSVOAetAHcUVwVz8T9MXzpNO0rWdUtINOg1Wa5s4oikdtKHKuQ8isThGJUAt6A4OEuviBpun3WqSp/bGpqtxZQRQQQxMu64jDR+T91iDnLbySCeOKAO+ori4/iFZPbFf7K1ZdWF+dNGklYjcmcRiUjIk8vb5Z37t+3HfPFbfhXX4vEenTXUVnd2TQ3EtrLBdhBIkkbbWB2MynnuCc0AbNFePr8SNeuvCWn6rJod/ZyHXBZv5KQSC5iF3JEYkUSu2/agDE7RuyVOMGurT4h2TWxB0rVhqw1A6YNJ2RG5M4jEuMiQx7fLIffv24754oA7Wisjwxr1v4h057q2hubZ4pnt57e5ULLBKhwyNgkZHqCQQQQTWYPGKw61HpuqaHq2myTJM9tNceQ8dx5Q3MFMcrkHbyAwXIB9DQB1VFcBp3xQ067sbe8uNH1qwtrvTZNUs5LqKLF1FGgdgm2RsNtIID7c9QSOayfF/wAS5B4Q1aTTrLVNF1YaZ/aVg99DCRNEHRS6gM4yN65VwD8wOKAPVaK4a88dWGlaxrNnIdWv72LULewhsUihy80lusoSA/L8u0lmaVuCG5xirl74yubTSDqL+EfEbQxrI9wgW2EluEJzlTMC+QMgx7wR09KAOtorz21+Ibv4s1m3k0ydvDllp1pqI1OMxBY4pUldpJA0oYpiMABULZV8jBUmR/ifptvpt5eajpOs6esGmtq0UdzFEHurZcbmjCyEZG5cq5VhuGRQB31FZuiajNqtm802mX+l/NiNbzyg7rgEOAjttHPRsMMcqK4jSvibZto2mPZ6b4k1p5tKGqmXybZZfI3MpaTDogf5T8qjntk8UAek0VW0y+g1PTbS/s38y1uoUnifGNyMAyn8iKs0AFFFFAHK/Ev/AJFyz/7DWk/+nG3rqq5X4l/8i5Z/9hrSf/Tjb11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcr8NP8AkXLz/sNat/6cbiuqrlfhp/yLl5/2GtW/9ONxQB1VFFFABXNeNvAvhvxvFZx+KdLjv1tHLwbpHQoTjPKMDg4GQeOBXS0UAMhjSGFIoUVIkUKqqMBQOAAK8vu/hFFLpnjG2g1mSCbXbuO7t51g5sCkxnVVG75h5ryN/D9816fcCVreUW7pHOVIjeRC6q2OCVBBIz2yM+orwbw/L4ovvD/wiuptWsLvUbqdngnuraViimwn3GY+aTM2MnIKZPpnIAPVNH8Hw6VrOhXlrcYg0rR30iODy/vKWhIfdnjAhxjB+91455aT4Tb/AA6ml/21jb4fm0Lzfsn/AD0kV/Nxv7bcbc9+tUpviTrWdP0tYbdNWa61CC6u4NKu76ELayrHuS3hJk+cunV8LzknK57zwtrWp6r4Jg1W90qW31VoZC1lIjwlpELKMLIAyh9oI3DIDDNAHMah8LLWbX7rUbZfD5+1zpcTSX+hx3dyjqqqfKmZwEB2A4ZXwWYjqAOp8b+F7XxdpVvp2oFDaJdw3MsUke9ZlRtxjIyOG6Z/Q1w+lfEDU20y/bXtX0fSb+K3gl8q60S8ilt5HfaUMLyA3CnlVeNhlu3Yx2nxB8RXlm9pbLpw1VNfi0n7Rc6bc20bRSQCYSG3kcSowzjBbBxkHBBABp6j8Lxe2enw3V9p+p/2XLMNOGs6aL1IreQLmKRTIpkKlV2vlSAoB3ck1bn4R2rxWMscfheS+gtntZPtfh2OW12GV5V8qBZF8oqZGGdzZB+bJ5ptt4x8WW9w02ptoUtjba/DoU629rKkk3mOiCZS0pEeDKnyEPnDfMOKb4W+Ieva3rmnMumO+k315LbmJNHvUe1iXeEma6YeS+SgBUAY3jBODQAp8Ba+dY1qysNStNM0a70Ww0yS4SwQtN5YnWTyUSRVgIDjGUZfn4Hy1sr8OYYtRkntb/yrc3mnXMcPkZ2LaIECZ3c7gOuOPQ1oeMNX1u38SeH9H0CTTYW1FblpZ72B5hGIlQjaqumSdx4JH19eX0Dxz4l8UXVppekpo1lqUVvdTXlxcwyzQSNDctbhYlV1IVmQtuLHaMDDGgC54m8IajYahdeINAkuLrWJNWGoQRRW0UgjVrVLd0dZJ4g6kJnIdWBIwDg53fhhpOq6T4blGv7RqV3e3F5KoCjb5khYAhSyg4xkAkAnGTjJ4x/iXrdzZ6VqaW9no+k3Vjb3P2m8sbi6gkldyskZuISFgC4GGcHduB4qumq67feL9Ot9AuNK0ZP7e1W2lRbGR47gpFkSTKsyb2PJJJ+9g9sEA6qz8BXtvbw2B1mB9KttY/te2i+xETITcNO0bSeZhgWcgHYCPeode+GNtq95qN5PNYXFxPqg1KGO/wBPF1bofsqW5jkjLjzAQm4EFSDt9OcrTPFeqTa4dB0K00XT7281jUla6a0Zotlv5e52jV1LyuZVyd46E81JpHjXxR4h1TStL0waLZXj22oNezXEEs8YltblID5QWRMoxYnk8A9TjBAO48F6APDejGxA04ZlaUrp9gtlAueyxqTjp1LEnua4LQ/hLLo+q2mpHUbC7uLOO5USrpnl3d4ZY2UefcGVi5GR2A9h27Dw74mn1f4a2viQwRRXUunm6aIZKCQISQO+3I+uKxLnxvqUWnabcLBZl7nwtda44KNgTxC3KqPm+5++bI68Dkc5AMTSvh9r7+BNMTXbyG41DTfDkmn2OmwW6xeTNJbiNhJIZGEjDGwMNq8k96uTfDPUtd0Mx+JNbhN9/Y40q2FvY7EtVYo0jMDK3mOTGg3AqMDgc1hePfEevXHgXxHpviA6XIL/AMLTapC1jBJH5JBVWjYu7b/9YpDAL0PFb134312G31rVLKLTBoWhX0Wnz20sbtc3A2xGR0kDhUI80bVKNu29RkYANLV/h3JdeINQ1yy1j7Lqcmpwanau1t5iQtHbC3aN13jzFdd2cFSMjnjnP8UfDLUvE1wtzrOu6XfTm1ktWS70bzoISzswkgiM2I3AbbubeSFHPXOj4d17xH4ma+1G3OkQaDDfXVkbZ4pDdFIS0Zk8wPtDF1zsKfd/irJ+AviS517wvo9paJbw6VpGk2dpKJVP2mafyEO4LkbIgOAxB3nJGAMsAakfw6liEtumrRNpt9osGialA9oS88cSSIHicSDymIlbOQ46VU1D4Z3+saTdWmu+IorqUaPLo9lLFYeUIEk275HXzD5kh8uMcFB8vAGafqs2vSfFPXbW31W3TSY9Bt52tJbeR8hpLlTtIlCq5K8vtORtGPlyeZ8JeMtZ8HeAPCz6xHp97pr+FXv7aK0ikjmj+zQQsqu5Zg25X5IVdp9RzQB7hXAeE/h1/wAI/YW9t/an2jydDXRt32fZnDu3mY3H+/jb7dab8P8AxVr2sa09lrNkzQNZC5F1Ho15YRwy7gGgJuP9YcMCGXGQrZUVH4u8X61o3iv7KRZ6fo6/ZxHdXmn3M0Vy0j7XU3EZ2QEcAb1OSR0FAHZ+GdL/ALD8N6TpPnef9gtIrXzdu3fsQLuxk4zjOMmtKvCND8Rx+G7m5uptPtLpI9X8TXTSvFunjWGRnKxN/Duxg8HOBWhqfiDXdA8Qf8JH4hXT7yaHwtd3cNpYQSRbD51ufLZmd9/JUbwF7nbQB7PRXjtx8QvFdppmoM1jbzzJ9i8i6m0a+0+3Ek11HC8LLPhnIEm4OpHuvGD6ro8eoxWKrrNzaXN5klpLS3aCPHYBWdz+O7n0FAGF8S/+Rcs/+wzpP/pxt66rNcr8S/8AkXLP/sM6T/6cbeupoAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzRmkooAXNGaSigBc0ZpKKAFzXK/DT/AJFy8/7DOrf+nG4rqa5b4af8i5ef9hnVv/TjcUAdVRRRQAUUUUAFcp4b8J+F4INMvtCVprS3ka7sHS/lngiLxuhMQLlFQpI42qNvOQOBXV14P8NZPENn4Q+H1np3iCeSDW9KmgEbW0BSwZLctHKhCbjtYBSHLglug6UAeq3PgrQp4in2a4hb7VNeCa2vJoJVllOZCJEcOAx6qDt4HHArQs9C06z0H+xYLc/2aY3hMTyM5ZWzuyzEsSdxySc81xXwy8Wav4x1SWacNaWml2i2WoW5jAD6lu/egEjO2MKMYOD5vPQVR8aa1rUXiDxn9l8TvpFnoejW9/BELeB0eVvtGd5dCxU+UoIUg8jBHcA6hfh14ZFpJbvZ3UwfygJZ9QuZZohE26MRytIXjCtyAjDmrOneBvD+nHdbWcpkN6motJNdzSu1wqeWJGZ3JJ28cnB6nnmuIvvHGrx+HvGd5Ldx2V3ZW9jLaxMifuHmgRmXBHzZcsBnPTAq1/b+uQePUXUdRvI9Jn1U2Nr9kitJ7Jx5ZIhkIP2iObcrEk/KMYxQB18Wi+G77S2u4Rbz6fc3kes+fHcs0bzIUdZgwbGAY0OAdvHTrUWleFvDkl3a61pfmTRs5vLbydQme03SZJkjhDmIbtzHcq8lie5NeafC691rRPCvgGP+2Zbqy1PRpj9kkt4lS2McKvGY2VQ5PUHczA5zgdKXS/EfivXNLhuE8Sz2TQeDbTWX8m0t2866fz9zNujOFPlrlVx7FecgHpfivwfbeJda0a9vLq6hj05Zx5dtPLbyOZAoyJY3Vlxt6DrnFVdZ8G+ELfSLIX9vFptjp0Zt4por2Sz2RyMAY2kR1LK7EZDEhmPOSa4XXvF+v3ug+J9XtddbRm0bT7SaG2hhgZZ5JoFlLP5qMdpZiihSvKHrXoPxR1a90PwPqGoaXN5F5E8ISTYrY3TIp4YEdGI6UALc+AfDdxNE72EiRpHFD9nhupooHSP7ivCriNwMDAZTUl54H0C7Qh7SaN/tsmoCa3vJoJUnkBDusiOGXcCQQCB7Vz/wtsZ49c8Z3Daze3ES63cRmzdYPLDFImD5WMPuwcfexjsTzVHxV4g1vTvGszTaleW2gwXdlbq1hHaXESGUqGS6Rz56sxYBWj4AYEj1AN46B4K1NoraCa3a5mvLi+he01KSO4M4Oydo5EkDjB+VwpwOhFalvoXh3wzFbahHDb6dDpdnJapPJMUjhgZld9xY45ZFYs3PB55OfHdK8Xar4W0G3fTcSwhPFF9JbFARLJBdbo8n7wA3tnBGQe/FX/iFd6pb+GPFml3viaXW4JfCst6weK3QJISF3J5SKdhBOAxb6mgD2TStG0/SdFg0ixtlTToYvJSBiXGz+6dxJI575rm9N8DeD9Pv5rO2hJvZNNezMEuozSulk5UFFV5CUjygA2gAEHGMmuD+JU2s2ukeMNA1LxBc3sCaPbaitw8EETRsZ3R0G1MeWdgIzlhz8x61oa9ba5YeNtRXRNUub7W7fwyJ4Li6jh3zlbtn8pgkaphgCmQoIBznPNAHoGp+DtC1OFob6x82NtPbSyPOkX/RmKlo+GHdF568daqav4Q8Lf2iNX1O3SGQzwM5e7kigmmVlSEyR7xHI4bYqllJztA7VT+GniW58ZjU9fhkkXw/M8cOmwPGFJCL+9lJxnmRmTGSB5WR1Ncj4yu9T1W0v7y81mS2s7XxRYafb6UkUISUJeW/zOxUyFycuNrAbQOOtAHoMfgjQI9ak1SKzljupJ2unRLuZYGmZSrSmEP5e8gnLbc89as6Z4V0bS7jTp9Ps/IlsLNdPgZJX4t1ACxtz84GBgtkjkjqa87svFWuyXFtrD6uWWbxM+iNofkRbEiEzRZ3bfN81VHnEltuM/KBiuXvPij4o0xLiS4kaeLSUuNHvj5CBptTJn8hhhcAHyYenH+kDjigD23UvDGlajrMOrXMM4v44fs/mw3UsO+PJOx1RgJFySQGBAyfWmxeE9Ejt9KgFgjQ6ZZvYWsbuzqkDIqMhBJ3Aqij5snj3NebeINZ8V6bB4uvP+EjmB8OQ2bLbra2+y5cwo0vmEx7sMS33SpGeDjivZaAMHQfCek6FeNdael4ZzF5Aa5v7i52R5B2IJXYIMgcLjpUeo+C9D1HV31K8trh7iRo3lQXkywzNHjYZIQ4jfGBjcp6CuiooA5+HwboEVws66cpkWa6n+eR2Be5OZyVJwQ3oRgdgKraf4B8OWNxPNHZTTyT2j2D/bLye6Bt2IJixK7AJ8o4HA5x1NdTRQBy8fgPw+scqSwXtyJDESbvUbm4I8qVZUCmSQlQHRTgYBxyCK6iiigDlfiX/wAi5Z/9hnSf/Tjb11Nct8S/+Rcs/wDsM6T/AOnG3rqaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5b4af8AIuXn/YZ1b/043FdTXLfDT/kXLz/sM6t/6cbigDqqKKKACiiigArH0XwxoGhTyTaHoel6bNIoR5LO0jhZlHQEqBke1bFFAGT4a0K28P2EtraSTTGa4luppp2DSSySOWZmIAHfA44AA7VQuvBGgXvii517UtOtr+/ligiT7XBHKsHlFyrR5XKsTIcnP8K9MV0tFAGRqnhnQdWvVvNV0TS727VPLWe5tI5HC/3QzAnHJ4pYfDehwa0+sQ6NpserPndepaxidsjBzIBu5HvWtRQBRh0fTIYrSKHTrOOKzQx2yLAoEKEYKoMfKCOMDtTYNE0q3jMdvpljFGbZbMqluijyFztiwB9wbmwvQbjxzVqzu7e9t1nsp4riBiQJInDqSCQRkccEEfUVNQBxHin4a6J4l1O1udRyILeJIEtY7S12+WpzsEhhMyKehCSKMccZOewvbO2v7Z7a+t4bm3fBaKZA6NggjIPHBAP4VPVA6zpYmEX9pWXmtcG0Ceeu4zhdxixn7+3nb1xzigBItE0qLWZdXi0yxTVZU8uS9WBBO6cfKXxuI4HGewqKfw3odxrUesT6NpkurR42Xr2qNOuBgYkI3DA96vy3MEVxDBLPEk8+RFGzgNJgZO0dTgcnFTUAZo0LTIwptrCzt5YxMIpYreMNEZTmQrlcAscFv7xHOa5vwt8M/D/h9tRYQpfG/i+zzrcWltHG0WclDHDFGhyepKknAGcACu2qhp2s6Xqd3eWunalZXdzZMEuoYJ1keBjnAdQSVPytwcdD6UASXOmWFzLPJc2VrNJPD9mlaSJWMkWSfLYkcrlm+U8cn1qnZeHNI022aLR9Os9LPktbpJY28cTRIxLELhcD5iWxjGecVcvdTsLGVI729tbaR45JlWaVUJSMAuwBP3VBGT0GRmrEEsc8Mc0EiSRSKHR0YFWUjIII6g0AUfDmj2nh7QrHSdPDi1s4liQucs2OrMe7E5JPck1Dd+GNBvNUGp3mh6XcakNhF3LaRtKNpBX5yM8EAjnggVo3l3bWMHn3txDbw7lTzJXCLuZgqjJ7liAB3JAqagDMXw/oy62dZXSdPGrkbTfC2TzyMYx5mN3Tjr0p76JpUkdxHJpliyXE63UytboRJMNuJGGOXG1cMeflHoK0KhS6t3u5bVJ4muokWSSEOC6KxYKxXqASrYPfafQ0AQXGk6dcpeJcWFpKt6ALkPCrCfAwN+R82AAOc1doooAKKKoNrOlrcvbtqVkJ0nW2aMzruWVl3LGRnIYryF6kc0AX6Kr3N9aW1xbQXN1BDPdMUgjkkCtKwBYhAeWIAJwOwzVigAooooA5X4l/8i5Z/wDYZ0n/ANONvXU1y3xL/wCRcs/+wzpP/pxt66mgAooooAKKKKACiiigAooooAKKKKACiiigAopDXDfET4gWXhjTrlbeWGXUVU4Un5Ij6uf6dT7ULUaVzuc0teK/s8av4g8Rz67q+q6jdXGmFxDCk3KvJ1Zl/ugDAwOPm9q9qptWdgas7BRRRSEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy3w0/5Fy8/wCwzq3/AKcbiuprlvhp/wAi5ef9hnVv/TjcUAdVRRRQAV5p8a/FvjPwra6Q/gXw1/bj3Errc/uJJvJAC7fljII3Zb5jwNvvXpdFAEVnJLLaQSXEXkzOis8W7dsYjlc98HjNfI11pmvj4GXOjeXcf8Ix9gOvC8525wR9kz6+f+++nFfX1YmtR6DpHhiWDU7Szi0FFWB7Y2waHa7BQvlgEYLMBjGOaAPNtQ8Va5HF4i1WDWRaroeqW2nw6N5ERS6RlhPzll8zfJ5rbCrKBgcNzWhb+K9cfxgPCH2pn1W11OW6nlEUe6TTAnmx8Y2glpI4d2AflY9ea9AuPD2i3OrQapcaRp0up24Ahu3tkaaMDoFcjcOp6GrYsLQai2oC1txftEIGuRGPNMYJIQtjO0Ek46ZNAHk/w38TeL9X1Hw3faot7/Z+sRSyXEd0bCOCL5C6C2EchnYqRtYSAnBJIUjFbXiGxuLr426CYdYvdPH9h3ZCwLARJtuLYsn7yNjhgRnGD8gwV+bPY2fhnQbLVpdVs9E0y31OUsZLyK0jSZy33iXA3HPfmptV0TStYa2bVtMsb5rZ/MgNzAkpif8AvLuB2ngcigDx7wXf614f0nwrcxapPe2OpajqFsdLMESooUXUqlHC+Zv3RY5Yghugxmtb4a+IfF2qah4fu9X+2Np+r2bzzC6+wJCjlQ6fZRDIZmUZIIkBOME7TkV3PhOfRdf0Kw1HTdMigtYbic2ySW6K0MiySRO6gZCknzOQckMc9SKuWHhrQtO1KbUdP0XTLXUJ8mW6gtY0lkycnc4GTk+poA4L4na/ruka1dT2upXlpoVjYR3E76bHZ3EkEhkbc1xFMRIYigXHlYP3vasqw1q+0nV7sadKVS+8dyWtwiorGWI2G/YMjjLIpyMHjr1r1PUfDmh6nqEF/qWjabd30GPJubi1SSSPByNrEEjnniks9OsLh5ZZdDhtpI71rhGlhiJeYLsFwpUtgleAxw+OCB0oA8os9U1aWXwT4l1DVZNRvr7TrzUk0tY4UjhJti6pHtUSHGQhLs2T6Vm3HjHxzY+ELrWJbm9CXGgT36TXi6cEjnCo8b2qQuzvHhiCJA38JJ5Ir2iy8M6DYalJqFjommW2oSMzvcw2kaSszdSXAyScnJz3qt/wiXhayTUJ18PaNCLqNxduljGDOh5YPhfmB6kHOaALmkade2dhLDfa1eahcykt9okihjMRIAwiogG0Hkbtx55Jryv4YXWoaPpPw+tjrFzPaau92ZoZ44Ao2xyPhSsatyw3Ekkk98cV6VF4q024fw59kaWeHXozLZTKmFKCLzQzBsMMr0GM564qze+HNEvtKi0u90bTbjTImDR2k1qjwoRnBCEYB5PbuaAPE/EGrz67Hpd/dXK3TNpniyJJUCgNFHMsceNvBARVGe+MnJ5rW/4SbX9Ih0jw3Zzv9q1/T7D+w7gQowtSEVbrPy4bYgEo3ZzuI6YA9Uk0HR7ezCw6HYukEU6RQR20Y+WXmVFBwB5h+8MgMetQ2+g2lxq2k61JBcW09lZNb29ixQR2wk2lvlTI3gKEyGKgZA65IBgfGxX/AOFdzrHP5Mn2/TgJmAOw/boPmI6HHWuevvEWqaRrGq+Hb/XNevZhdWkem3Vja2f2uaSWKR3gO+MQ4URbtxVcBhzXqep6dZarZSWeqWdve2cmC8FxEskbYIYZVgQcEAj3Arl/FOn+EfDXg1477w3p0mhJdQg2ENjCY/NllSJX8sgLnc4JPXGevSgDh9B8X+Idal8PaJcatPp0t3qGpW82omG2Nyy2xHlxYAeASMH5Kgg+Wcdar6hr2paV49ubW31dJEv7DS7a68SeSjRWyia9AYqMoHc4QEjYDknoFPrMvhXw9LpI0uXQdJfTPM837I1nGYd/97Zjbn3xU6aDo6Ws1smlWC200C2skQt0CPCu7bGwxgoN7YU8DcfU0AZPxH1S70LwVd31jc+VcwvbjzmVThWmjViQRj7pPbj2rkfGXijWY9a1rT9G1ZLYxaho1nG6wxy+R9onKS5BHJII4PTtivQdKuNI8ReGraaxSC70S+twYkeHEckLDgFGA4x2Iplj4W8P6fB5NhoWlWsPmRy7IbONF3xtujbAHVTyD2PIoA8n8RSatda1Bol74iv2OmeKLOGC/wDJtlmKy2hcBh5XlkqzEAhRndyCcVNrup6hc+L10y/vZLuDSvFelwW7SJGrYayDsTsVQSXZm6Y5wABgV6zfaFpGoRXkV/pVhcxXjK1yk1ujicqAFLgj5iAABnOMCmweH9Gg2eRpGnx7HjlXZbINrxoEjYYHVUAUHsBgcUAYfjbVb+y8ReDrGxumt4dSv5re52ojFkFrM4xuBwQyqfw5yMisz4E2c1v8OtLll1W7vkli+SKZYQtvtdwVTYik5PXcWORxiuz1eKLFtdNpZ1G4tpQ0ARYzJEW+RnUyMoXCs2cHOMgZzgppui6XpVxdz6ZptlZz3biS5kt4EjaZueXKgFjyeT6mgDQooooA5X4l/wDIuWf/AGGdJ/8ATjb11Nct8S/+Rcs/+wzpP/pxt66mgAooooAKKKKACiiigAooooAKM1larrMNlmNMST9lB4H1rnJ9Suro/vpDt/uqcCk2NK52xkQdXUfjWR4l8Q2Wgaa93deZIArFEhjZyxAzj5QcfU1zR6c0qEg8Z/A1POVyngHij47eINcWSCGMadbngQ2xIdv95+v4ACsvwH4S1n4na8tvdXP2PT4R5sx5yEzj5QerEnqff6H6I1fRtM1qMrqdjDcEjG9lw4+jD5h+dL4H8P6V4V1K6ubEThbiMIUYhtuDng8H+daqqraF3stDtPDmi2Xh3RbTStLi8q0tkCIO59ST3JPJPqa06hguoZwDFIre3epqkxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuW+Gn/IuXn/YZ1b/043FdTXLfDT/kXLz/ALDOrf8ApxuKAOqooooAKKKKAIL/AD9gucCYny24g/1nQ/d/2vT3r5zi8JtL4Z1eytvC/wBvhisbeR7uTQprG6mkS5RmjljkJW5lKByZU6nI/i5+kjnB2gE9gTiuO0z4iaDcaxY6NeanpMWqXdrHcxiC/jmglLsVVIpDtaRjjI+QZBFAHnPiLR9KlutYf/hEtSudLn0qOLw5Da6PNGLOcNL5gWPYDayGQxt5jBMjndgVm6/pYvb/AMY2V1o93qfjZrewisby3tJHFvdfZo/3gnA2Q4f5iSy5A79K920jxFoms3Fxb6PrGm389vxNHa3SStFzj5gpJHPHNcbqXjzTtP8AG+r6RpqeG4ry3t1uL641DVUs3kcRsVXAjdnCqo3M2NisOD0oA5u00mWL4pJdx6TLqF3Jqhee5vdGngmtkERUyRXwby3h+UbYTz83TNeo+EfENt4p0G31ewhuYrS4ZxF9oVVZ1Vyu8AE/KcZHqCDSXHifw/FqC6Xea3pEeoyMsX2OS8jEjMyghQhOSSGUgY5DD1pmn674Zt7+Pw7p2q6NFe2yiFNMguIlkiCrwgiByAB2xwKAPEB4a1JtM0H+3NPJ0qKLUVFte6BdaoqTveSMGMELqys0ZBWQggAHBBYZh8aaZqk/hWPTZPDsl7qFnoEa2Wr3Ph2e61CeUByqJJG/+iuhAPzuxy2cNkg+6+C/EH/CTaK+ofZvsu27ubXy/M3/AOpmeLdnA67M47Zxz1p1v4t8OXL3i2/iDSJWshm6Ed7GxgGcZfDfLzxzjmgDzfX9B1ifxZHo8VhcSaD4oNre6nOIz5du9uB56v2UzKkKY4z8/vVe08Jvqvia0h1vRZrjTf8AhJdVuZEuLdjE0bRfu2bIwUY4xng9Oa9K8YeKLXw5o99eZhuZ7PyGltvPCMiSyiNXbglR94gkc7COxxatPE2g3mmXOpWmt6ZPp1sSJ7qK7jaKIjrucHC9e5oA8e07SEsE0qHxb4e1C/8AC9m2rQ29j/Z0l1HC/wBsJgLQhT8vkgiNyNqjuMg13Xw0s0vvgtpFm1uskN1phj8mVQVdHU4BB4IIPfgg01tc8F+MYdYuddh8O3ujaLeLbw6heyQXFuxeCKQursNq8ybOCeU69h0snibw3Y6XaXcmt6RbabNGWt5mu40idFwCUbOCBkDjpkUAeReEvCOlX+l/DrTpvCckCWasutRT6S9uj3C2m0vKSgWUFx97LK3qarXXhzVF0nw/b3tj/wAU9p97q0X2K70S41ONM3RFqTbRsrMgi3hGwVUEccqR7E/jTwslyLd/EuiLcEEiI38QYgLuJxuz05+nNOfxh4Zj0iPVZPEWjLpckvkJeNfRCFpME7A+7aWwDxnPBoAwvCen3Nr8IhYu17cTrZXEcYuLVreUqS+xPKZmZcKVUAknAGeeK80/4Ql7/wAMeIJ9R8PTzana+CdOi01pbVjJHdpBcErECMiVXEfT5gSBxnn2GbxZanXPDllp/kX1prSXEkd5BOGQCJVbK4BDA5xkEYx3q/rXiPRNCKDW9Z03TS6l0F5dJDuUEAkbiMjJA/EUAeNeNfDcPh7RfE66ZpT2WmXPhu2NwIoiqTXKztksf4pdp5JO45Gaj1rQDNbeIpPBvh7ULDQZv7HUWv2CW3a4uY75XllWBlD/ACx7dzlRnbnJ2k17Fr2t+GobKCHxBqejx2moKPJS9niCXI4I2hzhxyOmeoqxe+IdFsdUg02+1jTrbUbjHk2k1yiSyZOBtQnJyfQUAeOG31C7+Jem38XhiHSryHXpFnltNBnSWS2xIvmy3wIjkVwQSoDYyMkEVZ8M+C47JPBl6NAaO/uNVv4tVke2Jd7WSO6+WbI/1RIiwG+XJXHJ57p/iLoVjqmm6brOpaTbXd+Llo3h1COSBRFKI9rO2wh2JxtCn5kdcnbk6g8V6VZ6Qt/ruraHp8LTyQCUaijQlldl2iRgnz/L8y4+UgjnGaAOa+BOm2ekeA7Cxj0WTStVt4Y4tSEmnNbGaZRgtvKgTdD86lhz15rmtL8JG0ubbWYdEmi1tvGV3JJdi3YTfZHuJxktjIhKMD/dOQe+a9S1XxRoGkJE2ra5pVisqCWM3N3HEHQ8BhuIyORzWlJdW8dm13JPEtqsfmtMzgIEAzuLdMY5zQB4Z4P8Nyy3Xhuzn0PULbxEr3aeJtRmtHjS7ieORWDTkbZ98jRsm1m2hT93pXP2vhfxjd2tlJqFhes2otF4TvY2jb5LGExZuWGMgN5d0c/dImXnpXv9j4s8OahY3V7Ya/pF1ZWuPtFxDeRvHDnpvYNhfxqSx8S6Ff2V3eWGtaZc2loSLieG6jdISBk72BwvHrQBg/GCyub7wHPbWFtNczm9sGEUMZdtq3kLMcDnAUEn0AJrih4TaG5bWYdFlXW/+EyEguxbt5wtGuMOQ2MiIozZx8pHJ9a9G8KeLbDxPf6zFpM1rdWdhLHGl5bXCzRz7owxwV4GCSvU9O3SujoAKKKKAOV+Jf8AyLln/wBhnSf/AE429dTXLfEv/kXLP/sM6T/6cbeupoAKKKKACiiigAooooACcVz/AIi1oWoNvbN/pBHzMP4P/r1Y8RaqNOttsfNzICEH933NcNud2Z5GLOxySe5qJSKirkynJLMSSeue59amU8iq69ualQ9MVJZYzSg1GDTxQBKpp4ZhtKEAgg8896iBqRTSAnfO/eFChuVx6Vat9QuYcYkLD0bms5f3KoY2dBFkqFPTrx9OTUrOoKEsWRsfMg3YB700BvQaxGQBNGVPqOavw3UM3+rkUn0zzXK8Z6/iacVKuQeCKpSJ5UdeKK5pLq5i4WZugODzxVmPV5hjfGrfQ4pqQuU3KKzY9XhYfOjofpmrMd9byY2yrz2PH86d0KxZopAwIypBHtRTuIWiko5oAWikoFAC0UhNGfyouAtFIDRmlcBaKTPvS07gFct8NP8AkXLz/sM6t/6cbiunLCuX+Gf/ACLl3/2GdW/9ONxQB1dFFFABRRRQAV434D8NeIfDNp4eS+0Ca8B8PJpV1HDdQr9nlWVm+clxlCH+8m4jHQ17JXlHgv4myP4J0ObUrPVNb1htJTU9RewhiHkxEsN7gsgySrYRAWO0/LQBc+F+ia3pWppHd2N9aaNa6ctrBHqjWcs8TB8iOKW35aEKP+WnzZAPrhnjbwvrGpWfxKSys/MbWNMgt7Eeai+dIscgI5I28sOWwOa3j4+sbjUTa6Lp2qazHHFBNcXNhGjRwLMA0e7c6sxKkNhFYhSCRVHwT4zOpGPS7lri+1d7zUBI1vGm20t47yeKJpTwFGECrwWYqTg4YgAxtY8G6pc2fj8xadG11ql3YyWbb490qRQ2wJyT8u145MZxyMjqM19b0vxvrHi6xa+tb57Gx1+O5g8prJbNbRWOHySbgy7Thh8o6gAjrraV8TbNtG0x7PTfEmtPNpQ1Uy+TbLL5G5lLSYdED/KflUc9snir+r/EvTbGzuLuy03VtWtLXT01S6mski228DoXUt5kiZJVSdq7iB1xkUAW/htpF/onhK4tNRthHdG/vp1iMincklzK6HKkgZVlPqM815xbeCvE7+G9R0my0u6tbCPR3tLW21WazkkSUSo6xQTwjeYsKwPm4Odh9cen/EPxFdeG/A+oa3plp9ruYI1dImxjlgMtll4APY5+tc5f+OtUsPF0kdxoGttZro/2x9OjW1aWFlmkVpGYS7eVUYUOSfTOaAMnxJo3iPxGnjK7Phm4tvt1ppcFraXNzbs8/kXM0kobbIyLw46tggjvkCTU/DGratrl74i/sG4toPP01jo0slv510LZpWLHbI0Wf3ibQXH+q5xxXSal8SdLtY3ntNP1XU7OGxj1G6ubOFDHawSDcrPudSTtBbagZgBnFb/iXxFZ6B4bm1u4Se5tIxGQtqod3DsqrtBIB5Yd6APLtQ8K+JNU1O713+zNR0wrr41KKyt5rKS5aP7BHAJF8wvBvDqThjxliDkKTq+FPB97a674evZ9OvVhgudRupzqMtq80ckwj2sVgAjUsVY4QHHOTzXQN8RLGG31D7bpWr2l/ZzQQf2fJHG1xM0/+q2BHZTuw3Vhjad2MUD4iWPltE2lasusi9GnjSDHEbkymPzRgiTy9vl/Pv37cDrnigDn9R8F391Z6qjaXDI914ttdSIYxnzLVJYCznJ5AVZPlPPUY55TVdL8Y6Zr/iG48PWtxHp2paxFcSvYtbNctCLKJGaJZ2EYJlQg7+ccgGuhh+IlldC3g0/SNXvNWladX0yNIlng8llWQyF5FjABdBkOd24bc1yvhj4gXsf9j33iG9dtPbw1Nqd0ogXe0q3EaAgKuc4YqFHBJ6ZoAPAXhHxBp194Vm1KxkiSyvdYmn8yaFmjS4kLREiPC5bOcIoA9F6VqeMbm4tPi5oc1pok+tTjQr4LbwvCjLma2G7MrqoHO04JOG6Hmup8N+Kota1G60+bTNS0nUbeGO4a2v1jDtE5YK6mN3UjKsCM5BHIFZOq+OLLRNV1qOZNZv5Le7s7QWsMMLBZJ0ygiwVYg9W3k4PTigDh9H8FeIPDNk8cmgR68b3w8ulmKGeJUs5BJK5jPmMv7k+aoymT+7+6eDViPwj4k0vVLK302yvJpANMS7vZ5bSewvPs6IryyRyfv45AFbaY+pCk98dh/wALGsvKWP8AsjVhqzag2mf2URAJxMIhKfmMvlY8shgfM5zgZPFJJ46sLW9nudSGtWCQ6R/aEtjc28YEaiVk6LlzKSMABipGCOTmgDmfDnhzxBoGo+HdQk0We7Frc60k8NvPB5iJdXSyRSfPIqldqcgHcNw46iq/h3wv4g8OalY6vPoD6ssY1a3ayiuIBJF9ovDNHKpkcIQyDDfMGAI4PIG/H4/ntfEOvza3p+qabptlpljLFYzxQvPJNNPPGCnlO+S5WJApbgjoOSeq8NeJYtcudQtHsL7TdQsCnn2l6I96q4JRgY3dCpw3RjypBxigDivBngjUNMvNE/tSyt5I7TQJrNiGV0hlkmDeSmedoQlc4xgVveG9P8QaN8HtN060hiTxNZ6NHBFFO4ZFuEhACswJBAYY4OPeua1n4g66NA8WzR6ReWTaTqQtYLxFgdGQSwqUK+YzGRlkbnYFwRyDxXSt8RLGG31D7bpWr2l/ZzQQf2fJHG1xM0/+q2BHZTuw3Vhjad2MUAef3XhPxdrMfiefULDU5ri/0aGzX+0XsFaSVZizIotztCAMcbyTz17V0Xi3wfqNz4n1O8sNNWbTPL0eQWsbxoLv7LcTPJEFLAZCNHjdhTgDIGcdx4Y8RQ6+L+MWd5YXthP9nurS8VBJExVXHKMykFWBBViP1rkdA8fzQ32o2+u2epPajXptMh1JYohbxEybIY2wwfqQu7YRkjLUAa/gS11P+3vFOqappEulJqNzC8EU00UjsqQqhLeWzAHK9Mn6muyri9O+Iul3t7aqbLUbfTbyeW2tNUnRFtrmSMMWVTvLjhHwWVQ204J4zjv8Q7m71zRriw0rWE0OfT7y+QvFBnUUjRGQxDeXU4JID+XncPwAPTKK57SPF2m6xqllZab51x9q01dUWZFHlpC5Aj3HOQzfNgYP3G6YroaAOV+Jf/IuWf8A2GdJ/wDTjb11Nct8S/8AkXLP/sM6T/6cbeupoAKKKKACiiigAooooA5rxLoqT77tJ3WZiqANyvJAHv3rjrH7Tc6je2ixJm28tgwfmRXGVYDt0PevTdRha4tHSMjzAQ656blIIz7ZFcMbZdL1pb6dxaxrbi2kW4BCsqtlCH6EgEg/zpqKe5EpSjsRvY3cYy1tLj/ZXd/6DmmH91gShkPo4I/nW/B4m0oJzfWwHvKv9DUo8S6QR/yELXpn/Wr/AI0OkuhKrvqc4ro33XU/Q1MuM8n6Vq3mt6HcW8oNzZSttOBuRufxNcx4Y1Gzt4pf7aOn4wpQxvGTnuODk0vZMtV1Y1x6DpSr9adLqGlupNpbNK56BXMeP++io/WgRGXBjns7Yf8ATS4D4+qj/wCLpezY/bLsOXFPGB0qe0tLRE/0nVo5XPUoyIo+g5/UmpDb2P8ABqcX/AnU/wAiKXs2P2sSqMvEUlVSORx3BPf8KcGUkod2cDBxkH8asCC1zxqVt+JH/wAVUcixJxDdQTufuojDLH6AmlyMaqxY1AsSogDY6DAzjj+VSVSt57me3jljtGZHUMp3joRmpC94P+XI5/66ioujWxawD1pCox0qm098P+XH/wAij/CmG41DBxYLkdMyii6Cxd24+6SPoad5kyj5ZpB9GNZhutUxxZxD6yA1H9s1U9LSEfV//r07isaouLkHi4m/77NI13dDpcy/99GqulzXNxeNBfpHCPL3oyHJOCAR+orVNrCesjn3Ao5rBYo/a7sdbiX/AL7NMa7uu9xN/wB9mtD7JB/ek/IUxrS2zgtL+BH+FLmDlZntc3B/5by/99mozcXH/PeX/vs1ota2v96Y/iP8KYba1/6a/mP8KOYfKZxuZz1mk/76NMaeY8mWT/vo1otbWoPCyn8R/hTPItem1yf97/61Fw5TNaaTn94//fRqNpZM/fb8602gtgfuN/31TDDbf88j/wB9Gi4cpls7cksa2vg6c+BwfXU9TP8A5P3FVHitTwIiD/vGrvwhCr4LKqMKNU1MAe32+4qoO5E1Y7OiiitCAooooAK8u0j4X6hoOl21toPiSO2nOkx6ReTS2HmCZELlJI18weXIPMccl15HHFek6jdLY6fdXcisyQRNKyr1IUEkD8q8k1Hxn4pbwrbXd3JpMKa/od1f2RtIZBJZOkHnKrsZP3nyHG8BMMBwQaAOl03wFeeH9Qlfwlraadp9xDaw3FvcWX2h/wBxGsStG+9QhMaKp3K44yAKf4Z+Hw8N6t/aOk6l5Vxc3VzPqS+QTHepLNJKgK7vlkj3hRIM8AgjBwDwRosugfC/ybL+yra7lsjcLLZWJgQyGEbXkXzC0j8Dc24Fsdq4jRn8U3mmfCW4fVdNudSurYyxXFxaSnYjWOWMv74maTkncCmT2FAHZ+E/h1/wj9hb239qfaPJ0NdG3fZ9mcO7eZjcf7+Nvt1rkvE/gfxLp+j3Xh7wn51xBqmiwaZe3UttB5O5IjBvDG4WSMlANwEcvGNpznFv/hZetzxaXYxQW8OqSfbheXUWk3d/EDbXBg+SGA7wHYZyzYUcfMSM+geH9cuL7wRBrOswDR7k2rTXCXUbKtuVB3MyttYLxuwcHHpQBN4r0BfEPhK/0Nrlrb7TB5InVAxQ8YbaevIHFZsHha/m1K61HV9Utp7y50s6a5trNoYx+8dg4VpHPRwMZ7ZyM4HDS/E7WLa31wRS2GpNb6WNQs7r+yLuwic+asZBWVz5incpDo2Ovtm/4g8beKfD0mr6beDRLvVYY9OuLWaGCWOHbc3Yt2SRDIzZU5IYMM/3RgggBcfB+2Mdr5D6BcTrp9tYzT6roSXrZhj8sSRbpB5ZIxkNvHyrx1z3Xifw8Nc8Ltoy3AtgTDiURAgeXIj42ggc7McdM/hXm3ijW9WudTh0LXmsZ7vTPEOjSrdWULwxyRzSEgFGdyGBRs/McgqeKs+GvF2q3zaTofh6z0PS7q9udVleU2jGCOO3ujHkRLIpaRywLHcOdxwelAHQeKfhzbeIdQ1e8uri2ka8aykihubMTwxvbGTHmIWHmIwkIK/KcZwc8jMf4TWs2mRxTx+GBcwXn2uGOHw9HHY8xGMrJb+YS/BzkyZDAYIAwYPGHj3WPDWfMv8ASbu9so4G1DTrXSLubYWK7iblXKQ5U7l8xPTk9aqweJPE2iWvi2+kvrHUEGv/ANm2VtNbyr5UkrwJGTJ5rYiUSZKBQSc4IzigDe0zwBfaM1vdaFqWjadqKRzW8n2fRRHbeXIyNhIUlXaylBhmZ85OQeMVV+E8E2k22n6hqhuYotEfSGP2VRvZpklEuCSOCg+Ugg+vaotW8a+JNKbU9KkXR7rWrW/0y3juFgkit5IryXyxuj8xmVlKv/EeNpxzivR9Kjv4rGNNWubW6vBnfLbW7QRtzxhGdyOMfxHPt0oA5nwN4MHhm9vLkx+HojcRrGI9H0VNPUYJOWO92Y8/3sDHTqaiv/An2vxDfap/aOz7TqNjf+V5Gdv2ZcbM7ud3rjj0NdtRQBwGseAJr2fWHjvdKmh1LUVv5LTVNJW9g4t44QpUupJHl7gwK/exg96dp8KoYbJbZ9WlkVdKXTlLQ5KutwZ1kGWPyqxACdlUDdXpdFAHnOp/Dm7199al8UavZX02oW9pDGsWm+XDCbaaSVCY3kfepZ/mUnkbhkA8bXgPwl/wi51BtmhRm6Kfu9I0hdPjUKD1Ad2c/MeS3HYDmusooA4G/wDAd7cp4gtI9agTStWvEv8Aymsi00MwaFjiQSAFD5R42ZG77xxgr4p+HNt4h1DV7y6uLaRrxrKSKG5sxPDG9sZMeYhYeYjCQgr8pxnBzyO9ooA5nwL4XHhe0vItujobiUSbNK0tLCFQFAxsDMSeM5Zj17DisVPAN691c295rNrNoU+sf2y1oLArN5glEqp5vmlSgdVJ/d5PIyM8egUUAed2Hw3lhSw0291kXPhvTrmW5tLEWvlzBnDgLJMHIdV818AIp6ZJxza8P+C9U0/WNCub/Xbe7stFs5LK0t4tPMLMjKihpHMjbnwgyQqg9gK7qigDgvhJ4QbwtYavNcW721zqN/LKlu8okNvbB28mIFSRgKS2B03kV3tFFAHK/Ev/AJFyz/7DOk/+nG3rqa5D4rTpa+E4biUkRxatpcjYGTgahbk1N/wnWi/89J/+/RpOSW5cYSl8KudTRXLf8J1ov/PSf/v0aP8AhOtF/wCek3/fo0uePcr2NT+VnU0Vy3/CdaL/AM9Jv+/Rpr+PdEVcmSc+3l0c8e4vY1P5WdX2rJ1jXLXTBsdvMuD92JTyT2z6f5wDXM3Hiy61UGLSoGt4W63EjfNj2H09PzFR2cCwksTvlblpG61w4nHwpaR1ZvTwzesxdS8Q6gyrJcXEOmQMcDPLH8OT/L6VkPr9wrEx6zBKvQEyTjP4BTit0khuvGas4ymRxXmf2jPeWp1ezS+FJfI5Q65fO3OoWxXP/PS5P/slM+2TXXWe2dR1O24P8466tux71PDJzgflT/tJ/wAv4h7OS1T/AARx8UTluJ4A3UEQzn/2UVaaG/bH+nqFHTEU/wDWupl5oVuPel/aP938WLll3/Bf5HMtp0shBluGY+psyf50g0kBgftc2P8AZ08c107Emmh8ZBxT/tF/y/iw5Jd/yOdTSgq4W9ujk99PX/EUNpb7SFupgP8AsHA/+z10g5WnKTyKn+0H/L+LHaXc5yHT5o3DC9nkx0B04DH4hxWhNq13YwFElVXI4/0DZu/HfjvWouV645pl5bR3ls8Mw+Vh1HBHuK0hmck9VoZTpKW5JYxLbWcMCnKxoEB+gxU3FZDXbaeVjvf9R0EwHX69h+NXEv7NhkTyY/65Z/ka9WFSM1eLM/Zz6ItEA9RSMintUH22z/57y/8Afn/69H22y/57S/8Afr/69Vddw9nP+V/cSGJCelJ5KelVb++iWynaxd3uQhMaOmFZuwJqIaiMfMHP/AP/AK9JtLqNUpv7LF1GPyDDcxZBhcFgOhQ8Nn6A7vqorQ3fl61i3V40kZVEyrDBDJ1pukXk0emWsd+CbpY1WQryCwHY9afMn1F7Govss2i/vUZbmqf26M9Nx/Cg3aejUuZdx+yn/Ky0TUbNVdrpD03fkaa1wh7/AKH/AAo5l3D2U/5WTM3B71GSOtRecnXcMfQ/4UnmKT98D8D/AIUXXcXsqn8r+4e7dwajJ96UNEesv/jjf4UEQYJMxH/bM0+Zdw9lU/lf3ETeua0PhF/yJjf9hTVP/S+4rNM1kf8Al7/8hNWl8Iip8GEqdynVNTwcYyPt9xWlNp7GNWEor3lY7OiiitTEKKKKAEIDAhgCDwQe9crY/D7wzY/aBbac4Sa2ks/Le6mdIoJPvxxKzkQqe4jC9B6CurooAht7aG3s4rWKMC3jjESoeQFAwBz149awtG8FaFoz2J0+2uEFi7vaJJeTypb7k2EIruQq7TjaAAOwFdHRQBzc3gnQZLeOJLa5t/LmnnSW1vZ7eVWmcyS4kjcPtZjkrnbwOOBjSh0TTodBbRVtlbTGha3aB2LhkYEMGJJJzk5JOTmtKigDgtV+FuhXGjajaWBure6vLMWH2q5u57xkh3q2wCWQ8ZUYAIxUutfDbSL3w9f6XZNcWz389rNc3c9xNdTyLBMkgQyPIXxhCo+b5dxIHr3FFAHN2ngjQLa3ESWUkn+mR6g0s91NNK88ZBR3kdi77cDAYkYGMYpk/gPw7NaWtv8AYpYRa3E11BLb3c0M0UkzFpSsqOHAYscgNjpxwK6eigDi7j4Y+E7hHjfTrhYXSKOSGO/uUjlEYAQuiyBXYAAbmBPA5q/d+BvD13PqslxZSOuqD/TIftUwhlb5fn8oNsEnyJ84UMMDmulooA5y18E6DbWrQJaTSBryG/eS4u5ppXniZWjdpHcu20ouASRxjGK6OiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4j4zY/4QN8jI/tLTeP+3+CuQ2R9oo/++a6340usfgCV5DhF1HTST6AX0FcL/a9hztul/I/4V5GZQlKUeU9HBUpzi3BNmikMTdY0/75FSm2hP8AyyT/AL5FZaarp/e7U/QH/Cp11nTwMfah+RrzPZVDt+r1v5H9zLn2aEH/AFaf98ilCRq2QiA9vlFUW1eyblLlfxBpf7Ts+puUyPY0eyqB7Cr/ACv7mblq/wA5BOe/NXvMPHSuci1azXn7Sn5GpBrFsT/x9oB9KTw9TsL2NT+V/czoskgHvVqN/krnE160A/4+Yz+Bpx1+2IwLlPwU1P1ar2D2VT+V/czeZuMiiFyDnjmueGr2zcNdqR+NLHqtsrD/AElcd+tP6rV7B7Op/K/uZ1Rk+UZFQs6schulYJ1mz6C4GMe9Nj1S1Vsi4XntzSWFq9heyn/K/uZ0Zk4z61EJMs1YR1WHGGulx9DU0Gs2yBszqSenBp/VavYPZz/lf3M3Vbj3qWNj1rnI9UhD5+0Ke3epk1aHBInXJ74pfVKv8ovZz/lf3M3i3OM80hbFYZ1W36+fz64p/wDa9ueGmyPpR9Urfyh7OX8r+5mxuqNreA8+VH/3yKx31K2IO2Y5pE1GFRgTnH0prC1l0D2cuz+5mylvb8fuo/8AvkVN9lgx/qYv++BWLBqtujHMmR9KlbWLYnmX9KX1av2JdOfZ/czUNtb4P7iL/vgU0QW5/wCWEX/fArNGs26jAlz+FINYt+8o/Kj6tX7MPZT7P7mahtbf/njH/wB8CmNbQf8APGP/AL4FZ41u1A4l/SmSaxbSDBmA9wKPq1fswVOfZ/czTNrARxDH/wB8ikS2gXrDH/3yKzo9ZtkGPNH5UPrNq3WYflR9WxHYfs59n9zNEwwZ/wBTF/3wKcsFuf8AljF/3wKyG1e1Ix5+Pwpi6vaqMC5GKX1av2Y/ZS7P7mbf2e37RRf98igW1uf+WMX/AHyKwzrVmpz9pHHsakHiGzA4uB/3yaTw1fsw9hPon9zNd7W3H/LGP/vgVCyQKcCCM/8AARWU2vWhbm6X6YNQya1Zn/l5QZ9M0fV6/YpUZ9Yv7maUqRF8eTH/AN8irPwkGPBrADAGq6p/6X3FYQ1qxxhrpPyNbfwgdZfBO+M7kbU9TYH1Bv7ivUyqlUhOTn2OTHQcYq6t8jtKKKK9s80K80+NfxS/4Vja6RN/Yc+rf2hK8fyTeUse0L1O1ssd3A74PPFel0UARWc/2m0gn8uSLzUV9kgwy5GcEdiK+c/CPifXdO0Pwrpms6xf3Emsajp99YXc1wzSTRNOiXNuzk5YKSDg5+WTHQV9I1zb+CPDr2GhWTaapt9DnS509TK+YJE+6Q27J69GJB7g4oA5XTPG+vXY0rWJI9LXQdT1aXSorZYn+0xYkkiSVpN+1stHkoEGAfvHBrmW+NOow24efT7NjFpskMxQMB/bC+ZttxluEPlPwfm5XnrXpTeFPC2k6zFrMsMdrcNdF4vNu5FgFzMdm5IWfyxK5bGVXcSx7mpJfAnhqWGaKTSomjm1QazIC7/NeAg+b168Dj7p545NAGb8VbjV7T4czzWN7HZamslqHmjV8AmaNWC4dSASfXpkd81yusz+KdM+IGuXdne6JLfWfhe3uLmSWxlEc22e8ZURBNlMgYLF2xjODnA9P1K00vxJpd9pt35N7ZuTb3MSyZ2sMEqSpyrDg9iODVS28J6Pb/aSIbmaS5sxp80tzeTTySQBpGCF3cseZX5znnGcAAAHnmr/ABP1t7u9Og6XJKlja205tF0i8vHvJJYlmMaTQjy4cK4ALhsnqAOa7P4o6kNN8FSXpsbO8Iu7JRBfQ+ZH891EmSufvLuyD2YA9qm1DwH4ev1RJ7W5SNYEtmjt764gSaJBhVlVHAlAHHzhuOK2db0ix1zTmsdUg8+1aSOUpvZctG6yIcqQeGVT+HPFAHm154w8Y+ZcXFkfD4s/+EgbQ4YZbaYyYLlFlZxJjg4yoXnnkVLJ4z8TbYdMiOjf2wPEp0KW6a1lEDR/ZGuRKsXm7gcbRtLnODyMgjspdE8PRXEFhKkKXE96+rQwNcMHknVgzSqu7JALKSB8oyOOazvEnw/03WZbRo5JrMLrA1i6ME0qPPKLdoPldXVozgocqf4OnJNAHGHxFeal4x8M/wBtvZRXmj6xqdlPcwoyQOEsmcSBWYlRtcZG44IPNOX4napDHrwSex1Rbbw9d6zZ3aaPdWETPBtG3Ert5qHep3Rt2I7g16Bb+CPDsFtZQJpqmOzaZ4g8ruS0yMkrOSxMhZWYEvk81Ttfhv4XtkuFWyupRcafJpT/AGjULmbFrJt3QrvkOxflGAuMdsZNAHDeNfE3i2Dw7rdjdXumW962kQ6nb3VhBNGYQZgjxnMuWPIw4K98rXpt2b608JX7axJY393HbTNIY7VooJAFYhTGzucYwD8xzz0ziq76D4a8SWklx5VtqNrc2baa0kc5dHgDnKAq2MhgeR8wI68Vb0W00qbw6LTTbp7/AEuRZIvNe+kuy4JIceazsxwdw+9xjHGKAPN7TxzrVrZ+H2NtpejaPNp+nyRvJply9rK0qjfGs0bbLYLkKocNnI5xXa+PtQFhJ4YzZWV0bjWoLcG5i3+TuV/3kfPyuMYDdsmhfh74aWWBlsrgJCkEYgF9OIXWEAReZFv2SbQq4LgngVu6rpNlqpsjfw+abO5S7g+dl2SqCFbgjOMng8UAee+GfGfiS6u/Ddzqw0c6Zrd/dWCQ20EqzRGNZmRy7SFTnyCCu0YyCD2rX8e6jNbeJNCtLS3sPtV1aaiYryeAyS2zJCpBQhlIBONwBGQAMjrW/beF9HtodLihs9semXEl1aDzXPlyuJAzdeciWTg5HzewxbvdHsb3UrHULq3El3ZCRYHLHCCQBXGM4OQB1BoA8l0nxP4z0r4f+Dbma5tbuC+0pLmbU20e7vDb4gjZFmWKYuzPuYmbgDacrzXT/EnVby4+Betarp17bLdTaMZxc225oyGjBYxnKtyCdrHkZBIOMHQj+GvhmKCCGG31GGOBWSERatdp5aNjMa4lGI+B8g+X2revdA0u98NyaBPZp/Y8lv8AZGtoyY1EW3bsBUggY44IoA8pu7+5+H93qum6RpPhdLyz0eznS4tNMa1WQzXskWxgJGbYBz94ncWbviujk8X6rpp8TWOv6potneaaLR4b9bCZ4WE5bEZgEu93yjAbXGcg44IrrNV8K6Lq17c3eoWfnXFxBFbSv5rrujilMqLgEAYck5HJ6HI4qPV/B+h6tLey39kzzXhgaWVJ5I33QEtEysrAoyliQy4PPWgDzKfxRe+IzpEGqKhudM8X2lt5qWM1kJUaAyKxgmJkjOHwQSc4yCQRXtlcxYeBPDtjzBZSs/25NSMk13NK7XCJsWRmdySdvHJIPU5NdPQAUUUUAFFFFAHnnx+z/wAKt1HHX7XYf+lsFeABpF6kHHtXv/x//wCSV6l/19WH/pbBXz2VbgApz6tXFit0fQ5K7Ql6lmOWT/Z/Kn+cwPKoTn0NUxGxP3k/OlCHPVT9TXIe2m31Lgun/ux/TaacLh2PCoD7A1U2Y/uH8aAcZ+VKC16lz7QT1ZPyNL57AZLIR+NVAxI+4tOWRumB+VI0RdFy2RwpPuTUq3DnkIv51nrK/r+lP85z1OPwoLReM7joFX8c1Kt7KOmz+dZ4kJ4JP4AU9ZGB5z+VFikjQF/KR92M/wDAaX7bJnOI/wDvgVSDFj3p31oGki/9ulPeMf8AABR9pkYdV/75FUlIPPapVbB4NIrRFv7TKe6/98inLcSccj8hVTe3rSq5zQUrFs3Eh6sPwAFOE8g6MQfXNVA57nNODHv0oK0LX2mYfxtini4k7yN+dUwadmkPQt+fJ/fb86PPkP8Ay0b86qbiRjFG7txQFkWvOf8Avn86T7RIDjefzqsGI70E5NMdkWTO5PUE0huHHGRn6CqxbPPNN389xQTZFgzyEcH9BTGmk9R+lQlh1BprOcdTigTsTNNJ6j8hTGlkPf8ASoS2DTAxoDQeZH/GmtPJjG/GKY7E9M+tMJz3piHNK56uaaZJP7+PxpjHA61G7Hpnigm7JTJMR945+te4fAbJ+GNjnr9s1DP/AIGz14QxbPBIr3b4Cf8AJMLD/r8v/wD0tnrrwm7PneIP4cPU9BoooruPlgooooAhvJDDZzyK8SMkbMHmOEUgdWPYeteJJ4v8S6Zo12dX1bUI9X+xW13suILKS2KtdRxvLbyw5/d4YgLKN2CDmvcnVXRkdQyMMEEZBFY9h4V8Padb3lvp+g6TawXg23McFnGizjnhwBhhyeuetAHmnxK1W71HUtU0yLUUihstY0EQOqo32aSS5BZjxyeFOG9PerL634lg8STeFF1qeVZNXgtF1mS3gE0MTWclw8eAgiMn7sBSY8YkGQSBXfReD/DMVhNYxeHdGSxmKGS3WxiEblTlSV24OCSRnpUqeGNATRW0dND0tdIY7jYi0jEBOc58vG3OeelAHkdtq2uaaTpOiXmo38l/4ivY5760SzN1IscKttXzSkAc4OTt6I2F9NXSdW8XarqvhnR77WZ9KlnXVDdSwR2cs8qwSwLEW2iSKOTbIQwXIzngcY9Hfwt4ffSG0p9C0ptLZxIbM2kZhLDGGKY254HOO1T2Gh6Tpy2o0/S7G1Fojx24gt0TyVcguqYHyhiqkgdcDPSgDyaLU/Fk6wXC+LrxBc+KLrRBF9itSsduks6Kw/d5Mg8sck7fVT3vjxLqS2suj3Or6/c6zHrNzY2j6Xb2X2m7jjRZP3nnIIV2q4yQEzge4r05dJ05VRVsLQKlw12oEK4WZiS0o4++SzEt1OT61V1HwzoOp28kGpaJpl5BJMbh47i0jkVpSMGQgggtgAZ60AeWeDNcvfEfiT4balqj+ZeNaa7C74QF/KuIYgxCEpkhATtJXJOOK6rxbd6rceOodJs/EkuhWK6PNfyyRQQOdyyKoYmVGAUBsn29OtdhZ6JpVkbU2WmWNubUSC38q3RPJEjbpAmB8u4gFsdTyazNa8F6Fruv2+q61YW+oSwW5t44buGOaJcuG3hWU4cYxkHoTQB5dpnjbxH4g0O9v59cTw/Lpnh211YItvEUu5JFkLO4kUkRfu1GEKn5z82cCtP/AISvxC3iOzvdRvL2y0ae7sII4rKO0uIEaaNN8FyrH7QkhkYgMvygFSR1r03VPDui6tLay6ro+nXslqc273NskphP+wWB29B09KRvDmhtrQ1htG006uOl8bVDOOMf6zG7px1oA8i8IXGq+JfHXhfUL3X722upNK1VCYIrcCRYtRjUJhom4KBQcYP7sEEfMWteGvE/iDxLcabp9x4kbSM2V/fPeR28BeYx3kkKriRCgREVS2ACcj5hyT6jceGdBuYbSG40TS5YbSUzW6SWkbLDIW3F0BHysTySOc80298LeH76ygs77QtKubSB2ligms43SN2JLMqkYBJJJI6kmgDyqz8UeKvEVq95DrkukCDwnb6wYba0hdZbhnuBuzKjERsIlO0YOMYI5J9f8P3smpaDpt9MqrJc20UzBegLICcfnUjaZYNJLI1lamSWAW0jGJcvCM4jJxyg3N8vT5j61YgijghjhgjSOKNQiIigKqgYAAHQCgB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAed/tAYHwr1LPT7VYZ/wDA2CvnvdECCBn8K+hPj/8A8kr1Lp/x9WHX/r9gr5+Tj70cX51x4rdH0GTfBL1HLJHjiPPtTxKneEfnQHTHMC5+tO8xM/8AHsv51yHuJLsBeP8A55D86aZI/wDnkPzqQSKf+XcfmaaXUdYFA+ppGiQizQgY8oZpROgH+pA/Gk3x/wDPBfzpfMTgfZl/OgnYkFyuB+6H50v2ncMAAUwSoelsPzNIXUf8sAB9TQXEmE3HJ4qQSk/dfFVPNXH+qH5mnLKB1Rf1osaJItLI5P36Gkc4y5qFZAeigfjShgetBaJ0c4+/+lSLL2z+lQKwz90Y+ppcjPWgCyHzycflR5nPAH5VCGHoDTg6gfcH5mkUmTK+fQYpQxqDfyTgClD+lFirk+/nANPL9cGq6t6jNO30rDuSq/5U4ucioFJz0p4f2HNFguPDkcg0vmuerVAWyelIW5oQE3mHGMmm7/cVCWoD8UWBslL8jpTQ/A6CoieKbu46U7E3Jml+n5VCZOcADFIXAOCOfrUbOOoUD9aBXHs3FRlueuKaz8mmFqYrjy5Bzk00ykZ60wtjtTN/HFArkhmf1OK95+AZz8L9PP8A093/AP6Wz14EZf8AZX8q99+ARz8LtOP/AE93/wD6Wz114Xdnz+f/AMOHqehUUUV2ny4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB53+0D/wAkq1P/AK+rH/0sgr55jj3dDX0N+0B/ySrUv+vqx/8ASyCvnjcnGf51xYrdH0OSv3JepMIQOSTQUTtn8SKYpjJyWA+pp+Yx0YfhXKe6mwVF7sPzpSqrzuBpV8v++fwFO2xn+JqCuYYFDd/ypGRff8SKVvLz97H1pMx9mH1FAm9QCL3YfnSlVHO4E0L5fOWP4U8LGf4moHcapHY/pTgR3Jo2xg43n8aXCdC4oLUkICM8VIG6U0ImeHH5H/ClCgZ+b9DSHzolDUu6ohgHqKcCMdaC0yXdgUu4kc81EDz1p+aBokDZp24VDmnKcHmgq5Nmjd71Hu69KUNx0FAXJN1G6mbh6UjMOMUBck3UhYVEXpM5PNAJku7mjdUeQOcmkLDtQFx8jZFMLDPAprE55NNJAoFccTzTSeO9Ix9KYzZ9aBCseOtMZqQmkJGKYgJBppakJHamk0CuBavoP4Af8kr03/r7v/8A0tnr57JBr6E+AH/JK9N/6+7/AP8AS2euvDbs8DP3enD1PQ6KKK7D5gKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA88+P8Aj/hVmpbvu/a7DP8A4GwV89FYD90Y+rGvpL4zaNqOv/DrUtO0S1a7v5JrWSOFZEQuEuYpGwXIUfKrHkjpXgX/AArrx7/0Kl9/4G2f/wAfrmrwcmrI9nLMRClGSnKxlLEmex/GnGNR0yPoK1h8PfHnfwjen/t9s/8A49Sj4e+O+/hG+/8AA2z/APj9c3sZ9j1lj6H86MwIoGd7A/SlwpUZmJrTb4feOyf+RRvfxvbP/wCP0n/CvfHf/Qo3v/gbZ/8Ax+j2M+w/r9C3xoyWjQnht350hiUdM/hWwfh947P/ADKF7/4G2f8A8epB8PfHWefCN9/4G2f/AMfo9jPsH1+h/wA/EZaIuOWcfhTwFI5mP5Vpn4feOsD/AIpG+/G9s/8A4/SH4feOf+hQvf8AwMs//j9HsZ9hrH0P50ZpSLH+sJpu2PP3z+taq/D7xyD/AMijf/he2f8A8fpw8AeOf+hRvv8AwMs//j9HsZ9ivr+H/wCfiMrEQ43H/P4UZiHqfx/+tWr/AMIB45/6FG+/8DLP/wCP07/hAvHP/Qo3/wD4GWf/AMfpexn2Gsww3WojKDwjs350CRM8KcVrf8IH44/6FC//APAyy/8Aj9OHgTxx38IX/wD4GWX/AMfo9jPsaLMcL/OjHVlxk5o3j8K1/wDhBPHH/QoX3/gZZf8Ax+nf8IL44/6FC/8A/Ayy/wDj9HsZ9h/2lhv50ZIkGP8A61SJIi8sCa0/+EG8cf8AQoah/wCBll/8fpf+EG8cf9Chf/8AgZZf/H6PYz7B/aOF/wCfiM4zoQQE/Ogyof4MfjWj/wAIP43/AOhQ1D/wMsv/AI/S/wDCEeN/+hQ1D/wMsv8A4/R7CfYX9oYX/n4jNE6r1U/nSGcE8cfjWofBHjf/AKFDUP8AwMsv/j9J/wAIP43/AOhQ1D/wMsv/AI/R7CfYf9o4X+dGctzgfdB+tKLhc5MYrQ/4Qfxt/wBChqH/AIGWX/x+j/hCPG/bwhqH/gZZf/H6PYT7CeYYT+dFL7So/wCWa/pSeeP+eaj8BV3/AIQfxuevhDUMf9fll/8AH6U+BvG3/Qoaj/4GWX/x+l7CfYX1/C/zooG5T05/3R/hUTzIcnA/75FaX/CDeN/+hQv/APwMsv8A4/Sf8IL444/4pC//APAyy/8Aj9P2E+wf2hhf50ZLSrnOVx9KY8ijkMCf92tc+BPHH/QoX/8A4GWX/wAfoPgPxx/0KF//AOBll/8AH6PYz7B/aGG/nRi+avt+VKHTByQfwx/StdvAPjnt4Rv/APwMs/8A4/SHwD45P/Mo33/gZZ//AB+n7GfYTzHDfzoxi6Z7D65/wpm9e2D+NbR8AeOj/wAyhff+Bln/APH6P+EA8c/9Chff+Bln/wDH6PYz7C/tDDfzoxNy45T9a+hPgB/ySzTcf8/V/wD+ls9eLHwB46xx4Rvs/wDX7Z//AB+vdvg1o+o6D8O9O0/WrRrS/Sa6kkgZ0coJLmWRclCVPysp4J610YeEot3R5Gb4mlWhFU5X1O2ooorqPBCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of MSD Oss B.V., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, New Jersey, USA. All rights reserved. NEXPLANON is a registered trademark of MSD Oss B.V. All requests to reproduce this copyrighted material should be directed to MSD Oss B.V.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38567=[""].join("\n");
var outline_f37_42_38567=null;
var title_f37_42_38568="Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis";
var content_f37_42_38568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38568/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38568/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38568/contributors\">",
"     John R Perfect, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38568/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38568/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/42/38568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14913496\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptococcal meningoencephalitis is a serious opportunistic infection that is seen among patients with untreated AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/1\">",
"     1",
"    </a>",
"    ]. The initial preferred approach to the patient with cryptococcal meningoencephalitis includes combination antifungal therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (for the induction phase of therapy) followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (for the consolidation phase) (",
"    <a class=\"graphic graphic_table graphicRef67612 \" href=\"mobipreview.htm?7/12/7373\">",
"     table 1",
"    </a>",
"    ). During therapy, patients should be monitored for recurrence of clinical symptoms that may suggest increased intracranial pressure, relapse of infection (from lack of adherence or drug resistance), adverse events related to antifungal therapy, and immune recovery syndromes secondary to antiretroviral therapy (ART). &nbsp;",
"   </p>",
"   <p>",
"    This topic is devoted to clinical monitoring of the HIV-infected host with cryptococcal meningitis. The epidemiology, clinical manifestations, diagnosis, and treatment of disease are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/24/37254?source=see_link\">",
"     \"Microbiology and epidemiology of cryptococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23929?source=see_link\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913503\">",
"    <span class=\"h1\">",
"     MONITORING FOR DRUG TOXICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913510\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion-related reactions, particularly nausea, vomiting, chills, and rigors, are common with intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate administration, usually occurring either during infusion (within 15 minutes to 3 hours following initiation) or immediately following administration of the dose. Infusion-related reactions may be pretreated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , or corticosteroids administered approximately 30 minutes before infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link&amp;anchor=H10#H10\">",
"     \"Pharmacology of amphotericin B\", section on 'Infusion-related reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is associated with renal insufficiency and hypocalcemia, hypophosphatemia, and hypokalemia. Patients treated with amphotericin B should have daily monitoring of serum creatinine and electrolytes. Many patients require significant amounts of potassium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnesium supplementation during therapy and hydration with normal saline during amphotericin B infusions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link&amp;anchor=H9#H9\">",
"     \"Pharmacology of amphotericin B\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts recommend that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    administration be held or a lipid-based formulation substituted if the plasma creatinine concentration exceeds 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (265",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    must be dose-adjusted for renal dysfunction as discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913517\">",
"    <span class=\"h2\">",
"     Flucytosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most significant toxicities of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (5-FC) are hematologic and hepatic. In particular, leukopenia and thrombocytopenia can limit its use, although dose reduction may ameliorate hematologic toxicities.",
"   </p>",
"   <p>",
"    In addition, renal dysfunction caused by the concomitant administration of nephrotoxic agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , can lead to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    accumulation and further contribute to dose-related toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, dose reduction is required for patients with renal insufficiency. Dosing recommendations for flucytosine are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a creatinine clearance of 20 to 40",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      37.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      is administered every 12 hours",
"     </li>",
"     <li>",
"      For patients with a creatinine clearance of 10 to 20",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      37.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      is administered once daily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Full dosing information is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=see_link&amp;anchor=H10#H10\">",
"     \"Pharmacology of flucytosine (5-FC)\", section on 'Dosing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23929?source=see_link&amp;anchor=H4521551#H4521551\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Induction and consolidation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, serum drug levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    should be monitored in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/5\">",
"     5",
"    </a>",
"    ]. Blood should be taken approximately three to five days after treatment initiation and two hours after an oral dose; serum drug levels should be &lt;80",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. However, since flucytosine levels are not readily available in many clinical settings, monitoring for bone marrow toxicity with a thrice weekly complete blood count can act as a surrogate of drug accumulation. For example, dose reduction or discontinuation of flucytosine should be considered when the absolute neutrophil count declines to &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or the platelet count drops below",
"    <span class=\"nowrap\">",
"     75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of flucytosine (5-FC)\", section on 'Dose modification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 5 percent of patients develop elevations in serum aminotransferases or alkaline phosphatase. Gastrointestinal complaints such as nausea, vomiting, and diarrhea also occur. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913524\">",
"    <span class=\"h2\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of patients develop rash while receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Monitoring of aminotransferases is suggested in patients on long-term therapy. The risk of drug-induced liver injury increases with high doses (eg, &gt;800 mg daily). Alopecia and chapped lips have been reported following long courses of high-dose fluconazole, but they are reversible after drug discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H11#H11\">",
"     \"Pharmacology of azoles\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913531\">",
"    <span class=\"h1\">",
"     LABORATORY MONITORING FOR FUNGAL INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913545\">",
"    <span class=\"h2\">",
"     Monitoring of serum cryptococcal antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial monitoring of serum cryptococcal antigen is not helpful in clinical management because changes in titer do not correlate with clinical improvement during induction or consolidation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts monitor serum cryptococcal antigen after discontinuation of maintenance therapy among patients who have attained a CD4 cell count &gt;100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    The frequency and duration of monitoring is unclear. We prefer to monitor cryptococcal antigen every three months until the CD4 cell count is &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    at which point maintenance therapy is discontinued. CD4 cell counts are usually monitored every three to four months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23929?source=see_link&amp;anchor=H7361633#H7361633\">",
"     \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Discontinuation of maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913552\">",
"    <span class=\"h2\">",
"     Sterilization of cerebrospinal fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association guidelines recommend repeat lumbar puncture for fungal culture after receipt of two weeks of antifungal therapy to confirm sterilization of the cerebrospinal fluid (CSF), even among patients who have clinically improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/2\">",
"     2",
"    </a>",
"    ]. The opening pressure should also be checked since increased intracranial pressure (ICP) can occasionally be asymptomatic. We agree with these recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14095130\">",
"    <span class=\"h2\">",
"     Drug resistance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifungal drug resistance should be considered if the CSF has not been sterilized after two weeks of combination therapy, or if a patient has relapsing infection. In this clinical scenario, an on-treatment cryptococcal isolate should be obtained and evaluated for changes in the minimum inhibitory concentration (MIC) against the antifungal agent that is being administered. Specifically, a threefold increase in MIC from the pre-treatment isolate to the on-treatment isolate would suggest emerging drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/7\">",
"     7",
"    </a>",
"    ]. An absolute MIC of &gt;16",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or &gt;32",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    for a single isolate may also be suggestive of drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H645246\">",
"    <span class=\"h1\">",
"     MONITORING OF INTRACRANIAL PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;AIDS patients with cryptococcal meningoencephalitis tend to have high fungal burden in the cerebrospinal fluid (CSF), which can lead to increased intracranial pressure (ICP) (defined as &gt;20 cm H20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/5,8-14\">",
"     5,8-14",
"    </a>",
"    ]. Increased ICP has been associated with persistently positive cultures and an increased risk of mortality; in one large trial, 93 percent of deaths that occurred within the first two weeks of therapy were associated with increased ICP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/8,15\">",
"     8,15",
"    </a>",
"    ]. The lumbar puncture, which leads to transient improvement in ICP, can be life-saving.",
"   </p>",
"   <p>",
"    Radiographic imaging of the brain is recommended prior to performance of the initial lumbar puncture in the patient with suspected cryptococcal meningoencephalitis to rule out the presence of a concomitant space-occupying lesion. The use of lumbar puncture for initial diagnosis and assessment of ICP in the patient with suspected cryptococcal meningoencephalitis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of patients who develop symptoms suggestive of increased ICP during",
"    <span class=\"nowrap\">",
"     induction/consolidation",
"    </span>",
"    therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H645332\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H645318\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of increased ICP in cryptococcal meningitis is not completely understood. Potential etiologies include increased vascular permeability secondary to cytokine-induced inflammation, and clogging of arachnoid villi with fungal antigen, leading to impairment of resorptive function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/16\">",
"     16",
"    </a>",
"    ]. One autopsy study demonstrated infiltration of cryptococci, inflammatory infiltrates, and fibrosis within arachnoid cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H645325\">",
"    <span class=\"h2\">",
"     Clinical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased ICP may be associated with headache, clouding of sensorium, visual and hearing loss, ataxia, cranial nerve palsies, and herniation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/8,10-14,16,18\">",
"     8,10-14,16,18",
"    </a>",
"    ]. Papilledema may be seen on clinical examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H645332\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased ICP in symptomatic patients with cryptococcal meningoencephalitis should be managed aggressively to decrease mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/19\">",
"     19",
"    </a>",
"    ]; whether reduction of ICP has a beneficial effect on other outcomes, such as visual acuity, is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/2,5,16,20\">",
"     2,5,16,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lumbar punctures should be performed to reduce the opening pressure to &lt;20 cmH2O; in patients with extremely high CSF pressures, the goal is to reduce the ICP by 50 percent of the initial value. We perform daily lumbar punctures until the patient is asymptomatic and the CSF pressure has been documented to be normal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stable. &nbsp;",
"     </li>",
"     <li>",
"      Lumbar or ventricular drains may be preferred in patients who require frequent lumbar punctures. Theoretical concerns about placing catheters into infected spinal fluid should not preclude their use, which can be life-saving [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A patient who has a continued requirement for serial lumbar punctures for ICP after appropriate antifungal therapy will likely need a permanent ventriculo-peritoneal shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. This device can be placed after the patient has completed the induction course of antifungal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/18,19,21\">",
"     18,19,21",
"    </a>",
"    ]. There is no role for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , or corticosteroids to reduce increased intracranial pressure in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/2,21\">",
"     2,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent headache, after initial clinical improvement on antifungal therapy and potent ART, may be due to the immune reconstitution inflammatory syndrome (IRIS). (See",
"    <a class=\"local\" href=\"#H14913615\">",
"     'Immune reconstitution syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913559\">",
"    <span class=\"h1\">",
"     CLINICAL MONITORING DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;During treatment, there may be three different outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Successful induction and consolidation antifungal therapy with switch to ongoing maintenance therapy with clinical improvement",
"     </li>",
"     <li>",
"      Successful induction and consolidation antifungal therapy followed by recurrent symptoms and cerebrospinal fluid (CSF) infection during maintenance therapy, consistent with relapse of infection or immune reconstitution inflammatory syndrome",
"     </li>",
"     <li>",
"      Unsuccessful induction or consolidation antifungal therapy with persistent documentation of viable cryptococci in the CSF; this outcome should prompt questions regarding adherence, drug resistance, and poor host response",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persistent or relapsing infection will prompt concerns regarding adherence, drug resistance, or poor host response, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913573\">",
"    <span class=\"h2\">",
"     Clinical management of persistent or relapsing infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical management of the patient&rsquo;s persistent or relapsing infection will depend on the suspected cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adherence: Barriers to adherence (lack of understanding of implications of untreated disease, psychosocial issues, adverse side effects) should be identified.",
"     </li>",
"     <li>",
"      Relapsing infection with a susceptible isolate: Patients with this clinical picture need a repeat course of",
"      <span class=\"nowrap\">",
"       induction/consolidative",
"      </span>",
"      therapy and drug resistance testing. If no drug resistance is documented, the patient should undergo repeat",
"      <span class=\"nowrap\">",
"       induction/consolidation",
"      </span>",
"      therapy followed by maintenance",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      at the usual dose with close follow-up to monitor adherence.",
"     </li>",
"     <li>",
"      Relapsing infection with drug-resistant cryptococci: When drug resistance is a concern or documented during consolidative therapy, the optimal approach is unclear. Alternative therapies may be preferred, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (200 to 400 mg twice daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"       posaconazole",
"      </a>",
"      (400 mg twice daily) based on limited data from case series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/5,22,23\">",
"       5,22,23",
"      </a>",
"      ]. However, prior to initiation, the in vitro susceptibility of the recent isolate must be evaluated to all antifungal agents.",
"     </li>",
"     <li>",
"      Refractory disease: Some patients have refractory disease (eg, positive cultures after four weeks of therapy) despite optimal antifungal management and HIV treatment. For patients with refractory cryptococcal disease, adjunctive immunologic therapy (eg, interferon gamma at 100",
"      <span class=\"nowrap\">",
"       mcg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      three times per week) for 10 weeks in combination with antifungal therapy may be beneficial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]; in a small phase 2b pilot trial, a trend towards clinical and microbiologic benefit was observed among patients who were randomly assigned to interferon gamma plus standard therapy compared with standard therapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/24\">",
"       24",
"      </a>",
"      ]. Of note, none of these patients were taking antiretroviral therapy (ART), which may be the most important factor contributing to clearance of infection in these refractory cases. We favor the initiation of potent ART prior to use of interferon gamma therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H644868\">",
"    <span class=\"h2\">",
"     Assessment of new clinical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;If new symptoms such as headache arise after initial clinical improvement, a lumbar puncture should be performed to rule out the possibility of increased intracranial pressure (ICP). (See",
"    <a class=\"local\" href=\"#H645246\">",
"     'Monitoring of intracranial pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Increased ICP may also be related to the immune reconstitution inflammatory syndrome (IRIS) among patients who have initiated ART. This diagnostic possibility is suggested by pleocytosis in the presence of a sterile CSF culture. (See",
"    <a class=\"local\" href=\"#H14913615\">",
"     'Immune reconstitution syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Alternatively, increased ICP may be related to a relapse of fungal infection, as suggested by a positive culture following sterilization during",
"    <span class=\"nowrap\">",
"     induction/consolidative",
"    </span>",
"    therapy. (See",
"    <a class=\"local\" href=\"#H14913559\">",
"     'Clinical monitoring during treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913615\">",
"    <span class=\"h1\">",
"     IMMUNE RECONSTITUTION SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913636\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"immune reconstitution inflammatory syndrome\" (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of pre-existing infectious processes following the initiation of potent antiretroviral therapy (ART) in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/26-31\">",
"     26-31",
"    </a>",
"    ]. If immune function improves rapidly following the commencement of ART, systemic or local inflammatory reactions may occur at the site or sites of the pre-existing infection. According to one meta-analysis, IRIS occurred in approximately 13 percent of all immunosuppressed patients initiating ART, but occurred with increased frequency among those with cryptococcal disease (ie, 20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This inflammatory reaction is usually self-limited, especially if the pre-existing infection is effectively treated. However, long-term sequelae and fatal outcomes may occur, particularly when the inflammatory reaction occurs within the central nervous system (CNS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913643\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial clinical improvement on antifungal therapy, HIV-infected patients with cryptococcal meningitis may develop symptoms and signs of immune reconstitution localized to the CNS during the initiation of ART, which can lead to significant morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Symptoms related to increased intracranial pressure (ICP), such as recurrent headache, nausea and vomiting, and decreased alertness usually occur one to six weeks after commencement of ART (median 29 to 33 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Repeat lumbar puncture typically demonstrates significantly more inflammatory cells than were found at baseline, despite sterile fungal CSF cultures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913650\">",
"    <span class=\"h2\">",
"     Management of IRIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most minor signs of IRIS resolve spontaneously after days to a few weeks. However, symptomatic patients with CSF pleocytosis and increased ICP are at risk for herniation. Serial lumbar punctures are important in managing ICP; serial lumbar punctures should be performed until stabilization of symptoms and normalization of ICP. Sometimes a ventriculo-peritoneal shunt is required. (See",
"    <a class=\"local\" href=\"#H645246\">",
"     'Monitoring of intracranial pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We and other experts also use corticosteroids (eg, 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily equivalent of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) in patients with symptomatic increased ICP related to IRIS based on case reports or by extension to other disease processes, such as TB meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. However, there are no controlled trials examining this approach and the duration of treatment is unclear. In addition, there are minimal data regarding any role for nonsteroidal antiinflammatory agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913657\">",
"    <span class=\"h2\">",
"     Timing of antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In light of the above concerns, the optimal timing of the initiation or reinstitution of ART after starting antifungal therapy is uncertain. The potential advantage of starting ART within approximately two weeks of initiating antifungal therapy is to boost CD4+ T cells and to decrease the patient&rsquo;s risk of additional opportunistic infections and mortality from AIDS. The potential disadvantage is whether ART may lead to IRIS, as discussed above. (See",
"    <a class=\"local\" href=\"#H14913615\">",
"     'Immune reconstitution syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Until more published data are available, we generally do not begin antiretroviral medications within the first two weeks of induction antifungal therapy; we subsequently initiate ART within two to eight weeks after the induction phase has been completed since most cases of IRIS occur before this time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/2,5,37\">",
"     2,5,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most IRIS reactions to a variety of opportunistic infections occur within approximately one month of initiating ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/34\">",
"     34",
"    </a>",
"    ]. There are no clear baseline predictors of who is at risk of developing IRIS (including CSF opening pressures) since most studies are retrospective and varying definitions of IRIS have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/33,34,38\">",
"     33,34,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest trials that evaluated the timing of ART relative to treatment of opportunistic infections randomly assigned 283 AIDS patients with a confirmed opportunistic infection to either early ART (within 14 days) or delayed ART (initiation of ART between week 6 through 12); most of the patients were in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients were stratified by baseline CD4 cell count (&lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or &gt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    and by the specific opportunistic infection (ie, Pneumocystis versus other opportunistic infections) with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patients had Pneumocystis (ie, 63 percent of the study participants); patients with cryptococcal meningoencephalitis represented the second largest group (12 percent).",
"     </li>",
"     <li>",
"      The risk of AIDS progression or death was significantly lower in the early ART arm compared with the deferred arm (OR 0.51; 95% CI 0.27-0.94).",
"     </li>",
"     <li>",
"      There were 20 cases of confirmed IRIS, which developed a median of 33 days after diagnosis; the risk of this complication was comparable in both arms of the study and was not associated with any particular opportunistic infection. There were no deaths related to IRIS in either arm and there was no difference in frequency of IRIS based on whether steroids were coadministered or not (6 versus 9.8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar observations have been made in HIV-infected patients with tuberculosis; AIDS-related morbidity and mortality were lower among those who had initiated ART within two weeks of starting tuberculosis therapy compared with delayed ART.",
"   </p>",
"   <p>",
"    However, there are few data to guide the optimal timing of ART in patients with cryptococcal meningitis and some observational and clinical trial data from resource-limited settings raise concerns about the safety of immediate ART. A trial of 174 patients in Uganda was discontinued when those patients assigned to &ldquo;immediate ART&rdquo; (ie, within 48 hours of enrollment) had significantly higher rates of mortality compared with patients who initiated &ldquo;delayed ART&rdquo; (ie, within four weeks of enrollment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/39\">",
"     39",
"    </a>",
"    ]. Of note, all patients were enrolled 7 to 11 days after initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    monotherapy; after 14 days of amphotericin B, all patients received oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . Whether these poor clinical outcomes were related to the timing of ART or other factors is unknown. For example, there were no data regarding the possible role that increased ICP may have played in the deaths of these patients since ICP was not measured.",
"   </p>",
"   <p>",
"    Furthermore, an open-label, randomized trial evaluated early versus delayed initiation of ART in 54 patients with a new diagnosis of HIV and cryptococcal meningitis in Zimbabwe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38568/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients were randomly assigned to receive early ART (within 72 hours after diagnosis of cryptococcal meningitis) or delayed ART (after 10 weeks of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    alone). The group that received early ART had a higher three-year mortality rate than the group that received delayed ART (88 versus 54 percent). The median durations of survival were 28 days and 637 days in the early and delayed ART groups, respectively. The risk of mortality was almost three times as great in the early ART group versus the delayed ART group (adjusted hazard ratio 2.85; 95% CI 1.1-7.2). Particularly in resource-limited settings, early ART administration after initiating antifungal therapy for cryptococcal meningitis is associated with increased mortality.",
"   </p>",
"   <p>",
"    Thus, although data in other opportunistic infections, such as Pneumocystis and tuberculosis, suggest that early ART (within two weeks) is clinically beneficial, it is difficult to directly apply these concepts to patients with cryptococcal meningoencephalitis, where CNS involvement may complicate therapeutic management. Furthermore, induction antifungal therapy is associated with significant toxicities that may be exacerbated by the addition of antiretroviral medications during this critical induction period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14913664\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryptococcal meningoencephalitis is a serious opportunistic infection that is seen among patients with untreated advanced AIDS. The management of cryptococcal meningoencephalitis is discussed in detail separately. (See",
"      <a class=\"local\" href=\"#H14913496\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23929?source=see_link\">",
"       \"Treatment of cryptococcal meningoencephalitis in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The antifungal drugs used in the treatment of cryptococcal meningoencephalitis are associated with significant toxicity, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      . Close laboratory monitoring is needed for renal insufficiency, hematologic abnormalities, and electrolyte disturbances during induction therapy. (See",
"      <a class=\"local\" href=\"#H14913503\">",
"       'Monitoring for drug toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After two weeks of induction antifungal therapy, a repeat lumbar puncture should be considered to confirm sterilization of the cerebrospinal fluid (CSF) and to reassess intracranial pressure. (See",
"      <a class=\"local\" href=\"#H14913552\">",
"       'Sterilization of cerebrospinal fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serial monitoring of serum cryptococcal antigen is not recommended since changes in this laboratory parameter do not correlate with clinical improvement. (See",
"      <a class=\"local\" href=\"#H14913531\">",
"       'Laboratory monitoring for fungal infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If new symptoms such as headache arise after initial clinical improvement, a lumbar puncture should be performed to rule out the possibility of increased intracranial pressure (ICP). Increased ICP may be related to the immune reconstitution inflammatory syndrome among patients who have initiated antiretroviral therapy (ART). Alternatively, increased ICP may be related to drug resistance or relapsing infection. (See",
"      <a class=\"local\" href=\"#H645246\">",
"       'Monitoring of intracranial pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical management of persistent or relapsing infection will depend on the suspected causes, which include poor adherence, drug resistance, or refractory disease. (See",
"      <a class=\"local\" href=\"#H14913573\">",
"       'Clinical management of persistent or relapsing infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the CSF has not been sterilized after two weeks of combination therapy, or if a patient has relapsing infection, a fungal isolate should be sent for in vitro resistance testing. (See",
"      <a class=\"local\" href=\"#H14913573\">",
"       'Clinical management of persistent or relapsing infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with symptoms related to increased ICP should be managed aggressively with daily lumbar punctures until clinical improvement and stabilization of the ICP have been documented. (See",
"      <a class=\"local\" href=\"#H645246\">",
"       'Monitoring of intracranial pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A minority of HIV-infected patients infected with Cryptococcus neoformans may develop symptoms and signs of immune reconstitution localized to the central nervous system during the initiation of ART, which can lead to significant morbidity and mortality due to increased ICP. However, delayed initiation of ART in patients with advanced immunosuppression is associated with higher rates of AIDS-related morbidity and mortality compared with early therapy. (See",
"      <a class=\"local\" href=\"#H14913615\">",
"       'Immune reconstitution syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal timing of ART during antifungal therapy for cryptococcal meningoencephalitis is uncertain. Until more published data are available, we generally avoid giving antiretroviral medications within the first two weeks of induction antifungal therapy. We suggest initiating ART within two to eight weeks after the antifungal treatment induction phase has been completed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14913657\">",
"       'Timing of antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/1\">",
"      Bamba S, Lortholary O, Sawadogo A, et al. Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy. AIDS 2012; 26:1039.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi_041009.pdf (Accessed on June 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/3\">",
"      Bennett JE. Flucytosine. Ann Intern Med 1977; 86:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/4\">",
"      Vermes A, Guchelaar HJ, Dankert J. Prediction of flucytosine-induced thrombocytopenia using creatinine clearance. Chemotherapy 2000; 46:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/5\">",
"      Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/6\">",
"      Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994; 18:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/7\">",
"      Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/8\">",
"      van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/9\">",
"      Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/10\">",
"      Tang LM. Ventriculoperitoneal shunt in cryptococcal meningitis with hydrocephalus. Surg Neurol 1990; 33:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/11\">",
"      Bach MC, Tally PW, Godofsky EW. Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension. Neurosurgery 1997; 41:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/12\">",
"      Claus JJ, Portegies P. Reversible blindness in AIDS-related cryptococcal meningitis. Clin Neurol Neurosurg 1998; 100:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/13\">",
"      Fessler RD, Sobel J, Guyot L, et al. Management of elevated intracranial pressure in patients with Cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/14\">",
"      Mylonakis E, Merriman NA, Rich JD, et al. Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis. Diagn Microbiol Infect Dis 1999; 34:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/15\">",
"      Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/16\">",
"      Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 2005; 40:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/17\">",
"      Loyse A, Wainwright H, Jarvis JN, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS 2010; 24:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/18\">",
"      Shoham S, Cover C, Donegan N, et al. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005; 40:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/19\">",
"      Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/20\">",
"      Rex JH, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/21\">",
"      Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002; 35:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/22\">",
"      Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/23\">",
"      Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/24\">",
"      Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/25\">",
"      Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-&gamma; immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/26\">",
"      DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/27\">",
"      French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/28\">",
"      Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/29\">",
"      Michelet C, Arvieux C, Fran&ccedil;ois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/30\">",
"      Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/31\">",
"      Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/32\">",
"      M&uuml;ller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/33\">",
"      Lortholary O, Fontanet A, M&eacute;main N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/34\">",
"      Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009; 51:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/35\">",
"      Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/36\">",
"      Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/37\">",
"      Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/38\">",
"      Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10:791.",
"     </a>",
"    </li>",
"    <li>",
"     file://clinicaltrials.gov/ct2/show/NCT01075152 (Accessed on August 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38568/abstract/40\">",
"      Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010; 50:1532.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85376 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38568=[""].join("\n");
var outline_f37_42_38568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14913664\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14913496\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14913503\">",
"      MONITORING FOR DRUG TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913510\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913517\">",
"      Flucytosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913524\">",
"      Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14913531\">",
"      LABORATORY MONITORING FOR FUNGAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913545\">",
"      Monitoring of serum cryptococcal antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913552\">",
"      Sterilization of cerebrospinal fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14095130\">",
"      Drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H645246\">",
"      MONITORING OF INTRACRANIAL PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H645318\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H645325\">",
"      Clinical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H645332\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14913559\">",
"      CLINICAL MONITORING DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913573\">",
"      Clinical management of persistent or relapsing infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H644868\">",
"      Assessment of new clinical symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14913615\">",
"      IMMUNE RECONSTITUTION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913636\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913643\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913650\">",
"      Management of IRIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14913657\">",
"      Timing of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14913664\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/85376\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/85376|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/12/7373\" title=\"table 1\">",
"      Rx crypto mening HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/24/37254?source=related_link\">",
"      Microbiology and epidemiology of cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23929?source=related_link\">",
"      Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_42_38569="Acute phase reactants";
var content_f37_42_38569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute phase reactants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38569/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38569/contributors\">",
"     Irving Kushner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38569/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/42/38569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/42/38569/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/42/38569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increase in concentration of acute phase reactants (APR) comprises a major pathophysiologic phenomenon that accompanies inflammation and tissue injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. With the acute phase response, normal homeostatic mechanisms are replaced by new set points that presumably contribute to defensive or adaptive capabilities.",
"   </p>",
"   <p>",
"    Focus on the acute phase phenomenon first occurred with the discovery of C-reactive protein (CRP) in the serum of patients during the acute phase of pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. CRP consists of five identical, non-covalently associated subunits, each with a molecular weight of approximately 23 kD, which are arranged symmetrically around a central pore [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/5\">",
"     5",
"    </a>",
"    ]. CRP and related proteins with this structure are termed pentraxins; others include serum amyloid P and a number of pattern recognition molecules referred to as long pentraxins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16986?source=see_link&amp;anchor=H9421037#H9421037\">",
"     \"An overview of the innate immune system\", section on 'Pentraxins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite its name, APR accompany both acute and chronic inflammatory states. They can occur in association with a wide variety of disorders, including infection, trauma, infarction, inflammatory arthritides, and various neoplasms.",
"   </p>",
"   <p>",
"    Acute phase proteins are defined as those proteins whose serum concentrations increase or decrease by at least 25 percent during inflammatory states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/1\">",
"     1",
"    </a>",
"    ]. Such proteins are termed either positive or negative APR, respectively. Changes in the levels of APR largely reflect altered production by hepatocytes.",
"   </p>",
"   <p>",
"    Increases in APR can vary from approximately 50 percent for ceruloplasmin and several components of the complement cascade to 1000-fold or more for CRP and serum amyloid A. Other positive APR include fibrinogen, alpha-1 antitrypsin, haptoglobin, interleukin (IL)-1 receptor antagonist, hepcidin, ferritin, and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Negative APR include albumin, transferrin, and transthyretin. The erythrocyte sedimentation rate (ESR), a nonprotein APR, reflects plasma viscosity and the presence of acute phase proteins, as well as other influences, some of which are as yet unidentified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the mechanisms mediating the APR as well as the uses of measuring APR is presented here. Detailed reviews of disorders associated with variations in APR are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDUCTION BY CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in levels of APR largely result from the effects of inflammatory molecules, called cytokines. During the inflammatory process, cytokines are primarily produced by macrophages, monocytes, and a variety of other cells. Some of the major cytokines relevant to the acute phase response are interleukin (IL)-6, IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), and interferon gamma. These proteins influence acute phase protein production in hepatocytes, with IL-6 being the major inducer of most APR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/10\">",
"     10",
"    </a>",
"    ]. These cytokines also suppresses the synthesis of albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytokines involved in the acute phase response are components of a large, complex signaling network that consists of other cytokines, hormones, cytokine receptor antagonists, and circulating receptors such as those for TNF and IL-6. Combinations of cytokines can have additive, inhibitory, or synergistic effects; complex molecular mechanisms regulate these processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/12\">",
"     12",
"    </a>",
"    ]. Patterns of cytokine production differ under various inflammatory conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/7,13,14\">",
"     7,13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=see_link\">",
"     \"Role of cytokines in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to changes in the levels of APR, a number of behavioral, physiologic, biochemical, and nutritional changes are induced by inflammation-associated cytokines. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neuroendocrine system effects, such as increased production of corticotropin-releasing hormone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Behavioral changes, such as anorexia, somnolence, and lethargy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impaired growth in children",
"     </li>",
"     <li>",
"      Muscle wasting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anemia of chronic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/23\">",
"       23",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Altered serum concentrations of various cations, including iron, copper and zinc",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FUNCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assumption that the APR are beneficial is based on the known functions of the involved proteins combined with speculation as to how they may serve useful purposes in inflammation, healing, or adaptation to noxious stimuli. Inflammation is a complex, highly orchestrated process that involves many cell types and molecules. These cells and proteins may initiate, amplify, sustain, attenuate, or abolish inflammation. A number of the participating molecules are also multifunctional, contributing to both the waxing and the waning of inflammation at different points in time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of CRP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many APR such as CRP can influence multiple stages of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A major function of CRP is its ability to bind phosphocholine, thereby permitting recognition both of foreign pathogens that display this moiety and of phospholipid constituents of damaged cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/27\">",
"     27",
"    </a>",
"    ]. CRP can activate the complement system and can bind to phagocytic cells via Fc receptors, suggesting that it can initiate elimination of pathogens and targeted cells by interaction with both humoral and cellular effector systems of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/26\">",
"     26",
"    </a>",
"    ]. The rapidity of the CRP response, in contrast to the slower adaptive immune response represented by antibody production, indicates that CRP is a component of the innate immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRP plays a role in host defense and in clearance of necrotic and apoptotic cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. It has both proinflammatory and antiinflammatory actions. Proinflammatory effects include activation of the complement system, the induction in monocytes of inflammatory cytokines and tissue factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], and shedding of the IL-6 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/32\">",
"     32",
"    </a>",
"    ]. As a result, the CRP response to tissue injury may worsen tissue damage in some settings. This was illustrated by the 40 percent increase in the size of experimentally produced myocardial infarctions observed in rodents when human CRP was injected in the periinfarction period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/33\">",
"     33",
"    </a>",
"    ]. The effect of CRP in this system was abrogated by depletion of complement before, or up to two hours after, coronary occlusion.",
"   </p>",
"   <p>",
"    However, the primary effect of CRP may be antiinflammatory. The net result of increased concentrations of CRP in transgenic mice that express rabbit CRP is a decrease in the severity of experimentally induced sepsis or inflammation of the lungs or joints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Fewer neutrophils accumulate at inflammatory sites because of reduced ability of the neutrophil to adhere to endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another function is the enhancement of apoptotic cell clearance by CRP. In one study, the binding of CRP to lymphocytes that were undergoing apoptosis prevented the insertion of the lytic terminal complement components into the cell membrane and enhanced phagocytosis of apoptotic cells by macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/38\">",
"     38",
"    </a>",
"    ]. Abnormalities in apoptosis are suspected of increasing the risk of autoimmune phenomena. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5735?source=see_link\">",
"     \"Apoptosis and autoimmune disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Role of SAA protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less is known about the actions of serum amyloid A (SAA) protein, the other major human acute phase protein. SAA consists of a family of apolipoproteins that are rapidly associated with high-density lipoprotein following their synthesis and secretion. Proteins in the SAA family have the potential to influence cholesterol metabolism during inflammatory states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. SAA may also cause adhesion and chemotaxis of phagocytic cells and lymphocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In some patients with chronic inflammation, the net effect of increased SAA production is deleterious, because of the deposition of SAA fragments into tissues and because of the development of systemic amyloidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of other proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other APR can initiate or sustain inflammation. As an example, the complement components serve proinflammatory roles, including chemotaxis, plasma protein exudation at sites of inflammation, and opsonization of infectious agents and damaged cells. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, other APR may be antiinflammatory. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antioxidants haptoglobin and hemopexin protect against reactive oxygen species by removing iron-containing cell-free hemoglobin and heme, respectively, from the circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The activity of proteolytic enzymes is antagonized by alpha-1 antitrypsin and by alpha-1-antichymotrypsin. Alpha-1-chymotrypsin also inhibits superoxide anion generation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hepcidin, a protein made by the liver, can contribute to decreases in serum iron by decreasing intestinal iron absorption and by impairing the release of iron from macrophages [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/8\">",
"       8",
"      </a>",
"      ]. In animal models, production of hepcidin is markedly increased by interleukin-6. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=see_link&amp;anchor=H5#H5\">",
"       \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Hepcidin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      At least two APR are known to influence wound healing. Fibrinogen causes endothelial cell adhesion, spreading, and proliferation, which are all critical to tissue repair. Haptoglobin aids in wound repair by stimulating angiogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute phase response is not uniformly beneficial. In addition to the development of anemia, it can lead to cachexia, impaired growth, and secondary (AA or reactive) amyloidosis. Cytokine overproduction and imbalance can be fatal, as in septic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL RELEVANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum APR level measurements are useful because they frequently reflect the presence and intensity of an inflammatory process. However, APR measurements in clinical use are not specific to any particular disease. The most widely used indicators of the acute phase response are the ESR and CRP.",
"   </p>",
"   <p>",
"    SAA concentrations usually parallel those of CRP. Although some studies suggest that SAA is a more sensitive marker of inflammatory disease, assays for SAA are not widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Erythrocyte sedimentation rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ESR, defined as the rate",
"    <span class=\"nowrap\">",
"     (mm/hour)",
"    </span>",
"    at which erythrocytes suspended in plasma settle when placed in a vertical tube, reflects a variety of factors, as indicated above, notably the plasma concentration of fibrinogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared with measurement of CRP, the ESR has the advantages of familiarity, simplicity, and an abundant literature compiled over many decades. However, the ESR has a number of disadvantages compared with CRP determination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ESR is only an indirect measurement of serum acute phase protein concentrations, particularly fibrinogen. It is also influenced greatly by the size, shape, and number of red blood cells (RBC), as well as by other constituents in the blood such as immunoglobulins. It has long been known that anemia increases the sedimentation rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/49\">",
"       49",
"      </a>",
"      ]. The sedimentation of RBC is presumably impeded by other RBC; sedimentation is thus more rapid in anemia, in which this retardation is lessened, thus increasing the ESR.",
"     </li>",
"     <li>",
"      As a patient&rsquo;s condition worsens or improves, the ESR changes relatively slowly; by comparison, CRP concentrations change rapidly.",
"     </li>",
"     <li>",
"      ESR values increase markedly with age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/50\">",
"       50",
"      </a>",
"      ] and are slightly higher among women than men. As a result, any single set of normal values will not be valid for the population at large. One can roughly correct ESR for age by using the following formulas: the upper limit of the reference range equals (age in",
"      <span class=\"nowrap\">",
"       years)/2",
"      </span>",
"      for men and (age in years +",
"      <span class=\"nowrap\">",
"       10)/2",
"      </span>",
"      for women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both ESR and CRP can be elevated in obesity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/52\">",
"       52",
"      </a>",
"      ]; this is due at least in part to IL-6 secretion by adipose tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Marked ESR elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a retrospective study of 1006 consecutive outpatients, markedly elevated ESR values of over 100",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    were most commonly due to infection (33 percent), with malignant neoplasms and renal disease responsible for 17 percent each and with inflammatory disorders responsible for 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23027305\">",
"    <span class=\"h3\">",
"     ESR in renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ESR is elevated (greater than 25",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    by the Westergren method) in almost all patients with the nephrotic syndrome or end-stage renal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Nearly 60 percent of patients have an ESR above 60",
"    <span class=\"nowrap\">",
"     mm/hour,",
"    </span>",
"    while 20 percent have extreme elevations above 100",
"    <span class=\"nowrap\">",
"     mm/hour.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Marked ESR elevation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The elevation in ESR is not affected by hemodialysis as the pre- and post-dialysis values are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/56\">",
"     56",
"    </a>",
"    ]. A direct relation between the degree of proteinuria and the ESR has been noted in patients with glomerular disease, in which the ESR was approximately 10 times the daily rate of protein excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/58\">",
"     58",
"    </a>",
"    ]. The precise mechanism by which this occurs is not known, although an underlying inflammatory renal disease process may cause both an elevated ESR and a reduction in the serum albumin beyond that from proteinuria alone, as albumin is a &ldquo;negative acute phase protein&rdquo; and as albumin synthesis by hepatocytes is decreased in response to inflammatory cytokines.",
"   </p>",
"   <p>",
"    The frequent elevation in ESR in renal insufficiency or in the nephrotic syndrome is important clinically, although this finding alone is not an indication to evaluate a patient for an underlying systemic disorder. This issue becomes important in a condition such as membranous nephropathy in which a minority of patients has an associated malignancy. Occult malignancy should be excluded if the patient has an elevated ESR and some other suggestive finding such as weight loss, heme-positive stools, or unexplained anemia. An isolated ESR, per se, without other systemic signs or symptoms need not lead to a search for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link\">",
"     \"Causes and diagnosis of membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     C-reactive protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of CRP that is truly normal or clinically innocuous is not known. Data from a study conducted by the National Health and Nutrition Evaluation Survey of over 21,000 people revealed that CRP levels vary with age, sex, and race (",
"    <a class=\"graphic graphic_table graphicRef59376 \" href=\"mobipreview.htm?37/53/38747\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is very important to note that there is no uniformity in the units that are used to report CRP levels. Some laboratories report CRP concentrations as",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    while others employ",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    Standard CRP determinations are usually, but not always, reported in units of",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    while determinations using a highly sensitive assay, generally referred to as high-sensitivity CRP (hs-CRP), are routinely reported in units of",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"   </p>",
"   <p>",
"    Markedly elevated levels of CRP are strongly associated with infection. Infections, most often bacterial, were found in approximately 80 percent of patients with values in excess of 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    and in 88 to 94 percent of patients with values over 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Levels of CRP may also be elevated in patients with viral infections, although often not to the degree seen in patients with bacterial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\", section on 'Procalcitonin and CRP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Population studies reveal a skewed, rather than Gaussian, distribution of the plasma CRP concentration. About 70 to 90 percent of samples from reference populations have CRP concentrations under 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/L),",
"    </span>",
"    but some individuals have minor elevations up to 1",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    It is useful to regard CRP levels from 0.3 to 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3 to 10",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    as minor CRP elevation. Values greater than 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    are felt to reflect clinically significant inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One can roughly correct the CRP for age by using the following formulas: the upper limit of the reference range",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    equals (age in",
"    <span class=\"nowrap\">",
"     years)/50",
"    </span>",
"    for men and (age in",
"    <span class=\"nowrap\">",
"     years/50)",
"    </span>",
"    + 0.6 for women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although CRP is a sensitive reflector of inflammation, it is not specific. Values between 0.3 and 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    may reflect minor degrees of inflammation, such as that seen in periodontitis, but may also reflect obesity, cigarette smoking, diabetes mellitus, uremia, hypertension, low levels of physical activity, oral hormone replacement therapy, sleep disturbance, chronic fatigue, low alcohol consumption, depression, aging, or other apparently noninflammatory states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurements of CRP concentrations are of prognostic value in rheumatoid arthritis and can help guide management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/29,69\">",
"     29,69",
"    </a>",
"    ]. The function and genetics of CRP have been reviewed from a rheumatology perspective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     High-sensitivity CRP and low-grade inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some confusion has arisen because of widespread use of the terms &ldquo;high-sensitivity CRP&rdquo; (hs-CRP) and &ldquo;low-grade inflammation&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/70\">",
"     70",
"    </a>",
"    ]. One common misunderstanding has been the incorrect belief that hs-CRP is different in some way from the CRP that has been measured for many years. It is not. High-sensitivity only means that the concentration of CRP was determined using an assay designed to measure very low levels of CRP. The CRP that is measured has no new or unique properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minor CRP elevation (concentrations between 3 and 10",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    has been generally regarded as a marker of what has been called low-grade inflammation. However, this poorly defined state, sometimes referred to as mini-inflammation or subclinical inflammation, occurs in many conditions in which there are minor degrees of metabolic malfunction, such as obesity and insulin resistance, and, in such circumstances, is not a marker of inflammation as we have traditionally thought of it.",
"   </p>",
"   <p>",
"    The low-grade inflammatory state differs in several important ways from the acute inflammation that occurs in response to infection or tissue injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/70,72\">",
"     70,72",
"    </a>",
"    ]. The latter exhibits the classic signs of inflammation (swelling, erythema, warmth, and pain), while low-grade inflammation does not. Acute inflammation generally shows a marked CRP response while low-grade inflammation shows only minor CRP elevation. The purpose of the inflammatory response to infection and tissue injury is defense, clearance of necrotic tissue, adaptation, and repair, while the purpose of low-grade inflammation appears to be restoration of homeostasis.",
"   </p>",
"   <p>",
"    Acute inflammation is largely triggered by components of an invading pathogen, referred to as pathogen-associated molecular patterns (PAMPs), and by products of damaged cells, danger (actually, damage)-associated molecular patterns (DAMPs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/72\">",
"     72",
"    </a>",
"    ]. The latter are sometimes referred to as alarmins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/73\">",
"     73",
"    </a>",
"    ]. One molecular mechanism that can trigger low-grade inflammation and CRP induction in response to metabolic stress that has been well-studied is the unfolded protein response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These differences between acute inflammation and low-grade inflammation are so great that two leading researchers in the field have suggested distinct nomenclatures for the latter; both &ldquo;para-inflammation&rdquo; and &ldquo;meta-flammation&rdquo; (metabolically-triggered inflammation) have been proposed to emphasize the distinction between metabolic perturbation and inflammation as it is traditionally viewed, both of which may result in increases in CRP levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/72,74\">",
"     72,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rationale for measuring ESR and CRP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although elevations in multiple components of APR commonly occur together, not all happen uniformly in all patients. Discordance between concentrations of different APR is common; some may be elevated while others are not. These variations may be explained by differences in the production of specific cytokines or their modulators in different diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Discrepancies between ESR and CRP are found with some frequency. An elevated ESR observed together with a normal CRP is often a false positive value for the ESR; this may reflect the effects of blood constituents, such as monoclonal immunoglobulins, that are not related to inflammation but that can influence the ESR. However, this conclusion is not always valid. As an example, the ESR may be markedly elevated in patients with active systemic lupus erythematosus (SLE), while the CRP response is muted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Lupus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since there undoubtedly are a number of other clinical situations in which similar discrepancies occur, there probably is no single best laboratory test to reflect inflammation. The optimal use of acute phase protein measurements may be to obtain several measurements, most commonly ESR and CRP, rather than a single test. The results are interpreted in light of the clinical context and the considerations previously indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of APR may be most helpful in patients with rheumatoid arthritis (RA), polymyalgia rheumatica, and giant cell arteritis. Reports also raise the possibility of other applications, such as assessment of the prognosis of patients with malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Rheumatoid arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although APR are usually of little use in distinguishing between early RA, osteoarthritis, and SLE, they are helpful in monitoring disease activity in RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/76\">",
"     76",
"    </a>",
"    ]. The ESR has been more widely used for this purpose in the past [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/77\">",
"     77",
"    </a>",
"    ], but CRP levels correlate somewhat better with activity than does ESR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When frozen serum samples, obtained in the years prior to development of symptoms, were subsequently tested, elevated and rising levels of CRP were found in patients who were subsequently diagnosed with RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/80\">",
"     80",
"    </a>",
"    ]. Age-adjusted controls did not demonstrate a similar degree of elevation. The mean CRP levels in the year before symptoms were noted were 0.22",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    versus 0.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for age-matched controls. Levels were slightly higher in the group of patients who had serologic abnormalities before the onset of symptoms than in those without such serologic abnormalities (eg, rheumatoid factor or anticyclic citrullinated peptide antibodies). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=see_link\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although CRP levels average 2 to 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in RA patients with moderate disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/81\">",
"     81",
"    </a>",
"    ], there is considerable variation. Approximately 10 percent of patients have values in the clinically insignificant range, while a few patients with severe disease activity show very high concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurements of the levels of APR are also of value in assessing the progression and prognosis of patients with RA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevations in both CRP and ESR are associated with radiographic progression at 6 and 12 months after study entry [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/83,84\">",
"       83,84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Time-integrated values of ESR and CRP correlate significantly with disease progression over periods of up to 20 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/69,85,86\">",
"       69,85,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      APR levels are significantly associated with early synovitis and erosions as detected by MRI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/87\">",
"       87",
"      </a>",
"      ], with cellular infiltrates on synovial histologic specimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/88\">",
"       88",
"      </a>",
"      ], with osteoclastic activation and reduced bone mineral density [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/89\">",
"       89",
"      </a>",
"      ], and with work disability on long-term follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     PMR and GCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are frequently accompanied by markedly elevated levels of the ESR (often higher than 100",
"    <span class=\"nowrap\">",
"     mm/hour),",
"    </span>",
"    these elevated levels should not be regarded as a sine qua non for these disorders. As many as 10 to 20 percent of patients with PMR have normal ESRs, depending on what value is regarded as the limit of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. It has been suggested that patients with PMR who have relatively low ESRs at onset require lower doses of steroids for shorter periods of time than those with elevated values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/94\">",
"     94",
"    </a>",
"    ]. However, they have the same frequency of positive temporal artery biopsies as those with high ESR. Only about 5 percent of patients with GCA have ESR values under 40",
"    <span class=\"nowrap\">",
"     mm/hour;",
"    </span>",
"    these patients had fewer visual and systemic symptoms than those with higher ESR values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40598?source=see_link\">",
"     \"Treatment of polymyalgia rheumatica\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with these diseases, CRP and ESR are regarded of approximately equal value in assessing disease activity. Limited data suggest that CRP levels are more sensitive for the detection of active disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/96\">",
"     96",
"    </a>",
"    ]. In addition, the uncertainty as to what ESR values are normal in older adults suggests that CRP levels may be more valuable in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lupus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ESR may be a useful marker of disease activity and a predictor of organ damage. This was illustrated in a prospective study of 553 patients with SLE whose ESR results were measured using the Westergren method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/97\">",
"     97",
"    </a>",
"    ]. Results for the ESR were expressed in four categories: &lt;25",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    (normal), 25 to 50",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    (mild elevation), 51 to 75",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    (moderate elevation), and &gt;75",
"    <span class=\"nowrap\">",
"     mm/hour",
"    </span>",
"    (marked elevation). Disease activity was assessed using indices of disease activity (systemic lupus activity measure [SLAM] from which the ESR was excluded) and of damage (systemic lupus erythematosus damage index [SLEDI]). Increasing values of ESR were associated with disease activity. Moderate or marked elevation of the ESR was associated with accrual of damage.",
"   </p>",
"   <p>",
"    SLE represents an exception to the generalization that CRP concentrations correlate with the extent and severity of inflammation in patients with rheumatic disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/75\">",
"     75",
"    </a>",
"    ]. The muted CRP response in SLE may result from the ability of type I interferons, which are highly expressed in most lupus patients, to inhibit CRP induction in hepatocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/98\">",
"     98",
"    </a>",
"    ]. While many patients with active SLE do not have elevated CRP concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/99\">",
"     99",
"    </a>",
"    ], CRP concentrations may be quite elevated in patients with active lupus serositis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/100\">",
"     100",
"    </a>",
"    ] or with chronic synovitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/101\">",
"     101",
"    </a>",
"    ]. In a febrile lupus patient, marked CRP elevation (greater than 6 or 7",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    favors the diagnosis of bacterial infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/99\">",
"     99",
"    </a>",
"    ]. In a landmark study, infection was present in all patients with CRP levels over 60",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    except for those with serositis, supporting the clinical utility of regarding marked CRP elevation as strongly suggestive of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum amyloid A levels also tend to be lower in SLE than in other chronic inflammatory disorders, which may explain why secondary amyloidosis is unusual in this disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurements of APR, particularly CRP, may be helpful in assessing the prognosis in some patients with malignancy, in assessing the presence or absence of tumor recurrence, and in distinguishing a clonal from a reactive process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 39 patients with non-Hodgkin lymphoma, the group with high serum CRP (mean 2.9",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      had a median survival of 8.5 months, whereas 75 percent of those with lower CRP levels (&lt;1",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      survived to 32 months after diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 91 patients with thrombocytosis, clonal thrombocytosis was associated with significantly lower levels of CRP and IL-6 than reactive disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ESR was found to be an independent risk factor for survival in multiple myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/106\">",
"       106",
"      </a>",
"      ] and can be markedly elevated in this condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a continually expanding literature on the predictive value of CRP in cardiovascular disease and on the possible role of serum CRP in screening for cardiovascular risk. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=see_link\">",
"     \"Screening for cardiovascular risk with C-reactive protein\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, infections are an important cause of elevated APR. Serial measurement of APR may be used to assess response of chronic infections to treatment. As an example, the ESR and CRP fall when osteomyelitis is effectively treated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other chronic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reflectors of inflammation have poor prognostic implications in many other conditions, including type II diabetes, peripheral vascular disease, uremia, and ischemic stroke. In older adults, elevated levels of APR predict &ldquo;failure to thrive&rdquo; and even increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/107\">",
"     107",
"    </a>",
"    ]. This may be because a minor acute phase response reflects the presence of some degree of ongoing metabolic perturbation which itself contributes to poor outcome. Alternatively, these minimally elevated acute phase protein levels may merely identify individuals who are biologically older and individuals who have sustained a greater load of minor body insults and damage, such as would result from the cumulative effect of oxidative stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/108\">",
"     108",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cell stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/42/38569/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increase in concentration of acute phase reactants (APR) comprises a major pathophysiologic phenomenon that accompanies inflammation and tissue injury. With the acute phase response, normal homeostatic mechanisms are replaced by new set points that presumably contribute to defensive or adaptive capabilities. The APR accompany both acute and chronic inflammatory states. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute phase proteins are defined as those proteins whose serum concentrations increase or decrease by at least 25 percent during inflammatory states. Such proteins are termed either positive or negative APR, respectively. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Changes in levels of APR largely result from the effects of cytokines, including interleukin (IL)-6, IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), and interferon gamma. These proteins influence acute phase protein production in hepatocytes, with IL-6 being the major inducer of most APR. In addition to changes in the levels of APR, a number of behavioral, physiologic, biochemical, and nutritional changes are induced by inflammation-associated cytokines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Induction by cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assumption that APR are beneficial is based on the known functions of the involved proteins combined with speculation as to how they may serve useful purposes in inflammation, healing, or adaptation to noxious stimuli. CRP is a component of the innate immune response, and has both proinflammatory and antiinflammatory actions. A number of other APR can initiate or sustain inflammation, while some APR may be antiinflammatory. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Functions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Role of CRP'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Role of other proteins'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ESR, defined as the rate",
"      <span class=\"nowrap\">",
"       (mm/hour)",
"      </span>",
"      at which erythrocytes suspended in plasma settle when placed in a vertical tube, reflects a variety of factors, most notably the plasma concentration of fibrinogen. The ESR has some advantages compared with measurement of CRP but has a number of significant disadvantages. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Erythrocyte sedimentation rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The level of CRP that is truly normal or clinically innocuous is not known. CRP levels vary with age, sex, and race. There is no uniformity in the units that are used to report CRP levels; some laboratories report CRP concentrations as",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      while others employ",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      Markedly elevated levels are strongly associated with infection. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'C-reactive protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although CRP is a sensitive reflector of inflammation, it is not specific for inflammation. Values between 0.3 and 1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      may reflect minor degrees of inflammation, such as that seen in periodontitis, but may also reflect apparently noninflammatory states in conditions in which there are minor degrees of metabolic malfunction, such as obesity and insulin resistance. Values greater than 1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      are felt to reflect clinically significant inflammation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'C-reactive protein'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'High-sensitivity CRP and low-grade inflammation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although elevations in multiple components of the APR commonly occur together, not all happen uniformly in all patients. Discordance between concentrations of different APR is common; discrepancies between ESR and CRP are found with some frequency. These variations may be partially explained by differences in the production of specific cytokines or their modulators in different diseases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Rationale for measuring ESR and CRP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assessment of APR may be most helpful in patients with rheumatoid arthritis (RA), polymyalgia rheumatica, and giant cell arteritis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Specific applications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/1\">",
"      Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982; 389:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/2\">",
"      Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/3\">",
"      Tillett WS, Francis T. SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. J Exp Med 1930; 52:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/4\">",
"      Kushner I, Samols D. Oswald Avery and the pneumococcus. Pharos Alpha Omega Alpha Honor Med Soc 2011; 74:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/5\">",
"      Osmand AP, Friedenson B, Gewurz H, et al. Characterization of C-reactive protein and the complement subcomponent C1t as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Natl Acad Sci U S A 1977; 74:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/6\">",
"      Inforzato A, Bottazzi B, Garlanda C, et al. Pentraxins in humoral innate immunity. Adv Exp Med Biol 2012; 946:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/7\">",
"      Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997; 99:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/8\">",
"      Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/9\">",
"      Bedell SE, Bush BT. Erythrocyte sedimentation rate. From folklore to facts. Am J Med 1985; 78:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/10\">",
"      Gauldie J, Richards C, Harnish D, et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 1987; 84:7251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/11\">",
"      Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/12\">",
"      Bode JG, Albrecht U, H&auml;ussinger D, et al. Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-&kappa;B-dependent signaling. Eur J Cell Biol 2012; 91:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/13\">",
"      Loyer P, Ilyin G, Abdel Razzak Z, et al. Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 1993; 336:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/14\">",
"      Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 1992; 149:2021.",
"     </a>",
"    </li>",
"    <li>",
"     Dinarello C. Cytokines as endogenous pyrogens. In: Fever: Basic mechanisms and management, Mackowiak P (Ed), Lippincott-Raven, Philadelphia 1997. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/16\">",
"      Goldbach JM, Roth J, Zeisberger E. Fever suppression by subdiaphragmatic vagotomy in guinea pigs depends on the route of pyrogen administration. Am J Physiol 1997; 272:R675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/17\">",
"      Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/18\">",
"      Sarraf P, Frederich RC, Turner EM, et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997; 185:171.",
"     </a>",
"    </li>",
"    <li>",
"     Krueger JM. Cytokine involvement in sleep responses to infection and physiological sleep. In: Cytokines in the Nervous System, Rothwell NJ (Ed), Landes Publishing, Austin 1996. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/20\">",
"      Moldawer LL, Copeland EM 3rd. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 1997; 79:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/21\">",
"      Wolf M, B&ouml;hm S, Brand M, Kreymann G. Proinflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor I synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996; 135:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/22\">",
"      Li YP, Schwartz RJ, Waddell ID, et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998; 12:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/23\">",
"      Means RT. Hepcidin and cytokines in anaemia. Hematology 2004; 9:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/24\">",
"      Kushner I. Semantics, inflammation, cytokines and common sense. Cytokine Growth Factor Rev 1998; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/25\">",
"      Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 279:48487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/26\">",
"      Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005; 117:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/27\">",
"      Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/28\">",
"      Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/29\">",
"      Rhodes B, F&uuml;rnrohr BG, Vyse TJ. C-reactive protein in rheumatology: biology and genetics. Nat Rev Rheumatol 2011; 7:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/30\">",
"      Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992; 4:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/31\">",
"      Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/32\">",
"      Jones SA, Novick D, Horiuchi S, et al. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J Exp Med 1999; 189:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/33\">",
"      Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/34\">",
"      Ahmed N, Thorley R, Xia D, et al. Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am J Respir Crit Care Med 1996; 153:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/35\">",
"      Xia D, Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc Natl Acad Sci U S A 1997; 94:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/36\">",
"      Jiang S, Xia D, Samols D. Expression of rabbit C-reactive protein in transgenic mice inhibits development of antigen-induced arthritis. Scand J Rheumatol 2006; 35:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/37\">",
"      Zouki C, Beauchamp M, Baron C, Filep JG. Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest 1997; 100:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/38\">",
"      Gershov D, Kim S, Brot N, Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/39\">",
"      Tam SP, Flexman A, Hulme J, Kisilevsky R. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 2002; 43:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/40\">",
"      Tam SP, Kisilevsky R, Ancsin JB. Acute-phase-HDL remodeling by heparan sulfate generates a novel lipoprotein with exceptional cholesterol efflux activity from macrophages. PLoS One 2008; 3:e3867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/41\">",
"      Su SB, Gong W, Gao JL, et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999; 189:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/42\">",
"      Mullan RH, Bresnihan B, Golden-Mason L, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 2006; 54:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/43\">",
"      Boretti FS, Buehler PW, D'Agnillo F, et al. Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J Clin Invest 2009; 119:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/44\">",
"      Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013; 121:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/45\">",
"      Kilpatrick L, McCawley L, Nachiappan V, et al. Alpha-1-antichymotrypsin inhibits the NADPH oxidase-enzyme complex in phorbol ester-stimulated neutrophil membranes. J Immunol 1992; 149:3059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/46\">",
"      Cid MC, Grant DS, Hoffman GS, et al. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993; 91:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/47\">",
"      Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/48\">",
"      Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996; 26:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/49\">",
"      Ham TC, Curtis FC. Sedimentation rate of erythrocytes. Medicine (Baltimore) 1938; 17:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/50\">",
"      Hayes GS, Stinson IN. Erythrocyte sedimentation rate and age. Arch Ophthalmol 1976; 94:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/51\">",
"      Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed) 1983; 286:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/52\">",
"      Leff RD, Akre SP. Obesity and the erythrocyte sedimentation rate. Ann Intern Med 1986; 105:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/53\">",
"      Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/54\">",
"      Fincher RM, Page MI. Clinical significance of extreme elevation of the erythrocyte sedimentation rate. Arch Intern Med 1986; 146:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/55\">",
"      Bathon J, Graves J, Jens P, et al. The erythrocyte sedimentation rate in end-stage renal failure. Am J Kidney Dis 1987; 10:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/56\">",
"      Shusterman N, Kimmel PL, Kiechle FL, et al. Factors influencing erythrocyte sedimentation in patients with chronic renal failure. Arch Intern Med 1985; 145:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/57\">",
"      Arik N, Bedir A, G&uuml;naydin M, et al. Do erythrocyte sedimentation rate and C-reactive protein levels have diagnostic usefulness in patients with renal failure? Nephron 2000; 86:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/58\">",
"      Liverman PC, Tucker FL, Bolton WK. Erythrocyte sedimentation rate in glomerular disease: association with urinary protein. Am J Nephrol 1988; 8:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/59\">",
"      Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005; 352:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/60\">",
"      Vanderschueren S, Deeren D, Knockaert DC, et al. Extremely elevated C-reactive protein. Eur J Intern Med 2006; 17:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/61\">",
"      Le Gall C, D&eacute;sid&eacute;ri-Vaillant C, Nicolas X. [Significations of extremely elevated C-reactive protein: about 91 cases in a French hospital center]. Pathol Biol (Paris) 2011; 59:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/62\">",
"      Kr&uuml;ger S, Ewig S, Papassotiriou J, et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/63\">",
"      Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/64\">",
"      Wener MH, Daum PR, McQuillan GM. The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. J Rheumatol 2000; 27:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/65\">",
"      Ranganath VK, Elashoff DA, Khanna D, et al. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol 2005; 32:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/66\">",
"      Slade GD, Ghezzi EM, Heiss G, et al. Relationship between periodontal disease and C-reactive protein among adults in the Atherosclerosis Risk in Communities study. Arch Intern Med 2003; 163:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/67\">",
"      Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006; 119:166.e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/68\">",
"      Giles JT, Bartlett SJ, Andersen R, et al. Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum 2008; 58:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/69\">",
"      van Leeuwen MA, van der Heijde DM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994; 21:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/70\">",
"      Kushner I, Samols D, Magrey M. A unifying biologic explanation for \"high-sensitivity\" C-reactive protein and \"low-grade\" inflammation. Arthritis Care Res (Hoboken) 2010; 62:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/71\">",
"      Casas JP, Shah T, Hingorani AD, et al. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/72\">",
"      Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/73\">",
"      Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/74\">",
"      Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/75\">",
"      Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum 2008; 59:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/76\">",
"      Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994; 24:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/77\">",
"      Donald F, Ward MM. Evaluative laboratory testing practices of United States rheumatologists. Arthritis Rheum 1998; 41:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/78\">",
"      Larsen A. The relation of radiographic changes to serum acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. Scand J Rheumatol 1988; 17:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/79\">",
"      Cohick CB, Furst DE, Quagliata S, et al. Analysis of elevated serum interleukin-6 levels in rheumatoid arthritis: correlation with erythrocyte sedimentation rate or C-reactive protein. J Lab Clin Med 1994; 123:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/80\">",
"      Nielen MM, van Schaardenburg D, Reesink HW, et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004; 50:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/81\">",
"      Cush JJ, Lipsky PE, Postlethwaite AE, et al. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum 1990; 33:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/82\">",
"      Amos RS, Crockson RA, Crockson AP, et al. Rheumatoid arthritis: C-reactive protein and erythrocyte sedimentation rate during initial treatment. Br Med J 1978; 1:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/83\">",
"      Coste J, Spira A, Clerc D, Paolaggi JB. Prediction of articular destruction in rheumatoid arthritis: disease activity markers revisited. J Rheumatol 1997; 24:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/84\">",
"      Matsuda Y, Yamanaka H, Higami K, Kashiwazaki S. Time lag between active joint inflammation and radiological progression in patients with early rheumatoid arthritis. J Rheumatol 1998; 25:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/85\">",
"      Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/86\">",
"      Plant MJ, Jones PW, Saklatvala J, et al. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 1998; 25:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/87\">",
"      McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998; 57:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/88\">",
"      Fujinami M, Sato K, Kashiwazaki S, Aotsuka S. Comparable histological appearance of synovitis in seropositive and seronegative rheumatoid arthritis. Clin Exp Rheumatol 1997; 15:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/89\">",
"      Gough A, Sambrook P, Devlin J, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/90\">",
"      Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol 1998; 25:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/91\">",
"      Proven A, Gabriel SE, O'Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999; 26:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/92\">",
"      Gonz&aacute;lez-Gay MA, Rodr&iacute;guez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997; 157:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/93\">",
"      Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum 1996; 39:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/94\">",
"      Weyand CM, Fulbright JW, Evans JM, et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999; 159:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/95\">",
"      Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum 2001; 45:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/96\">",
"      Cantini F, Salvarani C, Olivieri I. Erythrocyte sedimentation rate and C-reactive protein in the diagnosis of polymyalgia rheumatica. Ann Intern Med 1998; 128:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/97\">",
"      Vil&aacute; LM, Alarc&oacute;n GS, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol 2005; 32:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/98\">",
"      Enocsson H, Sj&ouml;wall C, Skogh T, et al. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares? Arthritis Rheum 2009; 60:3755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/99\">",
"      Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982; 8:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/100\">",
"      ter Borg EJ, Horst G, Limburg PC, et al. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990; 17:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/101\">",
"      Moutsopoulos HM, Mavridis AK, Acritidis NC, Avgerinos PC. High C-reactive protein response in lupus polyarthritis. Clin Exp Rheumatol 1983; 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/102\">",
"      De Beer FC, Mallya RK, Fagan EA, et al. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; 2:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/103\">",
"      Legouffe E, Rodriguez C, Picot MC, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 1998; 31:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/104\">",
"      Tefferi A, Ho TC, Ahmann GJ, et al. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994; 97:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/105\">",
"      Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998; 176:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/106\">",
"      Alexandrakis MG, Passam FH, Ganotakis ES, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol 2003; 25:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/107\">",
"      Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/42/38569/abstract/108\">",
"      Kushner I. C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging. Cleve Clin J Med 2001; 68:535.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7483 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38569=[""].join("\n");
var outline_f37_42_38569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDUCTION BY CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FUNCTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of CRP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Role of SAA protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of other proteins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL RELEVANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Erythrocyte sedimentation rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Marked ESR elevation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23027305\">",
"      - ESR in renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - High-sensitivity CRP and low-grade inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rationale for measuring ESR and CRP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PMR and GCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other chronic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7483\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7483|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/53/38747\" title=\"table 1\">",
"      CRP reactive adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/50/10025?source=related_link\">",
"      Role of cytokines in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40598?source=related_link\">",
"      Treatment of polymyalgia rheumatica",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_42_38570="Hand-foot-and-mouth disease - buccal";
var content_f37_42_38570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58566%7EDERM%2F71314%7EID%2F81027%7EPEDS%2F52800%7EDERM%2F53423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58566%7EDERM%2F71314%7EID%2F81027%7EPEDS%2F52800%7EDERM%2F53423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - buccal mucosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VNJThSUAJS4pcCigBKSnUUANopSKSgAooooAKUUlKOtAFzT0keZfL25J6t0Fer6CuyyhBGTjrXl+ljzJQxDsVxkhtv6163pEai2QKNoArnrHbhVuzTsI8ykjPB6AVuqQdm1geMg+ntWbpjmJyUYruzyDzWna85dlXGajoerS1ZNkHHZh6VDOzZxnj261PtOeAQo7elQSHB+bn2rKW56dNaDCTgA9Kz7tsAkH8a0Cue+ay71vnYelCYSsZ8jfNjvULAM3NTgHJJFNcHGQMVSM7FYjc4UdaRo9jEZzilIbdkdeop4XqScse9StyxhJb1zUWw5O41YC9B29c0rgD6VZm1Y6bwH/AK24X3U16bagCPPOOnNeVeBpgmsGIn/WLx9RXqygKijjoOneinHW55mLVpErOD0GAOgqKRuwFPIAB/rVedwq5J7VU9TCCIJOCTmqE+oJbttQ+YxP3e351Q1rV4rdGBkCg8Z9fpXJz68FbMUO49mc4/Sojc6Y0+Y9Ksb1XCup2tVmY+YSzYyea4nwxqUl2hdioZTgqBj6GuyQqY0ZCGz2rrg77nLUhyvQp3KhR0+lY1xguc9Ola2pTKnQ5Y9qxGAXLSOdx7DpUVEXTLPlDgqP1rY0aaKKTbcbhEwwSvb3965+0v0DGOT7nY+la6YxuU5HtV0rE1UXPEPledtgkEq4yXAI3H15rn5kCrnFacoyBk5rNu3C7j0HpVz0VyILoZN3noKzZLcyS5PQ9BV9gzsSelPjjAAyP0rinFzZ1Rlyor2+ntIyoilnJwAO9adno1ys6xsqxHdj52GfXoOTVjSJ47a43SqxXHVOoq1Z6jIl4ZpP3hz8pcZKjORj6VqqStqTKrJbF/TZRbvsDsSGwSRj8a7LTbgMAQea4lDp7+ZMZ5Vl3E7WGS/0OMdfWtXRtQwAp/XtUTp2ehvCp7RWe539vIGxnvV6E5AzWDYXAcDmtq3kzjipWpyVYNF9eRxTtv51GhyKlBFUkcT3DH0zRjBpx+lJSaEM4zTgP1pccUgGOtSB+YgpTQTzxSZrtOYKOKKKYCGgGikoAWijFJQAUUuDR2oASpYULngEn0A5NRipEzwBQwN3RLC4luEJ2xxqwyGYA/lXqumIFiTHpXmvhPY95ChZiVBO1QAB9e5NeqaZGCi54OMVy1H7x6WEXu3NK2jZiAo+Zu3tV2NQAA/rgY/z1qCBdnIzu6g1cg2iAo75A+bBHf2PaoTPTpqw7zAWI7VGTnGQD6UgBCg9yTgHtTwCMjNRI74PQjfBU8cVkXKbpG46GteWMhTVGVCBnGKQ9zOaPbkVA/H3RzVucYU81WVfWqTJZCE5PvRt+XpxU5AI5qIg9M4HpVIm5GRj61HM4UYHWnPn2qFuTTAm066a0v4LhTgxsCfp3r3K2lS4ihliYMjoGB9eK8G2nqOma29K8S6lplsLeCVWiUYUOM7R7VUHZnJiKLq2aPXLm5jhVmdlCgckmuK13xXbKzRWzGZxkfIePzrjdQ1G81Alrqd2B52g4UfhVW3Pk3CPtUgHkEcGpqTuVRwcVrJk99fyXczPIMHpjPCiq27g1Pf7XbeoQZOcKMAVAM5qEzpcFbQ0NG1BtOvRKAWjIw6juP8A61egWt1mFZLeXMTjIx/nrXmaYbOe1aOnanc6eCkW14ic7G6A+o9K1hJrc46tHm1W53U04ALuePVqw7/UoyWHmKqjqT/QVzt5qlzcsfMk2jsq8AVQc5ySTmnKXMTChbc1L/XAqlLVM/7bf4UzRfFN3p77LrNxbk8g/eX6H+lZDDnpxUEo4qOZrY19lFq1j1Wy8RaXfRBo7lFPdZDtI/A1XuGWeUleVB4z3ry7GMHv2PpXb6DqiXVniRgJUG1vf3rX2jnpI5alD2esTVkAA4pm4KMsagefccJwPWqtxIY+XyT2pOSWxny9zQ+0KvZs+wqS2uo5DsDbX67TwcVz73MhGATSQ5STeS2T3oi5MGkjruOCKntJjE45/OuYbW3tYszmMp3YnFX7S9SdEkVhtYAqQeoq3Z6ExutUei6PfBgF3ZxXWWM+V7fnXlOmX/luAT3613+i3fmopB/WsnGx0u1SNzr4ZOKsqc8isu3kyPXAq9E/ApHm1IWZbFHFRq369qfnjimc9gNB6UfoaQnioeoH5iYpNtTbfajb7V13ObmIgOKNpqXbjrSgUXDmIStGypio6jrR26cUXDmIQuaXHNSYz0ox+FFw5iOjHGaft9qCvYUXKGAZIqWMHgH7uecU3ac1KgwfT3obA7fwZGMfKMqOmSCa9IsEVY1OfrXDeBLTZbM7KfnOeRjFeiWkeEFcc37x7OFjaCLMaZYFlfHXFTphyARkDvikg3RHIMihh/CR19DUuSz/AHkLAdCetNHoLQjlfI+6cDt6Uiuf4VOKkSQLH8xPB6Dt+NMB2tuHCnv2pSj2NqcrAAcEuRj2qC4QNnHIHerqkODz/wDqpjDk5xUWZrzGPPDzUJiGQeABWpOgz/WqUuOeMUGbmUnTHQc1AVBJ65Hap5ZOeuR7VCSMcYq4mTmV3Q9O1RmPJNWWbPQ0IMjoKoFO5EIvl/xpvl4q1jJ6U5oz6CgpFVF/wpzR/Lz1p7pwcdaXOQP1pWua3sVthGcihVHJxn+lTOvYdKFTKgZA96XKDlci5B/pTt3HIqQRds5p3k8Y5qjJopyuc8CqrSHOO1aTQFuB0qpLbnNK9hqNyqzHI5Jz70Fx0wBT2jIYYwTTWX1FHMNwIm9MinW88lrIJIGKt09jQy56DpUTlscj2oZNr6Gi3iC92ELsB9QOayLnUbx5xLJcSmQdCx4x9Kep2KR1Pfiq7Qlz81TzCVNdjYtfESiIC6hcsP4kxzVe91+4mkxbDyox0JGWNZwi5AxTxFg9KvmZk6Eb3IbiWa4fdNIzn/aPH5Vr+H9YfTmEVwGktT6HlD6j/CqQjBpUTscYpXtqJwTVju012yEXmpdJj0PX8q6/wb4kS4kUKx29BmvFzGPxrZ8NX5sbxQWwpOetNyvuTCmobH1Jp84kjDA9a1ImyAa4PwjqouIUBbNdvbtuGKDmrws7l6Mk1Op45qGEY5qTNM4JbjxyMmndh61GO1PGe9IzaPzLwfSgin4+tAFdFziGYp3HenECgD1ouMaBRtp3T3pcc9KVwGHAoxnrTipPUU4L7UXGkRDAyKXbUmz2NOCcdKLlEQWrFmrGZQhRGbjc5AA/HtSLGau2enTXUgjtIJp39I0z/KlfuUlfY9C8BpHJp6lFwxY7uvPvzzXewINoB7Vx/gfw9r0KAPZtGmePM4P5cmvULTwrqM6IbhjGhOMKnOa5puO57GGbSSZhEoSfu4+nP51J50Zt2VZMuAOMDgCuztfAlpkSXrTOx6hiB+la9voGk2X+pslOOCW5H51l7dLY7ea55xbJNKo8q3kZj2xxV5dE1Cc7xa+WgHJJ6V6AyrKFW1QBRwNidqk+yMpxJjGO7dPfFZyxMnohqSRwiaFIAd7gH0UUraLIMbj17d67qZUhHyJx/eGB+tVHUFiQASeeCT+dZOc31LVS5xf9ipnDOwHQmmXGgWrjADt7nNdTMNu4quE6cDNV5FBydrbSOmeahyl3He5wd94aQDMRdD7HOD9KwNQ0u/sQXZRJGO46j8K9WFvGiBzsz78kVn3Vlbyhi/mMffjmtoVJIzaTPK45wxPIOO1Wou3euh1jw9HO+6JfJZf4h3+tcyFlt7hobgbZF6+hHqDXXCopEu6NBI9w4qby8qS2eabbEEDPSrW0bRzmrZpBmbKuDx0ppjz0471cdATnvR5fy9KjmsbrUpbDin7AB0qzsAOf6UjLx0z/AIU+YfKQIh54p+3nnn3oKlcc/rWjb2iXSxt50EAb5f3jY5FOzYm0ij5an8qqXKDacda65vDsKW/mf21pRbGdgkJOPyrm7qMBmAYMBxkCpcXHcIVE9jGcYYZxTHUYJAqzPCQc9qaIwE561LLv3KhjI5INIYsirfl5PHUdqQqwzkcU9ULQqPGo7VC6D0q6VHO7riomTgEdaSVxNlULjtg0hWrLJz6mmMnpzVEuxXAxT0welSLFnP8ASlWLA4607mTQmwelORcNkdven7PQc09Vz2pEnonw+1UhkRmOR717ZpkwkiVgc5r5k0K7NpfoV4UntXvfhDUBcWqDOeKakZ1Y80Ttom+XGe9WF+YVThYEDnrVqM9s1R5MlYmUcCnHpg00EZpw5FBgz8zwO1OxTwvFO21tc5EiHFOC1KI81KIjx1oKsVttKEzWpaaVd3bqttbTSE9NqE102mfDrX74jFoIc/8APRsfoKV0io05PZHDrESOaljhLMAqkn0Ar3Twv8G2ZQ+pxyTSZ5AO1B6dOSa9I0X4Z2GnohMFtC45yFyfyrGVaMdzphhZS3PlvS/C+ranIFtLCZs92XaPzNdfpPwr1CZl+2yqgPVIRuP59q+n7Pw7Y2w27XctxzWxb6dDbfJFEijnoBzWEsTfY6Y4SMfiZ4X4c+EdkpDfYzIR/HcNwPwr0XRPA1taIoY/Ln7sShFrtliCqS7nA5IAFTROm4enbPNYSqSk9WbpRivdRX02wtbGMrBbpGuOSBkmp5YVYYVcA/hUxk+bHTA6k1XL/OS0nAHSqT01JV73GPbxRoS2MjowFVmjjG6R0JPHB4qeV1KjaSCWzx3qu2xh+8HC579al2ZrFMq3EhB2xkgdQAMVUlVzCVyAQck7sfpV5/LZRsXcvbI7VWlVdvKfNnPPf6VDNolRtrKmSQP7qjmq8jFHzGu0Y6t1rQMUkiZxhQOemapuFYKwbgnglv1oNEzMlTk7nJYnoDUEkYC5LduAKuXEW0YV2YdsCq0i8jcwHv6VPU0RVdl42r83v3qN2ckkABR1JOMfSpZChLGMNjPfrUDoFj3FT1wc8VSEVLoLzuIPOSBXJ61ZG5+6jKycqcdK7FwxDEdvQf55rK1EOFII29z3JqruOorXOOs3KkpJw6nBq+hyOoxUGqQNHJ50ecgfMMdvWr2gafcazexWdkEMzgn5mwAByST7V2Up860DSOr2IGGeTR2xUtwiRSsiSLKFON65wfzqOiSszohZq4g6Ad6iJz25FOY5HNMY4BHY9qEi2xhGVPXNR5wQcHmp8A9Ofp2qGTcM4BPsK0RnLUeJRjnmgyKR1FUZGYA4/SqckjdzSZOpfuLiJF5NZct0XJ2dqayhwc5JFOWIAZ60tC0hElfjue5qXzTtPY9qVYwQOKDFz0oCxCck88mnhSV4P6VL5XNOVRg0XQWIBGeh6U7YMYNPA+b2p+3INJslkQQHFO8sAH1p4U8+1BOPzpXM2RgDuKQqB61JjJ9qUrnntSYiJDtYMM5r1P4e6sSqIWwcivLCMZrf8I3ptr5Rng0XA+lrKUSIrDByKuxZxzjrXPeG7oT2qkHoK6OKtUeXXjyyaJlPI9elSoelRgY49aeMCg4pH5ww2zyOEjRmY9lGSa6bS/A2tX4Ui1EKNyGmbb+nWvrDSPhl4e0xFCwgMMfcAH866Cz8OaZay7oraPJ7sNxrKWI7I0hho/aZ81+Hfg61wA9/dl8f8s4F4PsTXqvhn4R6LbFXeyw44+dA3T/ePNeqwQRxYWGNVUDooxVmMgE7hgis/bSka8kI7Ix9K8HaNaRnFqpPXk4/QAVprpdhAqi3tIlUc7tvNWomy2euPWnu6twvOO2aq+mplrcrm2hUcKQD2HFUZoxuxyFHGBzmr7uSMEgnriqsoLZySo9+9ZzR0U21uV44dpBA+mRUm0Hl2Oc/5NNCneep7c0/bk4XkDoayRo2IduCFBx35xUe4BdwwAemKk28kkjjrzwKQLtAI5AOOOKLBoiCRzyQc+5FQuS+TwfcVPMwjPCjJ57kVAS4P/1qls1hrqRyNjAQEjrj0qMjJ6Zx04p7fd+Uk/rQqEp98KAORioua6WIpR8oJC8+v9KidhESFKk5/IGrEgiAXk4B65/yaZgMRtzj1Ap3BFdzIYypJAbpjjNUWiOQxJA29snPsK1JEwxON59SeKrSshUZyxHrxiqGmZciKBjbz1OX/oKqXMTK2RgZGcd6u3Eyk/JGuRzj+76c1UZ5myCwAB/i6D/69LRmiv1KRQAfOTuAzgc/rVaVXPIDHHUnp+tXJNx5a4U4OcqM49qrTOEkJO4seMHjimkUUrovGQfU4Hciq0isFYtgAjueatySlj8zRjknPXFQOEDk5ZuMegpgYGowgg993B9xWZoSXcOrRRWkjRXRbETg45+tdBdxySDqNpHFYx1W50+WKO18tHSUTCXb84YcdfStsM7SsxSvbQv6zDfwiF9ThdXkDFWePYW55z64NZR4Fb3iPXr3xObe5ntx/o0QSR41OCSfvE9s1gkE+ma6qlrmtG/L724hBYcc96Z2qVQTmlZOOlRexsVGO09cc0hBbJ/lU7J1wOKVFPpQ5EWKTxHGcVVaLmtdlFV5Y1I+lK5SSM0Rr3p5iyeDVgquRilQDrQUkQiMCgDnAqwF9sigLz0/GgTIdvFMZOeKtKAfrSlRjpxQSyn5R79KTGOtTyEA4qM4GMUEsjIwM4NNI4qbGfamsMc80GbIh1pTwD6UDNDUhDG5qWzl8mdHB5BpnUe9Io/OmI9z8A6kJIEUmvSrZwRmvn74f6gyTLGT0Ne66VJ5kCt3xWqOPFwuuY2VGR608DjkVFF0qde1Ox5MmZvlgtn9aNmxQRgD1NNlMm3CYJI7UzBZsH8a835HarvqS7vUjipD9372B71HjsBj60c7gM8H8apSsJq45XRVJ5J6ZpOS5HBHXmlIY8jOO56YoBCrxy30puQvQR2CkFQc0nlsRkjCn8zUgD9Xwo7ZNI0g24ZzgelO99xJ9hioAeAW9Ka0ZB6gAdR1NEswVVCHgnknmo964O5yT2xSbSLSluNlVX4BOegz0pjRqi7Yzzjsc0rybe3FMeYyAryAeoX+tRdGiTIpcheASOMVHnIBbAz71NtfbtUMB1+lVGUDC5ABPrkmobNoakjYUbRgDBJ4qFs+WCzgIMcAevFDbOhfbnimKu3ChOO5apui0hsswQgZ3AnGD1qOWVduZFUnHCg4Jp5AOdvzMxxkDpTZN+cKoU+vcfjTv2LsQoZWLM/yjpjoPpUMgRAT8m89icmnyj958zEsvUdRmo5E2uQAVPG5sdfahNroVZFaYB2BPIPHTj86qSLGFCgZPYgdqvzRggAruHU4/wDr5qk5cMQqhf8AeOTj8aG2tzRK+xRkiEjk7CVAxjJ/Sqk8LfMqjaP9rjP4mr8qSN8zSsEzwAKpTpGAcjeenBqkw2KcsUYxukU84OwZxVUlcEKhJ3dSe30q0zKOQnzAdQKidmJwoAz3xVXCxn3Zd0wvB9MYNcxf2u2fJJ3fw4559DXXXURHcMccnuawLtQsqYHAPSrpy5ZDSujV0y2uz4dkisb1FEjl54CxViB0x6jrWMYtrMNwfB+8O9WIoz1Q4+lSLEVHzYrqnNPQ1pwcdSokWMn1p4Tjnp9asMuCOKRE69Ki6NLFKRCD0pBgdatSJnP1qFkqhWIHx2NQuvrU7YBpvFNMCoUx1pdmKnKeo5pCPXGKTGRbSMU7bS8Y49aFIpCGgY60MB+n5VIMdTUbsMHNArFCeDzJlbPC+lPCj/CpmIBqNDuY+1LYTENMdscVZI496idQDnt/OmZlf+KhunNOfrmmbvwoJaEOO1BximscdD+FMdsjrQSdB4RuRFqS845r6J8NSCSyjx6V8v6XMYb6JhxgivojwHcmWyjyewrSBhXV4M7yPHbpUintUMXK5HSpkHTFXc8SRRVQOfbuaZ5i72zjPUDNMIZuTgLjqetRui7sqSWrz2diiurHbg7k9RnvUylVAAA3fXpVcjYQOCRzxzT1Bw3yAZ/OhIpq4+STDZbknimtNtJIOO3So5PugsQD0A61FuyflJT3xS20GoponZmON4I9zRvyMDPHc0RbWxzub3pXIVsAcjrjiqsIhJJYB8nPrxSbSjcIuT0DVLIvIKt81JFDIG3OMnnhjjFTbUq+gjqwTDYPsO1QqSdpGee3rVmXaVOSDnjgVAQoYlR83T/9VVJDjsNfcMhlHPqf6VAcJu3duRgc1MS+CVAX2H3qZIvHz4/4EeahpFxIcAMH4y3Qk5pkqxIMuS7emalYA8/f469AKryvgnGMjsBUuyNY6kbSkr8qoijt3qF3YYDttA56Z/U0uNqgyphT/ealmA2BhyOuByKnfc1VtiEzICuF9yKbO7hhtIRSOvUmpHiC4yNq4z6VFIqggjbgHqTnI+lNXK0IJGyeTIc9zwDVIoWLKirjBYknGD9auFC0bBEfGD83QZqGSJ2AO0H1yetDj3LTRQnBMeSV+UduT9KpTgbOpBxzzWn5bMSHYlcZAA4z6VVliRWJYoGPYHNUkBllPm2xZYdye1RzROCMZHGavswCnaVU9cn+lVlYDJdgSfQZNPQNShcwNs+VlG386wJoib1N3PByDXR3cbMCB8uBnFYUUbfbmY4OOOKqmryNVojW8M2UU+s2kFwhaF3wy5xxTdUig+0SPZqywByoVjkgZ4q5okqWerWtxJ/q43BPsKu+JIrOFkS0VmaY+c8rng5zgKOwrqsuRjTftUvI5YpycGoUVhJ0q8V546Uxozt4BFY2OpOxWkU9OM1Xfr0q5IuQRVZgO9XFmbRUYY6DNNxnPHPpUrDn1pmKoVhpUY4qJxg7jVkjNQSUySFqZkbeDwKc/FQnrjpSYE6kEUxz1FJ0+tNYjrnFSgIiMtTlYDPrSHrxSHiqIuSMcioXOBzml9PamyN+NVYzbIJMZpvY0O3JFRt1pE3AsRUeTnOeBS5pCOxpoGS25/fJzjmvoH4cv/ocf0FfPcR2spPrXu3wznLW0f0FaRdjKp8LPUYZ4lLqXG5F3sM8gepqxYuZIRJ5kcisSVZOm3tWRCZrO4uGSGOZZm8wEyBGHGMHPUVpaRCYbUhmjLO7ORGcquT0FU2eDPcpINoOBnj0oIJ++fmNS7DJ90HAHFJjyx8oG786863c7bjVTbyCq/U05mAUYOeOwpGbcBufk9VApV+ThMgH16VSsL1IwqkHI6f3jSBUwcgk9gvSlZwgyQAT3xupwcAHClj9cVKK1GjIwFUYPrT2OxhwST3FNZto689PlGTTELHICszH+8eBTvYW+oNIzSHGF9/SlRVL7uW9yelG3PBCqfanAjGSCf5Uk9StOg1mOQI8AdKieUAdiR+FT7gDjYKaFH8ZLMew4xSdxp23RVmYYA5Hc7eKiZ1QZCrj+8eTViXYoCx8N0zjJqvKHZSSoP8AvtgD8KTTNI2IZMsVY55GBk9KjaMltzsqj09qm2llwST74xQQgHJ3MoyABUWvubXtsVCI1b7pZhzycCmOpd/vbMc4FTv8wbaAPrzTcNsGPwpWLREI9zHJJx/FTMJkmMEn6dD9KJSUOAenUnoRShcxFt7c9lIX8qpA+5DIrAsCCBg/xYFUnDqF2uoOeMdavSbVIwB/vMc/pWfPIVJCrlwSBTKRBcMyFQ+456Bj1PrVOfP8WAx7ippVLH55SoPIzz+VQNEDlygx6k4Gae5ZQlIJKgFu3H86YFfJ7Dvk1eKqmdpLE9QgwPzphQgEgKo/2jk0rFmVfu0NuSWB7ccVR0+LKl26nmpNUka4vBEWBAPPHarsUXlxD6VrS0VzVLZFfBySegqaaRpNiNJ5ixrtX2HpUU2AeucUkZXBIGCfSnc6eXQjYYPOcimElhUj4J56n2qFiBntTCxC5GTVaQLgnoanlPB61XlOOtNByld6Z14pznrzTcjBqrkuImOOKikAx0qQt61E/JxTuRYrSDBJA5qJvUVaZCBg4qrLxnjNAhuc8UhOelRF8NTk5oQmSDPXuPWmuw6Zp44FQSHn601oZsQn3zTHNB4NRu3FO5mNkIGfWoiQe/NOJz1/OkAI700hMBjjvTsDNKi8+1OkUYHUc1SViWEaZYcV7X8NEKwRj6V43aJulT3PfvXuPgK1WSxCksoYclTg/nVES2Z2MSRrd3JutOmudzArIIw3GBxzW7pxjFuPJt2t0yf3bLtP1xWZb6VFtH7+7/7/ABrWsoFt4RGrOwBJy7bjz71Vzwqm5Ao3Lu5AHqcCopCu0EN+PSlKMVwe46A1CyEH5QM4rz2zqjFdyQgIAwbGR6UjqHXKEYPcnJqBwVAyd2P0qdQzoCuFApJq+xbVtQiij2kE5PYipljUrkLz0BJqAA7huOfrQ07AYU8Ef55pppbktNvQe0YU9cDsOlK2xu+MdMHiq4cyYYYyB1605oXZclsZ9sCi/ZDtbdjwRjB+uc1BJIADgs5BxgVJFEIy2Bg4AJ65xQuGz+7xn+JjSfYasiOIyE8AKD+JNPm3M3QKO3PJp6eY4wxAAPRRUjRiP7uNx655JpqPcHLUoByMBVdj7DFIFcj5gsffGM1aPA9qryEiQhV6ckk1JoncqyFeDjc2cVExZgTjHv2x/jUrgYPdickk0km7yicL79jUtmyK5ViwSNM4GeTio2MqyZbb0wRnFWC+IwN+MjoKrYyeFyQep5pWRqtSI7w48xgR274pixeWArrx1BHQ1JIXJXcyhR/CB29TTW8tmbBJ9zwKEh3KkxUM2AT7Y4qnKCzkkbvXJ6VZ8w5KhsgjgY6VSmVy2EA549ad0XFDVkPyjhV9FHNVzKB91QT24/xp+FQcHLe5ximbh94Y3exouaJXIdsrgc4GPXrWdqN0lpbsxYFsd+a0LmUpDub5d3TvXIajeC+uvJjHyL9456+1OKu7Fol0zdLK80mSzHPPYVuO22AnOOO9ZlmAnAHFWZ3LbAucdxWz0VjopU7vUqSs2/PY9OasQx5iY5GRzyaQIH7fT2pFKjIxmoR1S1Wg1sdufrVduSPapXOOPWom6DnmnoTYjkPaqVy208DNWZW2gknAFZs8oLHkmndDUbkecyEk/h6Uzf8ANgnBqF5CGwD71GZDu9zTBwLmc0ZqFJMgc09Tj3q0c8lYe4zzVOcDp3q0zYHWqs3J9aGQimRgmhG570ko255qNTnHpTJZazkVFKeaN3vUbHimZMY5PeoSe9SHntUbKCPeqSIuAYHpUqLgZPWq6gBjnjNTK2ThTxVpEskCkY5GT2qZYSYzIwwM4z60+xt5LmdEjAJJwSeAPrVvUpIz5UEGCkS7Sw/iOeTVJaXM73dipZjddxKp/iHT61774DiKWyZ649K8S8P22b+M8ZzX0B4Sg8uzTHpSQqr5YM6T7TBCjtLIi7AC3PTPSp7AtJH5q3ImifJXCgY5rJNtt1FUeW3CPL54Ut87kDhcemRnNa+kxFLTczozSO0pMZyvJzge1Ox4U5alcsR1wuB60x2LquScnpSSLvODijkvgjj65rgOxIbGBkgDA+lA+YEBf6UMfmwpxj0pyKv1I9eTQo30RTIpcsRgc+3NPEQJJZcg8HJ/pU2wkAnC+lJsJ4HPsDT5BcwxAIxhfl56KMUojyoJXj9RT1TK4zgqeRUpbgk4xihIhsgOEAxyB2Heldzu4UD68mlYjO4HBxjioWPJIBzjApPQpaihyR1yc9qUHeclDn1zimxhiOVOQe1SPgNljk9eTQPbQjfhQOvsDmq7HcRlMY7mp95A4GBjrVWUhiSBnPBPak7GkURSEewx6VWwhbAyeeTUxCkgAAn0IpGjPbbkDgVna50JpFZydpAT67uTULM4b5SVI9f6CrUkg+6c7ewHAqpL+9JAUAnvjp+NKxrHUikBC5O/nr2zUDCPq3X0p5BLEfMzDuewo8sbcOQv0GDQi9inLk8KBgdQOahk3bsovHcnjNW3Chj8wPGOBVObAbbvy2M888UykVWjRmLE8dvQU2Z44Vy3yjHXNJc3KxR5chR9elcfretNcytFZjJ6FgOBRFOWxaQviDWjI5t7Xk9MnsKraVDsXJGW6knvVSztfL5Iyx6k961bcYAHAPeuuMOVGsFcnB2EbfSpt3AAHXrzUMnylTjIPr2ojOM81EjuitCRpCAABk49ajlDqFdgQG5B9aH4Hb6Vt2EU2p2DwbRNJGg8pOmMnHpyaUYKWgTlyK/QpaLp66lcGLcd2OFXqfaum1TwbBaW7Y1GNLhVyEkYAMe4zmsOBruPTCumIEubR2Fz5YzL14YdyvGOOlc/NcPI7GVizk8luprZKMI2aucUvaVZ3hKyRFqUPlF45MblPY5H6Vh3HyZ5rWuXBUisi6Oc4FY2Vz0YbGfPMN23B96iEnOO9SwqGm+b3zTLnb9oG3BA/SmWyzE5x0qUvgcdaqwnI4qVj78CrRxzRIZDjBppORVdmwaPM/OmYkc5GTtqAEdRTpTwahQkelCIbJyePemOeOv4U0v+fpTSRjP6VSRjIUkYPNRsecZo3g8DpUDP83etLGbJtynPc1LCCcKBzVdcnAHU+lXbNH+hPFOxPNYuwXDpaPDEgBfhm749KSOPbw33jVmOFY48uQMDmi1UljI3U+nYUO4om/4Ztg19GFHA65r3Xw9HstYwRzivKvAllvlVioPpXsunQ7IlGO1NIxxcuWFipNFPBfeYtrLODOJhJGATt242n6Vr6TFJDakSoIy7tIEHRAT0rGkis1v7o6i8sbM2Y/mYKVwORjvU+jRtBc2wj88bxIXVyTmPPyE56GnY8WViY4AUdB6d6YfMfPYfzqx5ak55z3pjxk4GQB9etec4tncpIai4AyVHrzUq9Mk8dh0ojhWMEtye2aaRwd4Pt3qtthXuEsm3G0Zb2GaYS3O7d0zipNhKfd/pTcEjglveizY1YTIwDnBPr2pSQo3MST7U4L/e4OeB7UEISSRkg9+lFmK4hAKg4x9ab90nYAPrUhOR91AO/ao94JPHT0HNNrqCFy+VCjg9fSomiBJBJPelPPJGPUk0hJIIDAr04qdC1oRSArgkDB9+ahlw5OB05GKsshK/NgnpUblV5VwvbgdKRpFlV93Cr93ufSq8r7cheSByB3qaRizMTggHjmo2jLISzHIqGdEfMiZG2A7gD/Fk4qElUBySRyfQGpZNoxxkkdzUUgBONuQPSkzRFdpFAO07B229zUEu4ycZHfmi+vbayQyT3EcfqCcZ+lctqXi+M5jsIHlOMbiMChRk9kaI3L6VUDMzYUDHX+dcxrHiaC33xwsJJOQBHzk/0rJvrq+1PIuHCRH+FP8AGq8VjHGAAgJ9q2jh237xSl2KE897qLZuJCkZ52LwKuWdqsY6VbECoPlFIIyAWyDz610xgo6I0jG+4FSuSV4FKhUMeaFdMEtxnpUEjYfsf6UmzspwsXWYEDg0qyBHBH1HGfzql55I9BThJubBGfoahmyXc6iGdTA0l1HYtbxkK0iJh2J67fXFNcWptn/suSZbhf3hUgqfqvpXP7xgBQM/ypxmcuGLNu9c80+fyMXRt1JrHVJ7HV4tRGJZlfcd5Pz+uaPEGpWuo3bXMNr9nkkbdIN24E9zmqUw7nqeapykjntSUnaxXs4uXP1IrgkKTgY/nWbcDqfarzNuBU9KqT9eOKk2izLlDBuDgmmqCck9e9WJBycnjtxSIPlyegoLlLQRMqKcW+X3o2DrQcDrVI5ZO7K8xP41Fv465p1weeOKql8HGKaRgx0jE5pyYxnNRMc9DShsL2zVWM5BI2D1phamSsO9RbuDVRMpEpPFMyc5puQSKcq7lLHp2rRIxci3bYQAkgsw49hWhbOAOnHqazbcAY9e9XE3NhV4FBL7F4t5mQp471oWy5dUyMniqtvGFIKjK9q3NEs/OukxnJ60r9TWMT0fwLaBVVyMH1r0i2OIxu/SuW8OWfk26cYrqIO1Ee552OlzSsjPupZ3uZWN7JCiXCxFFA+VSOG5961NGdns2EkrSukjIZCfvYPUe1Uj59xdXMZmtoVUhNkkYYuuMgnJ6Vp2MZhtljLxOFyAY1Crj0wKtanlPcq/MF+YgimtOikBR85HOO1RMgxksTx3pQQFwq8+mK8+7O/lQ/f6dc9+eaGyenJ9zTfmI4X60jDIwrcVSegWCRwGK4pquQCBwPagADJOD7nvTlAXpn1wKm7bK0GkucBV3D3pzNgfMQCfSk+pApm1Ty3Pt0ouA9GQLyu4DrxTZAWJKDAH8I70M+ARkbR7cUm4kgZIbHUUXHYaOAB90d80rZ2jaT+WKSNTjcwIBPG80rcEgnn0NT6jRG2EzlsnqTmozj+EZPtTbmWKFWeaRFQDJyeBXOan4z0i0Yrby/apOnlwDd+Z6frTs3saxVzoWDD72Bj3qjeXlrbRlp5lQHjk4rgtS8Vapebks40so2/iPzvj69BWDJbvcNvvJpZ2Jzl2z+nSj2TOmnScjtL3xjp8LMtqrTuONqDI/Oudutf1S+BCkW0Z7KcmqsECIAI1AH0q1HCT2AqlTijp9kzM+zb33zM00nq5zVlIlGBgfjVtoiD6j6VC7cYxWnN2KVJIjMa5JyMelB2AdeTxS7ex/wD11GRhsDj61VylBDZAu8YFRsCQcjjpzT9wPXtSvjj3pplxsis8ZxxjH86rTL8xB5NXZGLfKVNVZQAMA59zSZ005FdwR0pUkxgEg+1RytuHBwag8wrnP51LOiKbLpmOcEcVKsgK8np71kC4bv0zU8c2G5NSOUdDRMox61VlO7oOPrUJm/HvTGmyD09xT2MbDZeBx0qu+Gz2qVmz0INQk55poL2K8i5bjHHakA69qmIxk8cdqgYgn6UJCkx3ueneoZvu8c1KXz/nrVWWXng8etUYNlaXO7rVSRsEnv61PI2c85NUpWIyDQiGPaTjHpTTJwaru2T1prEgnnNUtTGTsPaTJoB+U1Lp9pLfTiOIe5bHAFdEPD8Cx4fczDvnFaxgzmqVUnY5mHDyBSwA9a07a08x+hAPQd8VbGjLCd0WXP8AtCtWwRI41AH7w8E1SV3YxlPS5Uj0/Yg8tFJHGM08wsjhDtzjJA7VouRGCSQT6VDFGWJZyCx5PHWiaS0HRbk7sdEpCHpzXb+B7DfKrsvU965axtzNMqkZ5/SvW/CFgsUSkjmszqb5YtnW2MISFR0rRiXNQQpwKsGLzYnjLOgIxlDgj6GrseBWm5Nszntwt7ctNpb3YdsrIdp4wOOT0rV09FW2AW2NqMn90cce/FVl0pcf8fd7/wB/jV22hFvD5YeSTBzukbcfzrRI5WzMYIclhlfringgrwQfp3pgU9G5zSLgnrwK8u9j0RQoCgAjj3ofG7v9etNfGML0PTAppYKrZHI6Z70NjSHbRjJ57kYpUYlSQtRRndyATTiTnOV/OlcdhSSRkD8aYzIFAyc+lRu4Hy85PbtWFr3izRNEiZ9S1O0tlHBDyDd+AHNLV7DS7m8WXI4/TNNMxC/LnI9OMfjXhnir4+6fao0Ph2ze9k/57XGUQfQdTXj/AIp+J/ijxCHS81SWO3bI8i3/AHaY98cn8a1jQnLyM514R8z6q8TeO/D3h0M2q6pCky9IY28yQ/8AARXkPiL9oEl3TQtL3AcCW7fGf+AL/jXz3JcM5JLEn1PJqEyknrXTDDRW+phLEyfw6Hsvh7x9qfinUpbfW7xmmlyY1GEjI/uhRXe6dGkSBSBnGRXzHa3MkM0ckMhSSNgyHPQivfvBfiVdY0VZelxGQko9/X/61VKNtEdeCq875ZPU6wAY+UED9abtIB96SW4iaQeTny8Dqcn8cU4EkjAHNYSue9TslcVO3bvxUwbHBPbio1BRiM8jg5pxz+JqbGkrEjucfX1qtIcggnBpzSbcetRSyBgf73vSIsRFsHknIqN3JPHUVDO+Dkc4qMSBiR700x8vUmZsDLU0SbgOwzzSB8jBxx3xUeSG55HrWhKLO7AHpVaYKQ22nF+ODz7U2Tpz3HNBpB2ZnyHg9jVWQjGT39quXKEnA4xVKUHoTUtHXCVxHjxAJd2M+1QxNz1pZLj/AEYxkc9j7VApIAx2qEjW+juXWbI7VVlY8YPPTNTI2Rnn8qjlTqRyTVtGSkkxYSxPPA9KmbrzmoIQVIDf/qqbueM0kZVJEE2OlQtgHnBqaTAeq0hHQdPeqMXIa749qozN71PI1UpnwapIzbGO2MnPFU7iTvUsrcVWbDkkngdql6CvbUjDE/Q1oW2lXlwuUhIXsW4rV8J6atzO91OmUj+VM9Ce5rs1RRH07cVrCOl2cVavZ2RjaHaQ2VtsY4kPLH1NXWTdwp/CkkhKuSuPpTGyDlcg1oqltDka5tSJDtJHT6iopSYnDrjPerZUSv0xjHSn6ham1jPnxlGwCFbg89Kb1V0C3SKDOZCM5x396nHYKPwqJYiFUfj9K2tH09riRDj5c8Vk2zvhTUVY2vCumGRldl5PtXqmkQeVGoHFYnh6wEUSErzXX2kQApxVzDGVUlyosxjKFWwQeMVOY2eEokjRkjAZeopETkenpViNfWq6niTdzDuJxBOYTqGoOwO0mONSAcZx061qaVKJbFXWSaRSThpgAx59qqTQYlu1huI96Ot0FIJKMOucdiB9as6Sv+h+Z5iSea7SZj+6MnoK0MCnkEg4pQqkZOeO3Soiy5yWwxHI9Kw9e8WaJoKhtX1C3ts9FkkwT9B1ryup6bN9mVcnPHpUckojBLAc9ABk14n4p+P2kWoZNBs5r2XoJJf3afh3NeOeJvir4m112D6g1pCePKtcoMehPU/nWiozkZyrQjufV+v+MdE0C3aTVNUtISvPltIC+PZRzXkfir4/2kTtH4e09rph0nuSUUH2UcmvnC4unlcvIxdyeWYkk1XaU10Rw6XxamEsS/sqx6F4k+K/inWwyzaibWJhgx2o8sH6nr+tcLcXTyuzu5d25LMck/jVMuc9aYzVsoJbIwc5S3ZM0nqajZyaiLU1mq0iSQvikLVFu4o3etPlAmVua6XwTrv9iasssjN5Eg2Oqn8ifpXJ7uetTI9JxNacnCSaPpnS9QLKWyjBcNuHPPbHtiteCbeDkfMK8i+Hmti405rKeQrLAMg55dOw/CvSbaddsEMB8yY4y2cZz2rkmrM+kw9fnSZuQsCc4qeUZUHOBSyIkk5SEsWjQBsAbenrUQZwuMYPQH2qDqUrleYdxye9Unf5jzitBupXHPrVC5Tg4/SpZomVpmAJPaqkcpWUqSSpPpUrn8cVVY8+gNVZDTtoXmIz9fSgNkY9sVVSXBA5qTcNpJ5B9KpGL0LCt6gdaVmXpnmoM7hQvC+ue9NlRkJKuRyDmqNwnXFaEvKAgc1TlwVIGc0WuaxnYzZF+bjGaYcqemKncYJ4wahftxz7UcpuqhKjd2/KpCoxnk57VXRiHx3qYyArwQMenWixEpAF+XJ54phOODSB+/OKQn5s56dKSMJNiOfeqcrdfSpZGwTk8VVmY8nrVJENkDvgHtiqcx5BqeQnBNU5n+XkUyWyCWTI5xVZN7zKidWIAolfr0FbHhfQrvULmO6AVLdGDBmH3sdgP60lHmdjOdVRR6FpFlHbWEMSfKqLjI7mrTxhScj9abCrKuzvTtrNyzfL6gda60ktDy2+pFJEhzjmoorVWbLdPerIgVhkMQT71BITGxAO4+3ek4K97CU+hp6NBbQy3FzLH5pto/MSMD5WbIA3f7I9O9ZOr3kt5dNJctvmJLOzdyaet0Y8lTxjBz6VQijknl3YzuPp2pVJpRsjXDU3KXMyS2gaSQKmTznNeg+GNLAC5GDWT4f0v5kJXAr0TSrUIi7QM1itT0aj9nC5esYNgAFbMH3R2Oar28WBxircSHua0Wh4depzu5YQEHPFSMwjUs7BVHJJPApFGMU90V1KuoZT1BGQaaRwyMlpZLG7ufKNrKsr7yHmCMpwBg56irmlR7LUnzI3Z3Z2MZyoJOcCqTRzXV3deTbaeyRvt3SoSzHAPNLpd3KHiilht40dnQCEEbWXqCP61TRB8b+JvjD4p1nckd59ggIwUtflJHu3X+VeeXl9PdSmW4mkmkbkvIxYn8TVEuM9TUbPk8ZqIwjHZBKcpbsmaTOc1Ez+lRl+1MLCqJJC2TjmmbuOKYWpCapIBxOBTSeOlMJyOabuqkgH5phNIW5puecCmkMeTTc0hP5UlOwDwacp4qIGnA+lDRSNjQtRfTtQiuEJwpww9V717hY3fmpbTRPuUqXHBr5+icgjGB716h8PNUe502S2dsyQ/IoPdTz+nNc9WB6GCrcsuU9e0l42ESGTakpZ29do7H9auOZZVeY5WNRhQTwB6CuasJdlsqAYbOVLHjiunhEr2lsJTgMCzIOuT0rmaPZhU6kJy0W8ZHrVWUZU5NTsSMr0XPrUMg7jFRY646mbOCDg1SlOK0rhSoyo3D3rPmAOR3o2Ka6kStk+9TRMc46+lVc7ThhS7irZ/lVmDbNDdkdcD2p6/pVRZcgY6+1To/GenvVqzM72HOcDFRMvGRinyOuOlRq68A9KLWNFLQqTLkE4qpJkNz0rQuZBycHis+Qg89KaRpGTGDqc04j3qAtznNKHHHr/ACoaLbJuB0zx2pjsDxjmmO57kfX1pD0yW7VCIkQzHJPYVXY9eM/jVmUemKpk7WPNWkZtkMhAGOPrWvpXhh76ES3UrQqeVQDkj1NHh/Tjf3gkkGYo8E56Fq71YUVBhhn2q4wucVety6I5FPBunK4eRpZMHO1mwDWy15Bp8YEmyKJRgAccegrRlGBxjn1rH8QaUupWHlbtpDBlb0I9apK2xySqN7kVtr1tfTGO3lJIHcYqe+1ezsAFnm+fGRGoyzfQVyOn6bc6ffgNGchWBIPynjjmuh0XQQ94l5fOZLk/Pg/dX/8AVQt9DO7a2NS3drmMSGN48jJVuD/9apmiBTAGK2YNNk+wS3aKPJjIBYkDJPoO9VJYtxAA61s4tLUqPvu0TEjgeacqm7aOozwa6TSNJ+ZCR0446VNo+lseWGRXVWFqFwMVyy1PYpQVJakulWIQDgZrqLKLaF4qlZQkEf4VtWyYA9aqKPOxldy0J4lIGanXtxTR29achHGDweaqx5MnclH8qkFNApwoSMWYt3E1zezmygfchCyyLOYgzY6YHU471a0yG2dI5o4WieINFsZs7Dn5vqfeny2Mgnkktbp4PNOXXYGBOMZGehp2liNbZli3nbIyuz9WYHk1TegI/NDf9aaWNM3e9N3+9XykEm7mkLYqMvzSFs96dgH7jjpTc00NTSTjmnYY8tTSSaQ0lOwC0lJRTAXNGaSlxQAvpSiko6UDRKhwe9dB4X1NtO1OEKMxuwD8ZP1rnVPNWYWCjJOSf4Qev1rOSuaRlyu575azlsMSAAVO0kY4rq7a5LIpDEkYVsf415Z4P1L7bpcG5svHlWGOuBxXb2Ny6GMIwLkcg9veuZo9yjPmSZ0tw2SWVcR9Pxqm83TJ4ApJLweVHHtC47g8n61EME5yDz0rOWjPSparUGKgHpn6VTmC4Pr7VZKEdM9aayZ524NRzX0OlGZIuR0w1RdgDxWnLEAuD1Pas+aMI2Bk571S03MakObWIwNtPt3qWOQgYziqpbacY5pY5AJMdj3qvQ5X5lzeSCOPWmq4B5zzUBcqcHP1pN539cCrTGmTT46jk4qhKT/AOauOeKpTEBiQeaEWpED4bpx7+9RMSeDUm7BIbrUMnPPOabNYyGOwD/MeKspygJ+YGqjKW6kZ61KmQMe3SsluXPVEshIGMYxW1pfhWa7tkubuQwRtyEAyxHr7VU8O2q3mr26TD92MsR64r1LyBLEMEfh2ropw5tWebia7p+6jmbPS4rSARQAqB/eOSTU5IRcMvT3rUmtXQErziuY1BdfmuRBaW0McZO0PncR789KbUlscPPd3ZoIDJIADxn86sXFnlSEyPer/AIe8OvCyxtI91dv8zknCj39hWjd2qwymPfG4X+KM7lP41Spu12Q5puyOYfToXUF1y3r6VFaWz2kr4dpFbnDDpW9MqgdBTIoPMIIGTSuo7bm9KhOoaVzLBNpFhAoMkkSN833cEtnGP85qjBaEsMitC2thwMfpV+C1A5waic3I9GjQjRRNp0ChAMCtm2tskGoLO3wAQOa2rSLA9KlIwxNbl2JrWHAGeTV6NcDp+FRxrgDjirCVpoeNUk2xwGO1PoFGaDnHr0FEwkMTCFlSQ/dZhkD8KE/lTbuZbe2knYEqgyQOpoRDRU8nVP8An8tv+/B/xqbT7d7aBklkEkjOzkqMDJOelRCTUz83kWqj+40jZH44xViyuPtMJcoY5FYo6k52sOvNDBH5hZwaTPpRRjNbkiE0UYopgJS0UUAFIaWigBtFKaSgAooooAWikpaAHg1JEyr1GT+lQg05aTRSZ2vga/khunSRlCSr8gJxyPQV6hp821mcjDYAxnmvDtLkSC8imll2lGB+TkmvYdHuASHPzoVyMmueasz0sLPSxvT3mCsoYEj5f/rVbhnzt98D6Vho3m3mzOYcFhn+dXbCU/aSr/d7VzyPapPSx0KxjBJ5pCPYUkL7hjtT2GeKjY64lZ48nnmqktpuJGa0cKpzjJpuVOc8U0ymYd5ZtGAeo9RVGM4baeoNbVyvLYY4FY1wv7xiBhq00OerSuuZD5eoIJzUcsh4PUUgk3oQcVExJQA9BVI5luTSPlQQc/WoScjtnFNDdM9aXd8uSKZdyGc5b1NIwUofT3FOfJzxhTRFG88ixQqWkb5VCjJJoHexWQkEhvw96lDk9BzWleeHdTtgC0CsD1CMCRUSaFqLAbY1B93FSHtYvqaPg9QupO3UquPzr0a3cgKQf/r15x4et7mwvZBdRMhIGCeh/GuzhvQqitadRRRw4im6srxNktubJ4xUl1cQbgYYvJGwK3zE7j3NYT3zuQEyRUbmdj3AqniEOnl85bnQw6n9limEXJljMbH0BP8A9aqIleVuAeelQW1qzEFq17S2CjipdVyOmGDhTd2ZzQOWAOa0bG3wvAqz9myw461egt+AAOKz9TruoxsiOGE5HH41pW8XQY5pbWACtGGDJzVJHHWrpaEltFwOOa0Y1AqKFNo71ZQZIxVnk1Ztsei8DP4VIpoXFKOKDlbJV+7Rjj3oUjHpS0ECgYpLjymtpBc7RCVw27gY96B1pXKbG8wLsx827pj3oJZkg2ajamtSqnZROvA+vWtGxW2S2UWjq8WT8wbdk98nuazbe60y3i8tD5kYJ2sYSQB6Zx0Fadu0bxK1uVMbDIK9KGSfmFSj3pBRmtyBTn04pB96ikzQAd6O3vRmgUxjaKU0UAJRRRQAUUUUAFFFFACilFNpQaB3LFuAXy2dvcivUfCNz9o0yNVIPljYecke2a8siZQwJGcdvWu28D6jJvltzgLwwCjAHtWVRXR04eVp+p6JpsqyW0m9T5kedv0rTsBiFZXXLMcKvr71kWeFuN5wQ3J+tbccyNMhAGxF4X0rmSPbhOxbglKPtPGDV0ncgKmsMy5k3jIGa0bWcbgO3as5LU9CnLQtsCVyBUTKRyKuR7XGcGmTINvHA71OxspFJ4yy9eazLm3bLHrWtKD8oXioWikbjFNNFXOclTY24de9RI3zEHoenFdINJMhywwD2qePREHLCmpHNUo3d0cogO4gjOD6VKI5C+AvGK6w6ZCmMKM0osY+ygU3UBYZnJSW8mD8ua6DwRbCK5mupgNyLtTPYnvV/wCxo3YCrMFuIwVXgUKrroEsLdWuac91HgggH61RdoySyrj6U5YR3qeO3J7UObkRHCQgUypYHjjNKsBOAO9agtTtzirFtafPz1qWzoioxWiIbOwJXkc1aFsEcDbWxaQgDGKmNqN2eM1SVzP2mpnR2+2r1vD681P9nC9sCrMceBjFapGcpjIo8gAYqzFFiiJTuHSr0Ue4ZH50JM5qlWwyFMHAHStO3Xjp+dRRxYxVuJTmrR5tWpzDwucEVKgoGMcU4DA60zkbHrS470g4xnr6UpNMzuAOKUHmkoB7ipAkXoahvoDdWksAbbvXGetPU8iodSSSWwuEhz5jIQMHGaHoS0QR3N+V2pa277eNyT/L+WOKm02EwW5DPGztIzts+6pJ5AqkLYLHFdabCbeZRzEw2hx3Vh6+hqfRNwtHMkbRs00jbWGCMmpuFj8zs0UlJXWZC0lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKKSigB610XhmWaPUbfAxGuV2j37mucFXdPnMU8bFjhWDY5I/KpktDSDsz2XT3wwjI5PWtGBvJmZHwayNKmEzpKAclQR71ajdpLkjuTzmuV6Ht03dGw7BEQ4wGqS2YNkA4YdDVUnqGHJ4FTWaEyBQcGokrndTnpY37GbcuG4x3qyzA4XtWWCyjg/OPSrttKCvJ5qGjaMiwUXsAaljiXriokG9wVNW1GMfSpsarUcgA6U5x1+lLkAUxun1pbGiIdv6UoT2609Uzipo48nikVzESx8VKIvTirUcORip1h9AKaWhDmVYoctzWjbW4+Xipre2z1FWo0wQvX3o5rGMp32K0sW0VYsoM8kVZMG4DirVrHtAHFVFGbnaIQxYarRjwf8aVV2nNPzmtkjmlNjTGCB7elOij547etKuT7/SpoUwemasyc9BViIq3br07Usa8CrEacg1VjjqVB6rkZxxU0aihRgU/t0zQcrbYDvxTxxjmm0p4oMxfp1o+tNzzzQaTAdu607gkHHzDoaYvX6U7NK4mIoYFy7kgngY+6KWSRY0Z3baqjJJ7CjqKrX8bS2kiRjcxAIB74OcfpQ3cSRH9rmK+Ytuvl5wA0oDn8MYz7E1agmWeJZEztPY9QfT61itMhtZoN0ASRmJZ2w4yc8pjJYVp6crLAzOpQyOz7T1APTPvSHY/Muiiius5wooooAKKKKACiiigAooooAKKKKACiiigAooooAUVIpwRiiiky4nqPhaeRtLtixydvX9K6Kw5uGY9QBRRXI9z2KOxo5zdqD6VZtj++J4yKKKXU64mlB69T71JnEgx3oorNnTTL9r2NXF5ooqGdEdyT0+lIeRRRSNUSRAZHvV6JRkDFFFBMi/DGvp0p6qOOBRRTZizQiQbRT0QB6KKkxL0SDaOKeoAziiit1sZseORz2obtRRVowe5NEoyKtoo4oopoyqFmNQBgVOOCMUUVRxSJhyDSBjg+1FFIxHnkDPNJnPPciiimA4dKD2570UUmJi5waU8UUUmIBz1pG70UUAN43AkDPrjmpKKKQH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small ulcers are present on the oral mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small ulcers are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Enanthem in coxsackievirus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scattered petechiae appear centrally, and there is a vesicle posteriorly at the junction of the hard and soft palates. Coxsackievirus produces lesions toward the posterior of the oropharynx, whereas herpes simplex virus appears anteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - lip and hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Oral lesion: note the oval shape and rim of erythema. B) Oval intact vesicles are noted on the palm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hand-foot-and-mouth disease - foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple vesicular lesions on an erythematous base are present on the foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38570=[""].join("\n");
var outline_f37_42_38570=null;
var title_f37_42_38571="Differential DX tremor";
var content_f37_42_38571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of tremor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Tremor",
"      </td>",
"      <td class=\"subtitle1\">",
"       Description",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Essential tremor",
"      </td>",
"      <td>",
"       Bilateral postural or kinetic tremor of the hands and forearms (usually 4 to 6 Hz) or isolated head tremor without evidence of dystonia. Absence of other neurologic signs or recent trauma preceding the onset of tremor.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Physiologic tremor",
"      </td>",
"      <td>",
"       Enhanced physiologic tremor. High frequency (10 to 12 Hz), presence of known cause (see text).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parkinson disease",
"      </td>",
"      <td>",
"       Mixture of rest and action tremors; occasionally action tremor alone. Leg or foot tremor more common than with essential tremor, usually does not produce head tremor. Frequency 4 to 6 Hz.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Orthostatic tremor",
"      </td>",
"      <td>",
"       Postural tremor in the torso and lower limbs while standing; may also occur in the upper limbs. Suppressed by walking. Tremor is high frequency (14 to 18 Hz) and synchronous among ipsilateral and contralateral muscles.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cerebellar tremor",
"      </td>",
"      <td>",
"       Postural, intention, or action tremor. Relatively low frequency (3 to 4 Hz). Associated with ataxia and dysmetria.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neuropathic tremor",
"      </td>",
"      <td>",
"       Variable tremor type and frequency, usually postural and kinetic tremor in the involved extremities. Other signs of peripheral neuropathy present.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rubral or midbrain tremor",
"      </td>",
"      <td>",
"       Mixture of rest, postural, and intention tremor with frequency of 2 to 5 Hz. Always associated with signs of brainstem or cerebellar damage.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Elble, RJ, Neurology 2000; 54(Suppl4):S2.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38571=[""].join("\n");
var outline_f37_42_38571=null;
var title_f37_42_38572="Distinguishing Crohns vs intestinal TB";
var content_f37_42_38572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F85948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F85948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features that help distinguish between Crohn's disease and intestinal tuberculosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Crohn's disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intestinal tuberculosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Clinical manifestations",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Perianal disease",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          High-swinging fever (&gt;38.5&deg;C) in absence of intra-abdominal abscess",
"         </li>",
"         <li>",
"          Evidence of pulmonary TB on chest x-ray",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Radiographic findings&nbsp;(CT/MRI)",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Symmetrical bowel wall thickening",
"         </li>",
"         <li>",
"          Mesenteric fibrofatty proliferation (creeping fat)",
"         </li>",
"         <li>",
"          Mesenteric vascular engorgement (comb sign)",
"         </li>",
"         <li>",
"          Small homogenous pericecal lymph nodes",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Asymmetrical bowel wall thickening",
"         </li>",
"         <li>",
"          Inflammatory mass centered around the cecum and enveloping the terminal ileum",
"         </li>",
"         <li>",
"          Large mesenteric nodes with necrotic centers",
"         </li>",
"         <li>",
"          Ascites",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Endoscopic findings",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Longitudinal ulcers",
"         </li>",
"         <li>",
"          Aphthous ulcers",
"         </li>",
"         <li>",
"          Cobblestoned mucosa",
"         </li>",
"         <li>",
"          Preservation of ileocecal valve",
"         </li>",
"         <li>",
"          Multiple skip lesions",
"         </li>",
"         <li>",
"          Anorectal lesions",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Transverse ulcers",
"         </li>",
"         <li>",
"          Hypertrophic mucosa",
"         </li>",
"         <li>",
"          Scars/fibrous bands/inflammatory polyps",
"         </li>",
"         <li>",
"          Gaping/destruction of ileocecal valve",
"         </li>",
"         <li>",
"          Hyperemic nodules",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Histopathologic findings",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Single granulomas",
"         </li>",
"         <li>",
"          Architectural distortion distant from granulomatous inflammation",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Caseating granulomas or positive acid fast bacilli staining*",
"         </li>",
"         <li>",
"          Confluent (&ge;5/biopsy) and large (diameter &gt;200 micrometers) granulomas; submucosal granulomas",
"         </li>",
"         <li>",
"          Ulcers lined by epithelioid histiocytes",
"         </li>",
"         <li>",
"          Disproportionate submucosal inflammation",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; MRI: magnetic resonance imaging.",
"     <br/>",
"     * Features pathognomonic for intestinal TB but present in &lt;30 percent of cases; no single variable described above is absolutely specific for either condition otherwise.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38572=[""].join("\n");
var outline_f37_42_38572=null;
var title_f37_42_38573="Cyclosporine and Ca blockers";
var content_f37_42_38573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Graph showing the effect of calcium channel blockers on cyclosporine-induced vasoconstriction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The administration of cyclosporine to 10 renal transplant recipients on chronic maintenance therapy is associated with daily transient reductions of approximately 50 percent in renal plasma flow (RPF) and glomerular filtration rate (GFR). These changes are prevented by chronic treatment with a calcium channel blocker (blue squares and circles), which also lowered the systemic blood pressure from mean values of 142/93 to 125/79.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ruggenenti, P, Perico, N, Mosconi, L, et al, Kidney Int 1993; 43:706.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38573=[""].join("\n");
var outline_f37_42_38573=null;
var title_f37_42_38574="CMV retinitis in pediatric AIDS";
var content_f37_42_38574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Funduscopic examination of an HIV-infected 16-year-old girl with cytomegalovirus retinitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There are extensive areas of hemorrhage with white retinal exudates. Children with cytomegalovirus retinitis usually present with painless visual impairment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. David Coats, Houston, Texas.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38574=[""].join("\n");
var outline_f37_42_38574=null;
var title_f37_42_38575="Spectrum growth hormone sensitivity";
var content_f37_42_38575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    The clinical spectrum of growth hormone sensitivity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 456px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A two-dimensional diagram of the different degrees of growth hormone sensitivity among disorders characterized by short stature. Approximate relative levels of growth hormone secretion are shown on the vertical axis and relative growth hormone sensitivity on the horizontal axis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cohen P. Problems with reclassification of insulin-like growth factor I production and action disorders. J Clin Endocrinol Metab 2006; 91:4235. Copyright &copy; 2006 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_42_38575=[""].join("\n");
var outline_f37_42_38575=null;
